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ABBREVIATIONS 
 
 
 
 
 
S.no Abbrevations Meaning 
1 ChrDDS Chronopharmaceutical drug delivery 
system 
2 CR Controlled release 
3 SR Sustained release 
4 ER Extended release 
5 IPEC Interpolyelectrolyte complex  
6 PEC Polyelectrolyte complex 
7 Mcc ph 102 Microcrystalline cellulose pH 102 
8 HPMC Hydroxypropyl methyl cellulose 
9 SS Salbutamol sulphate 
10 pm Physical mixture 
11 CP Carbopol 971 P 
12 EE Eudragit E po 
13 EL Eudragit L 100 
14 SI Swelling index 
15 CI Compressibility index 
16 TD Tapped density 
17 BD Bulk density 
18 HR Hausner ratio 
19 kPa kilopascals 
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INTRODUCTION: 
CONCEPT OF CHRONOPHARMACEUTICS 
Chronopharmaceutics is a branch of pharmaceutics dealing with design and 
evaluation of drug delivery system that delivers the therapeutic agent in rhythm that 
ideally matches the therapeutic need of the biological system [1]. 
The biological systems require varying concentrations of drug within the circadian 
cycle at specified time. Hence, existence of such delivery system is necessary to match 
the circadian rhythm associated with certain diseases. This can be achieved with 
Chronotherapeutic drug delivery system. These systems deliver the required dose at 
time when it is needed [2].  
The biological clock (24 hours rhythmic cycle) within our body drives various 
physiological body functions and pathophysiology of certain diseases. These diseases 
show up their symptoms at a peak level during a particular time period in a day. Such 
rhythms associated with disease symptoms are observed in bronchial asthma, ulcer, 
rheumatoid disease, hypertension and hyper cholesterolemia etc [3]. 
The possibility of deferring the drug release pattern within the system according 
to rhythmicity of diseases is a promising tool to treat certain diseases that emerge in 
circardian rhythm fashion. 
Need for chronopharmaceutics drug delivery system (ChrDDS) [4]:  
1.When possible variations in pharmacokinetic of drug responsible for time dependent  
variations in drug effects (e.g. some antimicrobial agents) 
2.When drugs have a narrow therapeutic range. 
3.When symptoms of certain diseases are circadian phase-dependent (e.g. Asthma, 
Angina pectoris,  myocardial infarction). 
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Hurdles of ChrDDS: 
1. Rhythmic bio-responsive materials and system design. 
2. Rhythm delivery system engineering and modeling. 
3. Regulatory guidance related to these types of modified dosage forms. 
CHRONOMODULATED DRUG DELIVERY SYSTEMS [5-7] : 
1. Pulsatile drug delivery system: 
This system releases the drug suddenly after a well-defined lag time according to 
the circadian rhythm of diseases. Drug is not released from the device within this lag 
time. This method is advantageous for drugs with extensive first pass metabolism and 
those which can be targeted to specific sites in the intestinal tract. Thus by developing a 
pulsatile release system colonic drug delivery, the plasma peak can be obtained at 
specified time. 
2. Enteric-coated system: 
This system contains a core which is film coated with polymers such as HPMC 
and gastro-resistant polymer (Eudragit). In this system the lag time can be controlled by 
thickness of the coating layer. The disadvantage of this system is the unpredictability of 
gastric residence. 
3. Osmotic system: 
This system depends on osmotic pressure as a driving force for the pulsatile drug 
delivery. It consists of a semi-permeable membrane around the core containing 
osmotically active drug or a drug combined with an osmotic agent. The delivery orifice is 
drilled into the system with the help of laser. Lag time of 1-10 hours can be achieved 
based on the thickness, orifice diameter and concentration of osmotic agent.eg. port 
system. 
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4. Swelling and erodible system: 
In this system the drug core is surrounded by polymeric barrier that swells and dissolves 
to release the drug after the lag time. The lag time of the system can be controlled by 
altering the thickness of the polymeric coating and its viscosity. 
5. Press coated system: 
It involves direct compression of coating layer over the core. The limitation of this 
system is that central positioning of the core within the coat cannot be assured. The lag 
time of this system can be adjusted by coating the tablet with semi-permeable polymer. 
6. Pulsincap: 
This system comprises a water insoluble capsule body enclosing the drug 
reservoir. The capsule is closed at one end with swellable hydrogel plug. When this 
capsule comes in contact with water it swells and pushes the plug after a lag time to 
release the drug. Rapid release of drugs can be achieved by inclusion of effervescent 
agents, super disintegrants and osmotic agent. 
7. Ultrasound drug delivery system: 
This system utilizes ultrasound effect that enhances the degradation of polymer 
in which the drug is incorporated. The drug released can be achieved by application of 
ultrasound. 
8. Multiparticulate system: 
The active agent is coated onto non-peril sugar pellets followed by coating with 
swellable polymer layer. The swelling agents may include super disintegrant, osmotic 
agent etc. upon ingress of water, the swellable layer swells and rupture the film resulting 
in rapid drug release. 
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CHRONOPHARMACEUTICAL TECHNOLOGIES: 
1. CONTIN technology: 
The Complex formed between the cellulose polymer and non polar solid aliphatic 
alcohol acts as a matrix system. This technology is used for more effective control of 
disease by reducing side effects. Eg: aminophylline, morphine etc [8,9] . 
2. CODAS technology: 
The chronotherapeutic oral drug absorption system (CODAS) is a multi-
particulate system designed for bedtime drug dosing, with 4-5 h delay in drug delivery 
coated with non-enteric release-controlling polymer applied to drug loaded pellets. E.g. 
CODAS-verapamil extended release capsules [10,11] . 
3. CEFORM technology: 
This approach is based on meltspining which produces uniform shaped 
microspheres of pharmaceutical compounds. This technology is used to develop 
cardizemR LA, a one day diltiazem formulation based on ChrDDS [12,13]. 
4. OROS technology: 
This delivery system reproducibly delivers a bolus drug dose within a specified 
time and in site specific manner to the gastrointestinal tract. This osmosis-based system 
is generally used in the designing of extended release tablet [14,15]. 
5. DIFFUCAPS technology: 
This technology involves drug delivery from a capsule system in a circadian 
release fashion. It is a multiparticulate technology for chronotherapeutic delivery of 
combination of two drugs. This technology has been used to formulate propranolol 
containing ChrDDS for the management of hypertension (first & recently FDA approved) 
[16,17]. 
6. EGALET: 
It is a delayed release dosage form consisting of impermeable shell with two lag 
plugs, enclosing a plug of active drug in the middle of its units. 
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7. GEOCLOCK: 
The system is designed based on the concept of geomatrix technology. The 
active core is coated partially over the bases. Upon erosion, the surface of the active 
core is exposed with increasing time to the outer environment, which helps drug release 
[18]. 
8. TIMERx: 
It is a hydrogel-based controlled drug delivery device. The drug release is 
controlled by rate of water penetration into the TIMERx gum matrix from the 
gastrointestinal tract. The system expands to form a gel and release the drug[19]. 
9. PORT® technology: 
The Programmable Oral Release Technologies (PORT) system is a unique 
encapsulated system that provides multiple programmed release of drug [20]. It 
contains of polymeric core or may be a capsule which is coated with a semi-permeable, 
rate-controlling polymer. A blend of active medicament and osmotic agent is plugged 
inside the capsule shell and sealed with water insoluble plug. Immediate release 
compartment can also be incorporated based on the disease profile. 
 
DISEASES WITH ESTABLISHED CIRCADIAN RHYTHMS IN THEIR 
PATHOGENESIS 
There diseases which are influenced by biological rhythms require the 
development of chronopharmaceutical drug delivery system than conventional drug 
administration [21].  
These include asthma, cancer, cardiovascular diseases, diabetes, etc. 
Bronchial asthma: 
It is characterized by airway inflammation which results in hyper responsiveness 
of lower respiratory tract in accordance with various environmental stimuli [22]. Airway 
resistance increases progressively at night in asthmatic subjects. Nocturnal asthma is 
an exacerbation of asthma at night with increase in symptoms, airway responsiveness 
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and lung function [23]. Antigen provokes the release of pro-inflammatory mediators from 
mast cells and eosinophils resulting in exacerbation of inflammation, smooth muscle 
bronchospasm and contraction. This can be best matched by targeting with 
chronotherapy because bronco constriction and exacerbation of symptoms vary on 
circadian fashion. 
 
Figure 1: Circadian rhythm 
Arthritis: 
Patients with rheumatoid arthritis, have pain that peaks in morning hours and 
decreases throughout the day. Circadian rhythm in the plasma concentration of c-
reactive proteins and interlukin-6 has been reported [24]. Chronotherapy of arthritis 
should be timed to ensure that blood levels of the drugs should coincide with peak pain.  
 
Allergic rhinitis [25]: 
The symptoms were found to occur most frequently in morning. The phases of 
allergic rhinitis include, early phase (developing within minutes) and late phase 
(manifesting after 12-16 h). The early phase occurs due to release of histamine, 
cytokines, prostaglandins, TNF-α, chemotactic factors etc. The late phase is due to 
distribution, adhesion and infiltration of circulating leukocytes, eosinophils, T cells 
causing nasal congestion, exacerbation of inflammation of upper airways. 
 
Duodenal ulcer: 
Generally gastric acid secretion is highest in the evening in subjects with 
duodenal ulcer and decreases in the early morning [26,27].A circadian rhythm has been 
found and duodenal perforations showed highest incidence in afternoon, which showed 
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a major peak around noon and secondary peak near midnight. Circadian pattern was 
characterized by 6-month rhythm, which significantly shows higher risk in May-June-
July [28]. 
 
Epilepsy: 
The circadian rhythm may also take part in epilepsy [29].The influence of the 
biological clock on seizure has been found in some experimental animal models. The 
methodology for measurement of the circadian rhythm in humans is also investigated. 
Behavioral chronobiology provides the detection of probable new regulation process 
concerning the central mechanisms of epilepsy [30]. 
 
Cardiovascular diseases: 
Cardiovascular diseases involving several factors such as blood pressure, heart 
rate, stroke volume, cardiac output and blood flow were subject to circadian rhythms. 
capillary resistance and vascular reactivity are higher in morning whereas decrease 
later in the day; Platelet agreeability is increased and fibrinolytic activity is decreased in 
the morning, leading to a state of relative hypercoagulability of the blood [31-33].It was 
postulated that modification of these circadian triggers by pharmacologic agents may 
lead to the prevention of adverse cardiac events [34]. 
 
The circadian pattern of blood pressure is at its lowest during the sleep cycle and 
rises steeply during the early morning awakening period. Most patients with essential 
hypertension have a similar circadian rhythm of Blood pressure [35]. 
 
Diabetes: 
In type I diabetes, circadian rhythms in insulin requirement and release involves 
pulsatile fashion.[36] Insulin release shows cyclic rhythmicity both in stimulated and 
inhibitory fashion based on requirement which induce a secondary feed-back signal on 
insulin release which can help to maintain blood glucose levels. The modulators of 
insulin release and action are secreted in a circadian fashion and secondarily impress 
the mode of insulin release. 
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CHRONOTHERAPY IN ASTHMA 
In nocturnal asthma, the delivery of the drugs which could address the 
progressive increase in airway resistance during early morning hours could offer better 
symptom control. In chronopharmacotherapy of asthma drug administration is 
synchronized with circadian rhythms. If the symptoms occur at daytime a conventional 
dosage form can be administrated. If symptoms of the disease worse during night or in 
early morning hours the timing of drug delivery should be synchronized in such fashion 
which provides better disease control [37]. 
Most asthma attacks occur at 04:00 to 06:00 hours. Nocturnal asthma is a 
complex interaction of several coincident circadian rhythms e.g. secretion of 
hydrocortisone and adrenalin. 
Enteric-coated formulations are used for site-specific delivery; they can also be 
used in time-controlled delivery systems when there is a necessity for lag time. Bogin 
and Ballard (1992) have successfully used salbutamol formulations for the treatment of 
nocturnal asthma. The polymers which dissolves in intestinal pH 6 were used [38]. 
 
Development of chronotherapy for nocturnal asthma, using theophylline, inhaled 
corticosteroid, inhaled anticholinergic agent and beta 2-agonist according to biological 
rhythm to maximize pharmacological effects and minimize side effects. The circadian 
rhythm of biological system is important in understanding the rhythmicity in lung function 
of asthmatics at night [39].  
 
The circadian rhythm in peak expiratory flow (PEF) was altered according to 
severity of asthma occurring in midnight and early morning. A chronotherapy of evening 
dose of theophylline can be used for nocturnal asthma attacks which could effectively 
improve the values of PEF and symptoms responsible for nocturnal asthmatics [39].  
 
Investigation of chronotherapeutically optimized, sustained-release theophylline 
formulation administered once daily in the evening at 8:00 P.M. is compared with a 
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conventional sustained-release theophylline administered twice daily at 8:00 A.M. and 
at 8:00 P.M. The improvement in PEF and FEV1 in once daily dose based on 
chronotherapy showed better symptom control than conventional sustained release 
formulation. Once-daily evening theophylline chronotherapy meets these goals, 
providing rising blood levels at night and in the early morning [40]. 
 
The theophylline levels remained practically constant for 24 hours under 
conventional theophylline treatment with twice-daily administration. In contrast, the 
variations of the theophylline serum levels and the night levels were higher after once-
daily dosage of Euphylong providing better symptom control [40]. 
 
Timed administration of once-daily theophylline drug might provide maximum 
blood levels when needed and helps to stabilize 24-hour airflow. Chronotherapeutic 
potential of single-daily evening doses of a controlled-release theophylline preparation 
(Uniphyl 400-mg tablets) in nocturnal asthma was investigated. Nighttime blood 
concentrations with this regimen were higher compared to Theo-Dur tablets, B.I.D., in 
the same total daily doses or with once-daily morning Uniphyl administration.  
In fed and fasted subjects, evening administration of Uniphyl 400-mg tablets was well 
tolerated and did not lead to 'dose dumping'[28]. 
 
MUCOADHESIVE DRUG DELIVERY SYSTEM IN COLON: 
Gastrointestinal Mucoadhesive drug delivery system prolongs the residence time 
of dosage form at the site of absorption. It facilitates an intimate contact of dosage form 
with that of the underling absorption surface thus contributing to improved therapeutic 
performance of drugs [41].  
 
The process of mucoadhesion involves a polymeric system that includes wetting, 
adsorption and interpenetration of polymer chains. 
The problem frequently encountered with sustained release dosage forms is the 
inability to increase the residence time in the stomach and proximal portion of the small 
intestine. 
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Therefore it would be beneficial to develop a sustained release formulation which 
remains in contact with the absorption site for an extended period of time. This greatly 
enhances the pharmacotherapy of the GIT leading to high drug concentrations at the 
gastric or intestinal mucosa. 
 
Mucosa of colon: 
The GI tract consists of four concentric layers:  
1. Mucosa 
2. Submucosa 
3. Muscularis externa (the external muscle layer), 
4. Adventitia or serosa.  
The mucosa is the innermost layer of GI tract that surrounds the lumen. 
This layer comes in direct contact with food (or bolus), and is responsible for absorption, 
secretion and other important processes in digestion. 
 
The mucosa can be divided into: 
 Epithelium 
 Lamina propria 
 Muscularis mucosae 
 
The mucosa are highly specialized parts of GI tract about 1mm thickness, facing low 
pH in stomach, absorbing a multitude of substances in small intestine, and absorbing 
specific quantities of water in the large intestine. 
 
During fasting state an interdigestive series of electrical events take place, which 
cycle through both stomach and intestine every 2 to 3 hours. This is called the 
interdigestive myoelectric cycle or migrating myoelectric cycle (MMC), which is further 
divided into following 4 phases: 
 
1.Phase I (basal phase) 
2.Phase II (pre burst phase) 
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3.Phase III (burst phase) 
4.Phase IV 
During the fed state, onset of MMC is delayed. 
Phase I - It is a quiescent period of about 30 to 60 min with no contractions. 
Phase II - It consists of intermittent contractions that gradually increase in intensity as 
the phase progresses. It lasts about 20 to 40 min. Gastric discharge of fluid and other 
small particles begin later in this phase.  
Phase III– It is a short period of intense distal and proximal gastric contractions (4–
5contractions per min) lasting about 10 to 20 min; these contractions are also known as 
‘‘house-keeper wave”. 
Phase IV– It is a short transitory period of about 0 to 5 min. The contractions dissipate 
between last part of phase III and quiescence (phase I). 
Mucoadhesion stages: 
The stages of mucoadhesion involves, 
1) An intimate contact between a bioadhesive and a membrane. 
2) Penetration of the bioadhesive into the crevice of the tissue surface. 
3) Mechanical interlocking between mucin and polymer. 
 
Forces involved in mucoadhesion: 
1) Ionic bond: 
Two oppositely charged ions attract each other via electrostatic interactions to 
form a strong bond (e.g. in a salt crystal). 
2) Covalent bond: 
Electrons are shared in pairs, between the bonded atoms in order to fill the 
orbital. These are also strong bonds. 
3) Hydrogen bond: 
Hydrogen atom covalently bonded to electronegative atoms such as oxygen, 
fluorine or nitrogen, carries a slight positive charge and is therefore attracted to 
other electronegative atoms. This bond is generally weaker than ionic or covalent 
bonds. 
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4) Van-der-Waals bond: 
These are weakest forms of interaction that arise from dipole– dipole and dipole-
induced attractions in polar molecules and dispersion forces with non-polar 
substances. 
5) Hydrophobic bond: 
These are indirect bonds that occur when non-polar groups are present in an 
aqueous solution. Water molecules adjacent to non-polar groups form hydrogen 
bonded structures. 
 
Mucus: structure, function and Composition: 
Mucus is a viscous adherent secretion which is secreted by specialized goblet 
cells. The thickness of this layer varies from 50-450 μm in humans. 
Composition of mucus [42]: 
 
Water    95.0 % 
Glycoprotein & lipids  0.5 - 5.0 % 
Mineral salts    1.0 % 
Free proteins   0.5 - 1.0 % 
 
Function of mucus layer [43]: 
The primary functions of the mucus layer are: - 
1. Protection- Resulting particularly from its hydrophobic nature. 
2. Barrier- The role of mucus layer as barrier in tissue absorption of drugs and other  
Substances influence the bioavailibity of the drug. 
3. Adhesion- Mucus has strong cohesional properties and firmly binds to the epithelial  
cells surface as continuous gel layer. 
4. Lubrication- role of mucus layer is to keep the mucosal membrane moist by 
continuous secretion of mucus from the goblet cells. It is necessary due to removal of  
mucus layer due to digestion, bacterial degradation and solubilization of mucin 
molecules. 
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MUCOADHESIVE POLYMERS: 
Mucoadhesive polymers may be water-insoluble and water-soluble polymers, 
which are swellable networks joined by cross-linking agents. These polymers possess 
optimal polarity to permit sufficient wetting by mucus secreations influencing 
interpenetration of polymer and mucus. 
 
Classification of mucoadhesive polymer: 
Natural /Semi-synthetic polymers: 
Na+ alginate, Agarose, Chitosan, Pectin, Tragacanth, Gelatin, Xanthan gum, 
Carragenan, Starch. 
 
Synthetic polymers: 
Poly vinyl alcohol, Polyamides, Polycarbonates, Poly alkylene glycols, Poly vinyl 
ethers, Esters and halides, Poly methacrylic acid, PMMA , Methyl cellulose,Ethyl 
cellulose, HPC, HPMC, Methyl cellulose, Sod. CMC.  
 
Bicompatible polymers: 
Esters of haluronic acid, Polyvinyl acetate, Ethylene glycol. 
 
Biodegradable polymers: 
Poly(lactides), Poly(lactide-coglycolides), Poly caprolactones, Poly alkyl 
cyanoacrylates, Poly orthoesters, Poly(glycolides), Poly phosphoesters, Poly 
anhydrides, Poly phosphazenes, Chitosan, Poly ethylene oxide. 
 
FACTORS AFFECTING MUCOADHESION: 
1) Polymer Related Factors[44]: 
a) Molecular weight:  
The interpenetration of polymer into the mucus layer is more for low molecular 
weight polymers than high molecular weight polymers since it favors entanglements. 
 
b) Concentration of active polymer:  
For solid dosage forms such as tablets, the higher the concentration of polymer, 
the stronger the bioadhesion force. 
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c) Spatial Conformation:  
Bioadhesive force is also dependent on conformation of polymers, i.e., helical or 
linear. The helical conformation may shield many active groups which are primarily 
responsible for adhesion thus reducing the mucoadhesive strength of the polymer. 
 
d) Chain flexibility of polymer: 
It is important for interpenetration and enlargement. As water-soluble polymers 
become more and more cross linked, the mobility of the individual polymer chain 
decreases, cross linking density increases, effective length of the chain which penetrate 
into mucus decreases and mucoadhesive strength is reduced [45]. 
 
e) Degree of Hydration: 
Another important factor which affects the mucoadhesive strength of polymeric 
components is the degree of hydration. Many polymers exhibit adhesive properties 
under conditions where the amount of water is limited. In such situation, adhesion is a 
result of combination of capillary attraction and osmotic forces between the polymer and 
mucosal surface. Hydration is essential for relaxation and interpenetration of polymer 
chains, excess hydration could lead to decreased mucoadhesion. Cross linked 
polymers that allows certain degree of hydration provides prolonged mucoadhesion 
[44]. 
 
f) Functional Group Contribution: 
The attachment and bonding of bioadhesive polymers to the biological substrates 
occurs mainly through interpenetration which is followed by secondary non-covalent 
bonding (hydrogen bonding) between the substrates. Mucoadhesive polymers 
possessing hydrophilic functional groups such as, carboxyl(COOH), hydroxyl (OH), 
amide (NH2) and sulphate groups (SO4H) favours targeted drug delivery. 
g) Influence of pH: 
pH influences surface charge on mucus and polymers. Mucus will have different 
charge density depending on pH, because of difference in dissociation of functional 
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groups such as carbohydrate moiety and amino acids of polypeptide backbone, which 
may affect adhesion [46-49]. 
 
 
Figure 2:  Mucosa of Colon 
 
  COLON TARGETING DRUG DELIVERY SYSTEM: 
Site-specific delivery of drugs to the colon would additionally be valuable in 
treatment of chronic medical conditions like nocturnal asthma, which is reported to be 
circadian rhythm dependent [50].  
Colon specific drug delivery can be achieved with suitable mechanism that 
triggers the drug release upon reaching colon. The physiological changes in the pH of 
the gastrointestinal tract and a pH-sensitive tablet in capsule system intended to match 
the chronobiology of nocturnal asthma is proposed for site specific release to the colon 
[51].  
The delivery of dosage form to the colon via gastrointestinal (GI) tract requires 
protection of delivery system from being released in stomach and small intestine. 
Sustained release of drugs into colon can be useful in treatment of certain diseases for 
which systemic absorption of drugs to be achieved for prolonged time period. 
The colon is most suitable site for absorption of peptides and protein drugs for the 
following reasons:  
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1. Less degradation by digestive enzymes. 
2. The proteolytic activity of colon is less than that observed in small intestine, thus 
CDDS protects the drugs from hydrolysis, and enzymatic degradation which 
provides greater systemic bioavailability. The colon has a long residence time 
and hence it is highly responsible for enhancement of absorption. 
 
ANATOMY AND PHYSIOLOGY OF COLON[52,53]: 
The large intestine extends from the distal end of the ileum to the anus. Human 
large intestine is about 1.5 m long. The pathway is called the lumen and is about 2-3 
inches in diameter. The cecum forms the first part of the colon followed by right colon, 
transverse colon, descending colon, sigmoid colon, rectum and the anal canal. 
Table 1: Length of colon 
Sr.
no.  
Large Intestine  Length 
(cm)  
1  Cecum  6-9  
2  Ascending colon  20-25  
3  Descending colon  10-15  
4  Transverse colon  40-45  
5  Sigmoid colon  35-40  
6  Rectum  12  
7  Anal canal  3  
pH in Colon :  
The change in pH along the gastrointestinal tract has been used as a means for 
targeted colon drug delivery. The pH in colon may be influenced by carbohydrate rich 
diet due to fermentation of polysaccharides by colonic bacteria resulting in formation of 
short chain fatty acids. polysaccharide based drugs alter colonic pH. Laxatives drugs 
like lactulose are known to be fermented by colonic bacteria to produce lactic acid and 
reduce colonic pH. 
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Table 2 : pH of colon 
Sr.
no.  
Location  pH  
1  Stomach  1.5 - 2.0  
2  Small intestine 
Jejunum 
Ileum  
 
6.5 to 7.8 
3  Large intestine  5.5 to 6.8 
 
There is a fall in pH on the entry into the colon due to presence of short chain 
fatty acids due to bacterial fermentation of polysaccharides. 
 
 
Figure 3: pH and transit time of GIT 
Transit of material in the colon: 
 Gastric emptying of dosage forms is highly variable and depends on propertiesof 
the dosage form such as size and density. The arrival of an oral dosage form at the 
colon is determined by the rate of gastric emptying and the small intestinal transit time. 
The movement of materials through the colon is slow and dosage forms such as 
capsules and tablets pass through the colon in approximately 20-30 hours to more than 
2 days can occur. Diseases state of colonic alters the transit time. 
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Table 3: Transit time of GIT 
Organ  Transit time 
(hours) 
Stomach  1-2  
Small 
intestine  
3-4  
Large 
intestine  
12 hours to > 2 
days 
 
Colonic Absorption:  
Different factors affecting colonic absorption involves, 
1. Passage through colonocytes (Transcellular transport).  
2. Passage between adjacent colonocytes (Paracellular transport).  
 
Transcellular absorption involves passage of lipophilic drugs through cells, where as 
paracellular absorption involves transport of Hydrophilic drugs through tight junctions 
between the cells. 
 
Drugs that are well absorbed in colon -glibenclamide, diclofencac, theophylline, 
salbutamol, ibuprofen, metoprolol and oxyprenolol.  
Drugs that are less absorbed in colon - furosemide, pyretanide, buflomedil, atenolol. 
 
Factors affecting colonic absorption:  
 Physical properties of drugs such as pKa and degree of ionization.  
 Colonic residence time and transit through GIT 
 Degradation by bacterial enzymes and metabolite products.  
 Adherence to mucus.  
 Diseased state of colon.  
 
Colonic microflora [54,55]:  
The presence of colon specific microflora formed basis for development of colon 
specific drug delivery system. Human colon is dynamic and ecologically diverse 
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environment, containing 400 distinct species of bacteria with a population of 1011 to 
1012CFU/mL, which includes Bacteroides, Bifidobacterium, Eubacterium, Lactobacillus, 
etc.  
Nitroreductase, azoreductase, N-oxide and sulfoxide reductase are the reductive 
enzymes, while glucosidase and glucronidase are the hydrolytic enzymes. The primary 
source of nutrition for these anaerobic bacteria is carbohydrates from the intestinal 
chime. Enzymes responsible for degradation of polysaccharides include α-
Larabinofuranosidase, β-D-fucosidase, β-Dgalactosidase, β-Dglucosidase, β-
xylosidase. A unique features of colon microflora is the growth and activity of certain 
specific species notably bifidobacteria and lactobacilli. 
 
 
HYDROGELS 
Hydrogels are cross linked polymers which have ability to swell in aqueous 
medium. Crosslinking in hydrogels occurs by chemical or physical means depending on 
the polymer properties. Intelligent hydrogels can able to respond to various 
environmental changes such as temperature, pH, and solvent composition, by changing 
their dimensions [56]. 
A cross linked hydrosol is called as hydrogel which can swell into certain swelling 
ratio, depending on the number of crosslinks, i.e., the crosslinking density. 
Responsive Hydrogels: 
Hydrogels can respond to environmental changes by changing its size or shape. 
Factors that triggers a hydrogel response includes pH, temperature, and swelling 
medium. 
Nonionic hydrogels are almost insensitive to pH changes, while ionic hydrogels 
display a dramatic change in size with the pH change. Hydrogels containing 
hydrophobic groups susceptible to chain aggregation respond to temperature changes. 
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Hydrogels classified according to their charge, 
1. Anionic polymers- carbopol, polyacrylates 
2. Cationic polymers- chitosan, Eudragit E 
3. Neural/ non ionic polymers- HPMC 
 
pH-Responsive Hydrogels: 
Polymers containing carboxyl groups or amino groups respond to the pH 
changes by changing their size in swollen state. At low pH values, the carboxyl-
containing anionic polymers display minimum ionization and hence shows reduced 
hydration. Once the pH of the swelling medium rises above the pKa of the polymer, the 
carboxyl groups start to ionize and hydrate, which results in polymer expansion and 
hence higher swelling.  
On contrary, cationic polymers containing amino groups(quaternary ammonium 
salts) display a stronger ionization and hence shows higher rate of swelling at low pH. 
Eudragit ® L100-55, L30D-55, L100, or S100 are anionic polymers with 
methacrylic acid as functional groups. They dissolved at pH above 5.5, which provide 
drug protection at lowpH and drug release at high pH environment, which makes them 
suitable for drug delivery in intestine.  
Eudragit ® E100 is, on contrary, a cationic polymer based on butyl and methyl 
methacrylate containing dimethylaminoethyl methacrylate providing pH-sensitive 
functionality. The polymer is soluble in low pH. 
 
STIMULI RESPONSIVE SMART POLYMERS: 
The Delivery systems that releases the drug based on the diseased state 
according to the physiological needs utilizes the advantages of ‘environmental-sensitive’ 
or ‘smart polymer’ systems [57]. These polymers experience rapid changes in their 
microstructure from a hydrophilic to hydrophobic state triggered by small environmental 
changes. 
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The changes are reversible; hence, the polymer is capable of returning to its 
initial state as soon as the trigger is removed. Stimuli may occur internally (e.g. a 
change in pH in certain organs or diseased states, a change in temperature or the 
presence of specific enzymes or antigens). 
 
Smart polymeric drug delivery systems have been defined as “intelligent” drug 
delivery systems which are able to release bioactive agents at an appropriate time and 
site of action. These polymers releases the  entrapped drugs in response to specific 
physiological triggers and  exhibit a non-linear response to a small stimulus leading to a 
macroscopic alteration in their structure/properties [58]. 
 
STIMULI RESPONSIVE SMART POLYMERS: 
Environmental stimulus Responsive polymers: 
Temperature responsive: 
Poloxamers, Poly(N-alkylacrylamide)s, Poly(N-vinylcaprolactam)s, Cellulose, 
xyloglucan, Chitosan. 
pH responsives: 
Poly(methacrylicacid)s, Poly(vinylpyridine)s, Poly(vinylimidazole)s. 
Light Modified resposives:  
Poly(acrylamide)s. 
Electric field responsive: 
Sulfonated polystyrenes, Poly(thiophene)s, Poly(ethyloxazoline) 
Ultrasound responsives: 
Ethylenevinylacetate 
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MECHANISM INVOLVED IN pH RESPONSIVE POLYMERS: 
A stimuli-sensitive or smart polymer or intelligent polymers undergoes an abrupt 
change in its physical properties in response to a small environmental stimulus. They 
have the ability to return to their original shape after the trigger is removed [59-61]. 
 
These transitions are reversible and include changes in physical state, shape 
and solubility, solvent interactions, hydrophilic and lipophilic balances and conductivity. 
The driving forces behind these transitions include neutralisation of charged 
groups by the addition of oppositely charged polymers or by pH shift, and change in the 
hydrophilic/lipophilic balance or changes in hydrogen bonding due to increase or 
decrease in temperature.  
 
The major benefits of smart polymer-based drug delivery systems includes 
reduced dosing frequency, ease of preparation, maintenance of desired therapeutic 
concentration with single dose, prolonged release of incorporated drug, reduced side 
effects and improved stability[62-64] 
 
MECHANISMS INVOLVED IN POLYELECTROLYTES: 
 
All pH-sensitive polymers consist of pendant acidic or basic group that can either 
accept or release a proton in response to changes in environmental pH. Polymers with 
a large number of ionisable groups are known as polyelectrolytes.  
 
Polyelectrolytes are classified into two types: weak polyacids and weak 
polybases. Weak polyacids accept protons at low pH and release protons at neutral and 
high pH [64]. Poly(acrylic acid) (PAAc) and poly(methacrylicacid)(PMAAc) are 
commonly used pH-responsive polyacids. 
 
As the environmental pH changes, the pendant acidic group undergoes 
ionisation at specific pH called as pKa. This rapid change in net charge of the attached 
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group causes alteration in the molecular structure of the polymeric chain. This transition 
to expanded state is mediated by the osmotic pressure exerted by mobile counter ions 
neutralised by network charges [64].  
 
STIMULUS HYDROGEL TYPE RELEASE MECHANISM: 
 
A change in pH causes swelling of the hydrogel. Mechanisms capable of 
responding to these physiological variations can be used to design drug delivery 
systems in order to synchronize drug release profiles with changing physiological 
conditions. Ideally, a drug delivery system should respond to physiological 
requirements, sense the changes and alter the drug-release profile accordingly [65]. 
This paves the way for development of self regulated drug delivery which is 
adjusted to the staging of biological rhythms, since the onset of certain diseases exhibit 
strong circadian temporal dependence. 
The macroscopic changes that occur are reversible; therefore the system is capable of 
returning to its initial state when the trigger is removed [65]. 
 
Responses to these stimuli may be manifested as changes in shape, surface 
characteristics, solubility, and formation of an intricate molecular assembly or sol-to-gel 
or gel-to-sol transition [65] 
 
The swelling of pH-responsive hydrogels is governed by their degree of 
ionization i.e. protonation or deprotonation. On exposure to appropriate pH and ionic 
strength, the pendant groups ionize and develop fixed charges on the polymer network, 
causing electrostatic repulsive forces responsible for pH-dependent swelling or 
deswelling of the hydrogel, which ultimately controls & alters drug release profiles [65] 
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LITERATURE REVIEW 
Literatures pertaining to incidence of circadian rhythm in asthma: 
 
Calhoun., et al., (1992) [66] demonstrated that the patients with nocturnal 
asthma had increased proportion of low-density eosinophils at 4:00 A.M. as compared 
with 4:00 P.M. 
 
Ballard., et al., (1989) [67] studied that the lower airway resistance to airflow 
rose progressively from 12 midnight to 6 AM in asleep asthmatic subjects.  
 
D’Alonzo., et al.,[68] studied the sustained-release theophylline formulation 
administered once daily at evening 8:00 P.M in comparison with conventional 
sustained-release theophylline formulation administered twice daily at 8:00 A.M and at 
8:00 P.M in same dose. However, between 2:00 and 6:00 A.M., PEF and FEV1 were 
significantly greater with Once daily dose.  
 
Rofstad., et al., (2006) [69] stated that an obvious pH changes occurs along 
gastrointestinal tract Chronic inflammation  and in cancer tissue, hasbeen reported to be 
acidic extracellularly. The same is true for different cellular compartments of thebody. 
Since variations in pH occur within the body this property can be exploited to directa 
response and exploited for modulating drug release. 
 
Ekbom et al., (2008) [70] showed higher risk of CD in COPD sufferersby relating 
the relationship between gut and lung. Specific intestinal manifestations of COPD 
include atrophic gastritis etc. The report also showed the prevalence of colonic 
inflammation was higher in COPD and in other respiratory diseases. 
Black et al.[71] performed a literature survey that indicated 55 articles citing 
respiratory disorders in IBD patients which involves airway inflammation accounting for 
39% of these associations. Three more specific studies inIBD patients showed 
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increased incidence rates of pulmonary organ involvement at about 50%. Pulmonary 
involvement was more likely in colonic diseases. 
Kinoseet al.,(2011) [72]have recently identified increase in prevalence of 
NOD2single-nucleotide polymorphism (SNP) in COPD patients. NOD2 leads to factor-
κB activation and enhances inflammatory cytokine response upon stimulation. Defect in 
NOD2 signaling leads to impaired epithelial barrier function which leads to increased IL-
1β and TLR2 response, which increases serum IL-12. NOD2 mutations were found in 
CD population. Thus, NOD2 may therefore be a common link between COPD and CD. 
 
Literatures pertaining to polymers: 
 
Perez-Marcos et al., (1995) studied decrease in Atenolol release rate from 
tablets with increasing level of Carbopol ® polymer attributed to formation of thicker and 
stronger gel on tablet surface that controlled drug release in more efficient way. 
Khan and Jiabi., (1998) studied drug release profile by Increasing Carbopol  
polymer in Ibuprofen tablets resulted in reduction of drug release rate and linearization 
of drug release curve was achieved (release profiles in pH=7.2 buffer shiftedfrom 
anomalous type of drug release towards swelling-controlled, Case II mechanism). This 
phenomenonwas considered due to reduction in regions of microviscosity and the 
closing of micropores in swollen tablets. Carbopol ® polymers have pKa of 6, so at pH 
1.2 they are un-ionized; but ionize at above pH 4.5. At lower pH, polymer is not fully 
swollen, and there are larger regions of low microviscosity; hence solvent can penetrate 
fast and deep into the glassy core and drug is released faster. As the pH increases, 
ionization of carboxylic acid groups causesmaximum swelling, resulting in fewer regions 
of microviscosity. Rapid gel formation actsas barrier thus prolonging the drug release. 
Efentakis., et al., (2000)studied formulations containing Carbopol ® 974P NF 
polymer in pH=5.8 bufferwhich attributed to polymer relaxation followed by diffusion of 
drug from surface ofthe tablet. This is due to strong entanglement of polymer molecules 
which delays movement of drug molecules from interior of polymer mass toward the 
surface. 
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Bulut-Oner., et al., (1989) showed that the release of Isoniazid (a water soluble 
drug) from carbomer tablets was faster in simulated gastric fluid and prolonged drug 
release in simulated intestinal fluid releasing 50 % of drug in seven hours. 
Parojcic., et al., (2004) evaluated the rate ofdrug release from Acetaminophen 
tablets containing Carbopol ® polymer matrices in different buffered and unbuffered 
media, the results showed that most rapiddrug release was observed in unbuffered 
0.1N HCI, where as drug release from phosphate buffers medium (pH=5.8, 6.8) showed 
slower rate of drug released 60 – 70 % for a period of 8 hours. 
Tatavarti., et al., (2004) reported that the incorporation of Carbopol ® 71G NF 
polymer in matrix tablets resultedin enhanced release of drugin buffer pH 6.8. Verapamil 
HCl (solubility at pH=6.8 2.71 mg/ml) is used as model drug. The phenomenon was 
attributed to modulation of microenvironmental pH to acidic side and observed that 
there is an increased solubility of the active ingredients insidethe matrix which 
enhanced drug release. 
Draganoiu., et al., (2004) studied that the anionic nature of  Carbopol ® 
polymers that forms ionic complexes with cationic soluble drugs, which is advantageous 
for retarding drug release from the matrix. The release of Propranolol hydrochloride, a 
cationic drug with solubility over physiological range (220 mg/ml in 0.1N HCl and 254 
mg/ml in pH=7.4 phosphate buffer) was extended by incorporating Carbopol ® 71G NF 
polymer in matrix attributed to drug – polymer ionic complex formation. 
Khamanga and Walker., (2005) reported that when Carbopol ® 974P NF 
polymer was used in combinationwith other polymers, controlled-release performance 
can be enhanced as a result of interaction betweenthe polymers. Tablets prepared with 
the blends of HPMC (Methocel ® K100M) and Carbopol ® 974P NF polymer using 
Surelease ® E-7-19010 (ethyl cellulose) or Eudragit ® NE 30D as granulating agents 
sustained the drug release of Verapamil, better than when Carbopol ® 974P NF 
polymer or Eudragit ® RS were used alone (in direct compression).The authors finally 
concluded that combination of Carbopol ® 974P NF and Methocel ® K100M 
producedsynergistic increase in viscosity due to stronger hydrogen bonding between 
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carbomer and HPMC resulting in stronger cross-link forming more rigid structurethrough 
which drug diffusion occurs. 
Samani., et al., (2003) evaluated the effect of polymer blends on in vitro release 
profile of diclofenacsodium. The author concluded that when an appropriate blend of 
carbomer and HPMC was used, the drug release was moreuniform, fluctuations were 
diminished and kinetics well fitted to zero order. They also concluded thatwith blend of 
polymersit was possible to reduce total amounts of polymer in formulation, thus 
reducing the size and weight of tablets. 
Perez-Marcos., et al., (1996) investigated the release profile of Propranolol 
hydrochloride tablets containing Carbopol ® 974P NF polymer and HPMC K4M  in 
various media such as 0.1N HCl or phosphate buffer at pH 4.5 or pH 7.5. At buffer pH 
7.5, synergistic interaction of two polymers was observed, thus contributing to matrix 
integrity and controls drug release. 
Sharma., et al., (2004) investigated the combination of Carbopol ® 971P NF and 
hydroxypropyl cellulose in sustained-release portion of Nitrofurantoin controlled-release 
dosage form, which alsohad an immediate release portion. 
Singh and Ahuja (2002) formulated Diltiazem controlled-release buccoadhesive 
hydrophilic matrices with varying amount of carbomer and HPMC. Suitable 
combinations of two polymers gave adequate bioadhesive strength and drug release for 
prolonged period. Bioadhesive strength varied linearly with varying amount of each 
polymer. Drug release pattern for all combinations were found to be non-fickian, 
approaching zero-order kinetics. The values of permeation coefficient tends tovary non-
linearly depicting possible interaction between  two polymers. 
Kenneth chibuzor., et al., (2013)[73]studied the formation of interpolyelectrolyte 
complexes (IPECs), formed between Eudragit RL100 (EL) and chitosan (CS) by wet 
granulation method were evaluatedfor oral CTDDSs for ibuprofen (IBF). The results 
showed that tablets formed by IPECs shows pH-dependent swelling properties and 
prolonged the in vitro release of IBF from the tablets. An electrostatic interaction 
between the carbonyl (–CO–) group of Eudragit and amino (–NH3 
+) group of Chitosan. 
Tablet formulated with IPECs was capable of preventing drug release. Kinetic analysis 
of drug release profiles showed that the systems predominantly released IBF in a zero-
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order manner. IPECs based formulations can be successfully for colon-targeted delivery 
of IBF in the treatment of IBDs. 
Mustafin., et al., (2005) [74] studied the swelling behavior of potential polymeric 
carriers which can be used as controlled release. They evaluated the swelling behavior 
of polycomplex matrices made from CS and EL 100 in simulated gastro-intestinal tract 
(GIT) pH 1.2 and in pH 6.8 medium. According to specifications of Degussa, dissolution 
of EL depends on copolymer structure and is regulated by the ratio between methyl 
methacrylate or ethyl acrylate and methacrylic acid. The swelling behavior of IPECs 
films is completely different from normal matrix systems. In these systems, the factor 
responsible for swelling is the electrostatic repulsion of free ionized amino groups. In 
case of IPEC made up of CS : EL 2 : 3 ratio, the degree of swelling was 150% at pH 
1.2,and then two-fold increase in swelling at pH 6.8 could be observed. 
Asghar LF., et al., (2016)[75] investigated the effect of incorporating pH-
responsive polymers Eudragit (L100 or S100) in matrix bases of hydrophilic polymers 
like polycarbophil and carbopol to design controlled release formulations with sigmoidal 
release profile to target the dosage form to colon. Matrix tablets were prepared by wet 
granulation technique using indomethacin as model drug. The gastrointestinal (GI) 
transit of selected formulations was also investigated in human subjects using gamma 
scintigraphy. In vitro release studies, showed 10-15% drug release in 6 h followed by 
controlled release for next 8-10 h in simulated GI fluid pH (without enzymes). The 
presence of Eudragit L (alkaline soluble polymer) in hydrophilic matrix base retarded the 
rate of swelling in acidic to weakly acidic pH, but in alkaline pH, enhancement in drug 
release rate of 80-90% release in 14 h was observed due to dissolution of EudragitL 
from matrix base resulting in porous matrix structure. In vivo gamma scintigraphystudies 
in healthy human subjects proved that the formulations had acceptable matrix strength 
to withstandcolonic transit. The mean colonic residence time varied between 15 and 19 
h. such matrix systems have application as pH dependent and time dependent release 
systems. 
Monica RP Roa., et al., [76] studied the mucoadhesive properties of HPMC and 
carbopol in combination  in matrix tablets .The formulations containing carbopol-HPMC 
combinations were found to have uniform thickness, weight, drug content and adequate 
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mucoadhesive strength and swelling index. Higher swelling index of Carbopol-HPMC 
matrix is relatively due to higher hydrophilicity of carbopol.  
Mishra S.K., et al.,[77]developed once daily controlled release matrix tablets of 
Tramadol Hcl. Controlled release matrix tablets of Eudragit RS-100 and Carbopol 934P 
were formulated and showed satisfactory controlled release of drug for 24hours with 
maximum release of 95.73 % 
Kim., et al.,used anionic hydrogels as delivery carriers due to their pH-
responsive swelling behavior. The dynamicswelling behavior of poly(methacrylic acid-
co-methacryloxyethylglucoside) and poly(methacrylic acid-g-ethylene glycol) hydrogels 
wasinvestigated to determine the mechanism of water transport throughthese anionic 
hydrogels. Mechanism of water transport was significantly affectedby pH of medium and 
became more relaxation controlled in medium of pH 7.0. 
Cilurzo., et al.,developedlow swelling mucoadhesive dosage forms based on 
methacrylic copolymers of Eudragit L100 and Eudragit S100. The adhesion properties 
of these materials, measuredby texture analyzer, were similar to Carbopol 934P. When 
these polymers are used in combination they promote adequate bioadhesive strength 
with good patient compliance due to their low swelling properties. 
Bravo., et al.,(2004) [78] evaluated therelease behavior of diclofenac sodium 
from swellable matrix tabletcontaining hydroxypropyl methylcellulose (HPMC) and 
Carbopolmade by wet granulation. Drug release was studied in terms of polymer 
content, polymer ratio, and pH. The overall releasewas found to be pH dependent and 
follows zero order kinetics. While a lowpH medium increases the drug release from 
carbopol, and retards drug release as pH increases. 
Parthiban et al., (2015) [79] developed mucoadhesive tablets of cephalexin 
monohydrate and studied the effect of Carbopol and HPMC K100M to achieve desired 
mucoadhesion and controlled release. The selected formulation FC2 exhibited 99.51% 
of drug release over a period of 24 hours with mucoadhesive strength found to be 95.04 
gm. Hence it has the ability to adhere on the mucosa for an extended period of time. 
Kinetic study follows zero order release and matches with Higuchi regression.  
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Prajapathi., et al., (2009)[80] developed floating matrix tablets of domperidone 
for prolong gastric residence time and thereby increasing drug bioavailability. The 
tablets were prepared by wet granulation method, using polymers such as 
hydroxypropylmethylcellulose K4M, carbopol 934P, and sodium alginate, alone and in 
combination. Tablets were evaluated for in vitro release study  and was found to prolong 
the drug release for a period of 24 hours. Release mechanism followed linear 
regression analysis. Carbopol loading showed negative effect on floating properties but 
were found helpful to control the release rate of drug. 
 
Literature pertaining to salbutamol sulphate: 
Shahnooshijavad F., et al., (2014)[81] developed bucco adhesive tablets of 
salbutamol sulphate using bioadhesive polymers like carbopol 934P,Hydroxy  Propyl  
Methyl  Cellulose  (HPMC  K4M) and present study demonstrated that salbutamol 
sulphate can be successfully developed as buccal adhesive tablets and offers better 
route for oral drug delivery to by pass first pass metabolism. 
Venkateswaran., et al., (2013)[82] formulated an Extended-Release (ER) tablets 
of Albuterol Sulphate which is simple in design and cost effective to patients. Matrix 
tablets were prepared by wet granulation process using Methocel K100M CR as release 
rate controlling polymer. The tablets were coated with Opadry Clear YS-1-7006 followed 
by 4% coating with ethyl cellulose to  prevent initial burst release from matrix tablets. 
The drug release rate of 8 hours was achieved and comparable to marketed product of 
VOSPIRE®  follows Higuchi‟s model of drug release kinetics indicating fickian diffusion. 
Zahirul., et al., (1999)[83] stated that Eudragit L100 and Eudragit S100 which 
dissolves at pH 6.0, and 7.0,respectively, do not dissolve in stomach pH due to 
hydrogen bondingbetween hydroxyl groups of carboxylic moietyand carbonyl oxygen of 
ester groups in polymermolecules. Hence, they dissolves in colon due to ionization of 
their carboxyl functional groups and releases the drug. He also stated that by alteric 
polymer characteristics (using combination of polymers in varying ratio) drug delivery 
can be targeted at specified site in GIT.    
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Threveenchalla., et al., (2011)[84] stated that in comparison to other region of 
GIT,movement of material through the colon is slow. Total time required totransit tends 
to be highly variable and influenced by number offactors such as diet, stress, diseased 
condition and drugs. The colonic transit time ranges from 20 to 30 hours, and can be 
increase in presence of active disease upto 50 to 70 hours. Longer residence time and 
contact of dosage formwith micro flora in colon govern the release andabsorption of 
drug from its dosage form. 
Rana., et al., (2013) [85] stated that intestinal-colonic transit time influences the 
performance of CDDS and colonic bioavailability of drugs. Transit times was also 
influenced by colonic disease and the study showed that in patients with IBD, the 
orocecal transit time was delayed. 
Sarfaraz MD., et al., (2013)[86] developed immediate release solid dosage form 
of salbutamol sulphate. Immediate release dosage forms are fast growing drug delivery 
systems that improve the onset of action of drugs. The attempt was for the selection of 
superdisintegrants like croscarmellose sodium, crospovidone and sodium starch 
glycolate in different concentrations (2.5 – 7.5%w/w). Tablets were evaluated for their 
disintegration behavior. Microcrystalline cellulose andlactose were used as diluents. 
The tablets were prepared by direct compression method and evaluated for drug 
release. Formulation containing 7.5 % of croscarmellose sodium released 99.26% and 
99.75% of drug in 12 minutes in pH 6.8 and pH 7.4 phosphate buffer. 
 
Literature pertaining to tablets in capsule system & enteric coating of capsules: 
Marilena Vlachou., (2017) [87]investigated the release behavior of multiple-unit 
modified release formulations (“tablets incapsule system”) of theophylline. Mono-layered 
and three-layered minitablets, filled into capsules, (flat mini tablets of 6.5 mm diameter, 
compressed at hardness of 8 – 10 kpa) were prepared using theophylline and dextran 
or pectin, as excipients.Their release behavior was compared with that of powder filled 
capsules and commercially available Theodur® 200 mg tablets. The Dissolution tests 
wasperformed in three different pH media (1.5, 7.4 and 6.0 pH) in presence and in 
absence of enzyme Pectinex® Ultra SP-L solution, which degrades polysaccharides. 
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Theresults indicated that the enteric-coated capsules showed no release of drugs in 
acidic media for a period of 2 hours. Dextran forms thicker gelled layer than pectinand 
therefore suitable forextended release formulation as “tablets in capsule” system. Drug 
is released from 3-layered mini tablets at slower rate compared to matrix mini tablets. 
Pectinex® Ultra SP-L, gives accurate dissolution results when used in dissolution 
medium, mimicking the large intestine/colon. 
Asnani., et al., (2013)[88] investigated the enteric-coated capsules which played 
importantrole in initial drug release retardation. In all cases, release of drug enteric 
coated capsules was found to be 0% in acidic medium for a period of 2 hours.Hence 
this Enteric coating capsule system can be used to modify their release and to achieve 
targeted release into other regions of GIT tract. 
Leopold., et al.,[89] studied the colonic pH in healthy individuals which is about 
6.4 to 7.0 pH but can drop to pH 2.3 to 4.7 in UC. Developed dexamethasone mini 
tablets coated with acid soluble polymers (eudragit E) and found that eudragit E rapidly 
dissolves in buffer at pH range of 2.0 to 5.0 which releases drug within in 10 to 50 min. 
Stubbs et al., studied the effect of dawn and dusk of dosage forms on mobility of 
colon. The results revealed that colonic transit of dosage form was delayed during sleep 
and larger dosage form. The study also showed that enteric coated capsule transited 
faster compared to enteric coated tablets and smaller dosage forms (dispersed particles 
or pellets). 
 
Literature pertaining to relationship between gut and lung: 
Seham Ahmed ali., et al., (2010)[90] investigated that significantly larger 
population (74.1%) of asthmatics had IBS. Higher proportion of females with IBS were 
observed (61.54%). Patients with known IBS 87% cases using inhalers, 13% with 
additional oral theophylline. As 66.6% cases, had IBS with relatively short duration of 
asthma. Predominant symptoms of IBS were found in asthmatics (64.8%). This study 
relatively confirmed that IBS is significantly higher in asthmatic patients. This in turn 
might be addressed in treatment of asthma, for better health care. The link in the 
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pathogenesis between asthma and IBS needs further studies to document the role of 
smooth muscle dysfunction. 
Roussos., et al., (2003) [91] reported excess prevalence of bronchial hyper-
responsiveness has been shown among patients with IBS (inflammatory bowel 
syndrome). Colonic inflammation was also investigated in asthmatic patient. Hence, 
reveals that both conditions coexist and they are related. Further to explore this 
association, studies have been conducted among asthma patients for IBS, and among 
IBS patients for asthma. They evaluated 150 patients with asthma, 130 patients with 
other pulmonary disorders and 120 healthy subjects. They final found that patients with 
bronchial asthma have an increased prevalence of IBS. An association of 
gastrointestinal symptoms like IBS in asthma has been reported in large case-control 
study conducted by Nick Powell. 
White., et al., (1991)[92] reported an increased prevalence of bronchial hyper-
responsiveness in IBS patients. To support his study, Yazar et al., found that there is 
anhigher rate of asthma symptoms in IBS patients and speculated that gastrointestinal 
system and respiratory system may reflex common symptoms. 
Kennedy et al., (1998)[93] found that IBS, GERD and symptomatic bronchial 
hyper-reactivity occur more frequently in asthmatics and vice versa and these 
conditions are independently associated with each other. To support his study, 
BabakAmra et al., reported similar observations that symptoms of IBS and asthma 
occur more frequently together and are independently associated with each other. 
Panicker., et al., (2008)[94] conducted study in larger population of women and 
reported that IBS was more common in asthmatic women. Higher prevalence of IBS 
among asthmatic women is well documented. Stress, anxiety and psychosomatic 
factors were implicated in asthmatics and IBS patients, and these may also influence 
the pathogenesis of IBS in asthma.  
Ekici., et al.,(2005) [95] compared two groups of asthmatic patients ageing  >60 
and < 60 years with age-matched controls. The prevalence of IBS was high among 
asthmatics with age <60 years and this observation supports that most of the asthma 
patients with IBS (68.4%) were in age group of 31-50 years. This finding correlates the 
relationship between asthmatics and inflammation in colon. 
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Lodi et al., (1997)[96] stated that gastrointestinal symptoms might indicate 
common pathology of smooth muscle dysfunction in asthma and IBS which involves 
generalized disorders of bronchial, gastro-intestinal and other smooth muscles. In 
asthmatics with GERD, there is an evidence of primary autonomic dysfunction with 
hyper-vagal responsiveness. 
Jan Fallingborg., et al.,[97] measured Intraluminal gastrointestinal pH using 
radiotelemetry capsules and its location was determined by fluoroscopy. pH levels were 
normal in stomach and small intestine but very low pH levels (2.3, 2.9, and 3.4 pH) were 
found in proximal parts of colon. Increased fecal concentrations of lactate occurs in 
active disease. The study demonstrated that very low intraluminal pH levels were found 
in colon. He also stated that this might be an indicator of severe activity of the disease. 
Babakamra., (2003)[98] conducted study at iran in 4762 subjects with 86.7% 
response showedprevalence rates of IBS in asthmatics. Logistic regression showed 
independent associations between IBS and most asthma symptom categories.  
Brassard paul., et al.,(2014) [99]resent study published in the European 
Respiratory Journal, that researchers found an increased rate of inflammatory bowel 
disease among asthmatics and COPD patients. The study involves data collected from 
health records of 136,178 people with asthma and 143,904 people with COPD.  The 
result concluded that, compared to general population, people with asthma had 27% 
higher rate of ulcerative colitis where as COPD patients had 55% higher rate of Crohn’s 
disease.  
Hauptmann., et al., (1998) [100] The median gastric pH values in patient with 
Crohn’s disease showed an average pH value of 2.4 (range 1.5–4.1 pH); in ulcerative 
colitis an average pH value of 1.95(range 1.55–4.4 pH) were significantly higher than 
those observed in the controls (1.55, range 0.95–2.6). In small bowel and in colonic 
segments, all pH values of colonic disease were comparable with controls. Patients with 
active disease had comparable gastrointestinal pH values to patients in remission. 
Tzanakis N., et al., (1998)[101] reported that, in patients with inflammatory 
bowel disease (IBD), the airways are involved with number of clinical manifestations. 
LITERATURE REVIEW 
Department of pharmaceutics                                                                        J.K.K.Nattraja college of pharmacy  35 
The study investigated the function of the small airways in IBD. 30 patients with IBD, 12 
with Crohn's disease and 18 with ulcerative colitis, were studied and compared with a 
control group. Maximal expiratory flow-volume curves were performed. The differences 
of flows at 50% of FVC and volume of equal flows indicated as small airways function. 
In addition, spirometry, lung volumes, and diffusing capacity were measured. The result 
was significantly greater in patients with either CD or UC than in control subjects. 
Reduction in TL(CO), was noticed in active stage of the disease in both groups of 
patients. This indicates that lung parenchyma is also involved in active IBD.  
 Songur., et al., [102] studied pulmonary function abnormality was present in 21 
out of 36 IBD patients. In IBD patients, DLCO were significantly lower, but RV/TLC was 
significantly higher than those of the controls. HRCT revealed air trapping, fibrosis, 
emphysema, bronchiectasis and alveolitis in 19 patients. About 80% of patients with 
pulmonary involvement had active bowel disease. Hence concluded, Pulmonary 
involvement is common in patients with IBD. 
Ekbom A., et al., (2008) [103] investigated the occurrence of IBD among COPD 
patients, indicating common inflammatory pathways and shared vulnerability on genetic 
basis. Investigational study was designed as population-based cohort study. Peoples 
with COPD from 1987 to 2002 were identified in Swedish Inpatient Register (n=180,239) 
which is compared with discharges involving diagnosis of UC or CD. The Hazard ratios 
(HR) for IBD were determined by Cox proportional hazards regression analysis. COPD 
patients had a significantly higher risk of both UC and CD. Finally,results suggested that 
COPD and IBD may have inflammatory pathways in common, which may include 
genetic variants of genes predisposing for disease. 
Keely S., et al., (2012) [104] stated that COPD and IBDs are chronic 
inflammatory diseases of mucosal tissues that affect respiratory and gastrointestinal 
tracts. They share many similarities in epidemiological and clinical characteristics, as 
well as in inflammatory pathologies.  
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Ceyhan BB., et al., (2003) [105]investigated the prevalence of abnormal 
pulmonary function tests, BHR and atopic status in patients with IBD. 30 patients with 
IBD (19 with ulcerative colitis and 11 with Crohn's disease) and 16 controls without any 
GI disease were included. Patients were questioned  forpulmonary and allergic 
symptoms.Lung function tests, BHR, skin prick test positivity, peripheral eosinophilia 
and serum IgE levels were evaluated and compared with control subjects.IBD patients 
had significantly more associated respiratory symptoms in comparison with controls. 
Previous diagnosis of asthma and drug treatment were noted in 10% IBD patients. 
Allergic symptoms, respiratory symptoms, abnormal lung function tests and skin prick 
test positivity were common among IBD patients in comparison with controls. 
 
Colby et al., (2007)[106] reported that bronchial hyper-reactivity occurred 48% of 
patients with UC and CD, even in absence of any clinical, radiological and functional 
evidence of airway disease. Bronchial hyper-reactivity occurred in 71% of CD subjects. 
Exaggerated immune response is trigerred by allergens, which can aggravate an 
immediately atopic allergic reaction. Combination of histological examination andHRCT 
revealed multiple centers of pulmonary inflammatory responses, which share similar 
characteristics with atopic allergic reactions.Lungsmay duplicates the “social” 
inflammatory reaction associated with intestine. 
Abrahamsson TR et al, (2014) [107] stated that Chronic lung disorders such as 
asthma and chronic obstructive pulmonary disease (COPD) exhibit intestinal disease 
manifestation. Respiratory infections are often accompanied by intestinal symptoms. 
 
Literatures pertaining to 72 hours drug delivery: 
Javid Ali., et al., (2013)[108] Studied the drug loading and Drug Release 
Behavior ofPoly (N-Vinyl-2-Pyrrolidone) Gel evaluated using ketotifen as model drugs. 
The hydrogel was cut into small discs (3 mm thickness and diameter) and immersed in 
the solutions of the ketotifen for three days. The hydrogel immersed in 0.1 N HCl and 
phosphate buffers (pH 6.8) showed 31.82 % and 29.78% loading of ketotifen. Under 
acidic condition (0.1 N Hcl) only 10 % of drug was released in about 72 hours 
andfollowed Higuchi model and release follows Fickian diffusion. 
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Sreenivas SA., et al., [109] Formulated cefuroxime axetilmucoadhesive matrix 
tablets and microspheres exhibit prolonged controlled drug release.The cumulative % 
drug release of cefuroxime axetil matrix tablets was found to be 89.93% at the end of 72 
hours whereas themicrospheres released 96.15% of drugs at the end of 72 hours. 
Jaymin shah., et al., [110] developed an extended-release formulation of 
bupivacainethat after a single-dose administration could provide prolonged post surgery 
local analgesia up to 72 hours. SABER-Bupivacaine contains 132 mg bupivacaine 
base/mL. SABER-Bupivacaine is a sustained-release formulationin a controlled-release 
matrixcomposed of esterified sugar derivative such as sucrose acetate isobutyrate 
(SAIB) and benzyl alcohol, administered together as solution. 
Omwoyo WN., et al., (2014) [111] designed primaquine (PQ)-loaded solid lipid 
nanoparticles (SLNs) (PQ-SLNs) as potential drug-delivery system. PQ-SLNs were 
prepared by modified solvent emulsification evaporation method (w/o/w) double 
emulsion. A spherical morphology of PQ-SLNs was seen in scanning electron 
microscope. In vitro drug release showed steady drug release over a period of 72 hours. 
DSC thermograms demonstrated the presence of drug-loaded nanoparticles suggesting 
stability of drugs in prepared formulations.  
Das., et al,(2012) developed formulation based on nanotechnology which 
overcomes the poor bioavailability of drugs in posterior chamber of eyescompared to 
conventional ophthalmic dosage forms.nanoparticles based on albumin / xanthum gum 
prepared by coacervation and loaded with acetyl salicylic acid produced drug release in 
a sustained manner releasing 90 % of drugs over a period of 72 hours. 
 
Literature pertaining to mucoadhesion: 
Shweta Agarwal., et al.,(2015) studied different polymer concentration and its 
effect on drug release and as well as mucoadhesive gastro retentive properties. HPMC 
has mucoadhesive properties and also gives good controlled release. Since, it is a non-
ionic polymer, its mucoadhesion is independent of pH of the medium. The 
mucoadhesive property of HPMC is attributed to hydrogen bond formation with mucus 
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components in intestine. It possess large number of hydroxyl bonds which are 
responsible for adhesion. 
Banerjee., et al., compared the adhesion force between eudragit E po– porcine 
intestine and carbopol -porcine intestine. To measure the Mucoadhesive strength, the 
device was incubated in pH 7.4 phosphate buffer for 30 min in solution at 37ₒ Calong 
with porcine intestine. The force required to completely detach the device from the 
intestine was noted. Eudragit E po (24.2 ± 0.95 mN ) possess higher mucoadhesive 
force compared to carbopol devices (17.5 ± 1.3 mN) .  
Ashwini madgukar., et al., (2008)[112] Formulated itraconazole sustained 
release mucoadhesive tablets using Eudragit E po spray dried and incorporated into 
hydrophilic matrix of carbopol 934 P and methocel k4M (HPMC). Finally reported that 
fairly regulated release profiles and Increased mucoadhesion strength was found 
polymers used in combination. 
Robinson and bologna reported that polycarbophil (carbomer ) has the ability to adhere 
to mucus membrane for 3 to 4 days and provides excellent drug delivery of 
progesterone. 
 
Literature pertaining to interpolyelectrolyte complex: 
Wasfy M., et al., (2015) [113] investigated the ability of polymer to modify the 
release rate of paracetamol (water soluble drug) by the influence of eudragit E 100 and 
carbopol 971 P NF prepared by direct compression method. Eudragit E in combination 
with carbopol 971 P NF was capable of sustaining the release properties of water 
soluble drugs. They do no dissolve in aqueous environment but swells to form 3-D 
hydrophilic gel structure called interpolyelectrolyte complex. At lower pH values, 
polymers are not fully swollen and drug is released faster from the matrix. At higher pH 
values, shows maximum swelling due to ionization of carboxylic acid groups, resulting in 
fewer/smaller regions of microviscosity, thus prolonging the drug release. 
 
Kuldeepmalodia., et al., (2013) [114] developed extended release matrix tablets 
of Salbutamol sulphate, for the treatment of Chronic Obstructive Pulmonary Disease 
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(COPD). The matrix tablets were prepared by direct compression method using 
hydroxyl propyl methyl cellulose (HPMC K100M)in varying ratios. In vitro dissolution 
study was carried out by using type II dissolution apparatus for a period of 24 hours and 
F7 shows 96.49% of drug release at the end and hence capableof providing extended 
drug release. 
 
Sabitha P., et al., (2010) [115] designed Chitosan coated alginate microcapsules 
as oral sustained delivery carriers for antitubercular drugs (rifampicin, isoniazide, 
pyrazinamide) to reduce dosing frequency and to improve patient compliance in 
management of tuberculosis (TB).Ionotropic/external gelation method is used to 
encapsulate anti-tuberculosis drugs (ATDs) within Alginate–chitosan microparticles.The 
formulation was designed in the ratio of 1:2:2 (drug: sodium alginate: chitosan). By In-
vitro drug release studies, carried out in pH 1.2 (2 hour) and then in pH 7.4 (72 hours), 
microcapsules exhibited sustained release of drugs 95.33 % (isoniazide) , 96.46 % 
(rifampicin) and 97.27 % (isoniazide) over a period of 72 hours. 
 
Sreenivas SA., et al., (2009) [116] designed of the formulation containing 
cefuroxime axetil mucoadhesive matrix tablets and microspheres using thiolated 
chitosan which exhibited controlled drug release for prolonged period.The cumulative 
drug release of cefuroxime axetil from matrix tablet was about 89.93% at the end of 72 
hours while microspheres released 96.15% at the end of 72 hours. 
 
Omwoyo WN., et al., (2014) [117] formulated dosage form containing 
primaquine which is an antimalarial drug entrapped into SLNs and exhibited sustained 
release of drug over a period of 72 hours and suppression of 94 % of plasmodium in 
mouse was achieved by SLNs.  
 
Jagdishbidada., et al., (2011) [118] developed Ranolazine (anti-anginal drugs) 
matrix tablets containing different ratios of Carbopol 971 P(hydrophilic & pH dependent ) 
and ethylcellulose (Ethocel N20/N50), water-insoluble and pH-independentpolymers. in 
vitro drug release was studied using USP Type II (Paddle) apparatus. The release 
kinetics indicates, drug release from matrix tablets depends on drug diffusion and 
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polymer relaxation. Hence , followed non-Fickian oranomalous release. The developed 
ER matrix tablets of Ranolazine provided drug release up to 12 hours. 
 
Sobhitarani., et al., (2014)[119] formulated enteric coated capsules for site 
specific drug delivery of Satranidazole to colon. The capsules containing carbopol and 
drug is coated with HPMC & Eudragit S-100. Theenteric coated capsules shell was 
capable of delaying drug release for a period of 3-5 h in simulated upper gastrointestinal 
pH. 
 
Literature pertaining to mucoadhesive colon targeting: 
Ramesh Reddy., et al., (2015) [120] developed mucoadhesive tablets using 
PVP and Pectin inter polymer complexes containing Prednisolone. Mucoadhesive 
tables were prepared by direct compression method and enteric coated with polymers 
to target into colon.  
 
Literatures pertaining to mucoadhesive tablets in capsule system: 
Tapan kumar panda., et al., (2016) [121]formulated once daily multiple unit 
mucoadhesive sustain release (SR) mini tablets filled into capsule. The matrix tablets 
consists of bosentan, gelucire, hydroxypropyl methyl cellulose (HPMCK4M), sodium 
carboxymethyl cellulose (NaCMC) and chitosan in various proportions to sustain drug 
release for a period of 24 h. The release of bosentan from gelucire based SR mini 
tablets extended drug release over a period of 24 h with an initial burst release of  32 %. 
Incorporation of Na+ CMC, HPMCK4M and chitosan into the mini tablets controlled 
initial burst release and produced adequate mucoadhesion. 
Lu Z., et al.,(2010)[122] studied interpolyelectrolyte complex between chitosan 
and polycarbophil and its matrix forming ability to control the release of water-soluble 
drugs. Swelling, erosion, and drug release performance of matrix tablets containing 
chitosan-polycarbophil complex was compared with matrix tablets containing HPMC 
and mixture of chitosan and polycarbophil. IPECs complex showed good swelling, low 
erosion and slower drug release compared to polymeric matrix approaching zero-order 
kinetics. The mechanism of drug release followed diffusion from swollen systems. 
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BhusnureOmprkash G., et al., (2016)[123] investigated extended release tablet 
forming interpolyelectrolyte complex (IPEC) containing Eudragit E100 (cationic polymer) 
and Eudragit L100 (anionic polymer) polymers. Controlled drug delivery is can be 
achieved at location determined by needs of body or disease state over a specified 
period of time. The network formed between Eudragit E100 and L100 polymers had 
been coupled satisfactorily with controlled release of dugs. The results concluded that 
wetting forms interpolyelectrolyte complex (IPEC) and is suitable to formulate controlled 
release dosage form of Desvenlafaxine succinate. 
Rosalia Rodriguez., et al., (2001) [124] reported the influence of structural 
properties and rheological behavior of Carbopol polymer. The results showed pH-
sensitivity of Carbopol when used in the formulation. The rheological consistency of 
carbopol polymer increased dramatically when pH changed from 4.5 to 7.4 and vise 
versa. This structural property can be used to design pharmaceuticals with gelling 
system. 
Sabar MH., et al., [125] investigatedthe formation of polyelectrolyte complex 
(PECs) using sustained release oral tablet of ketoprofen composed of chitosan (cationic 
polymer) and carbopol (anionic polymer).Using FT-IR spectra formation of 
Polyelectrolyte complex were analysed and found due to electrostatic interaction 
between the carboxyl group of Carbopol and amine group of Chitosan at pH5. Different 
factors influencing swelling index and release rate were studied and results showed that 
carbopol retarded drug release and also concluded pH dependent drug release 
characteristics of PECs complex containing carbopol.  
Mustafin RI., (2011)[126] studied interpolyelectrolyte complex (IPEC) between 
Carbomer 940 and Eudragit® EPO using polycomplex matrix system (PMS) containing 
diclofenac sodium. Evaluation of pharmacokinetic parameters of PMS matrix revealed a 
close relationship with in vitro/in vivo correlation. By enteric coating of PMS matrix, it 
can be targeted to deliver the drug in colon region.  
Hemant., et al.,[127] formulated theophylline extended release matrix tablets 
containing pH sensitive hydrogels like CMC and carbopol 934 which shows high 
swelling in basic pH and thus can delay the drug release in intestinal tract. In 
vivo studies exhibited controlled release of theophylline from hydrogel formulation for 
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prolonged period compared to marketed sustained release formulation. The study also 
stated that pH-sensitive hydrogel can be successfully used for extended release of 
theophylline in intestine in treating nocturnal asthma symptoms. 
 Parojcic J., et al.,[128] studied the pH dependent nature of Carbopol®971P NF 
which is a hydrophilic lightly cross-linked polymer of Carbomer series. Unlike other 
hydrophilic polymers, Carbopol® polymers do not dissolve, but swells in aqueous 
environments to forms 3-D gel structure. Due to anionic nature of Carbopol® polymers, 
drug release from matrices is pH-dependent. At low pH values, the drug is released 
faster. As pH increases, ionizationof carboxylic acid groups causes maximum 
swelling,resulting in fewer and smaller regions of microviscosity causing prolonged drug  
release. 
Rouslan., et al.,[129] studied Eudragit®E100 based interpolyelectrolyte complex 
that shows solubility and drug release in weakly acidic buffer solutions up to pH 
5.Presence of Eudragit®E100 modifies the swelling behavior of accompanying 
hydrophilic polymer. The pKa of eudragit E 100 is 7.0–7.3; hence it is partially 
protonated at pH close to 5, hence an electrostatic interaction with anotherionized 
polymers could contribute to drug release. 
Lu., et al. (2007) [130] investigatedthe formation of separate chemical entity 
which is not just a simple mixture between chitosan and polycarbophil (oppositely 
charged polymers) was confirmedby differential scanning calorimetry. And the formation 
of interactions betweenthese two polymers was further confirmed byFT-IR 
spectroscopy. From FT-IR spectra, it is clear that a peak appeared at 1561 cm−1which 
maybe due to carboxylate groups of polycarbophil that formes ionic bond with the 
protonated amino groups of chitosan resulting in formation of interpolyelectrolyte 
complex. This was also studied in Eudragit E and Eudragit L (Moustafine., et al., 2005) 
where ionic bond is the primary binding force for formation of IPECcomplex. 
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AIM & OBJECTIVES 
 
The main  aim of the project was to develop a delivery system that claims the 
futuristic approach in the field of pharmaceutical science based on bioresponsiveness 
and timed delivery of drugs into the body. 
 
 The objective of the present study is to develop the delivery system and to 
evaluate its delivery profile based on triggered release, timed release and site targeting.  
 
           Salbutamol sulphate was chosen as the model drug for the present study to 
designa dosage form for treatment of asthma. Carbopol 971 P and eudragit E was 
chosen as key ingredients in the formulation to attain goal in this study.  
 
           The development of tablets-filled-capsule systems offer benefits for the production 
of sustained release multiple unit dosage form. This system has specific advantages over 
conventional single unit dosage forms. Advantages of multiple unit dosage forms such as 
Mini-tablet-in capsule systems include a lower risk of dose dumping, less inter and intra 
such variability and a high degree of dispersion in the digestive tract, thus minimizing the 
risks of high local drug concentrations. 
 
Oral drug delivery represents by far the most common & convenient way of drug 
delivery. The gastro-Intestinal tract is still the route of choice for drug administration & 
absorption. 
 
Chronopharmaceutics is a branch of pharmaceutics devoted to design and 
evaluation of drug delivery system that release a bioactive agent at a rhythm that ideally 
matches the biological requirement of a given disease therapy. Ideally 
chronopharmaceutical drug delivery system (ChrDDS) should embody time controlled 
and site specific drug delivery system. 
 
 A Bioresponsive drug delivery system is necessary since it works on the 
mechanisms capable of responding to physiological variations in the body, in order to 
synchronize drug- release profiles with changing physiological conditions. 
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PLAN OF WORK 
 
1. literatue survey 
2. procurement of drug , polymers and other excipients 
3. Preformulation studies of mucoadhesive mini-tablets system (controlled release) by 
using different polymers 
4. evaluation of preliminary batches of mucoadhesive mini tablets system (controlled 
release) 
5. formulation of mucoadhesive mini tablets system (controlled release) using 
combination of polymers 
6. evaluation of mucoadhesive mini tablets system (controlled release) 
A) Physical characterization of preliminary and Finalmucoadhesive mini tablets  
system (controlled release) 
a) weight variation 
b)Friability 
C)Hardness 
d)Thickness 
e) drug content 
B) In-vitro swelling study 
C) surface pH determination 
D) In-vitro bioadhesion study 
E) In-vitro drug release study 
F) In-Vitro permeation study 
7. selection of capsule shell size for filling of mini tablets system (controlled release). 
 
 
8. selection of polymers and other excipients for enteric coating (colon targeting) of mini 
tablets filled capsule system. 
9. enteric coating (colon targeting) of mini tablets filled capsule system. 
10. In-Vitro evaluation of enteric coated capsule system for colon targetting. 
11.Selection and procurement of excipients for formulation of Immediate release tablets 
& pellets 
12. formulation of immediate release tablets & pellets. 
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13. evaluation of physical parameters of immediate release tablets. 
14. in-vitro drug release study of immediate release tablets. 
15. selection of capsule shell for filling of enteric coated capsule system and an 
immediate release tablets. 
16. Stability studies 
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DISEASE PROFILE 
 Asthma is common respiratory disease among adults and children whose 
prevalence is increasing worldwide; affecting 15 to 20 million Indians. Asthma leads to 
significant degrees of morbidity and mortality. It is characterized pathologically by 
lymphocytic and eosinophilic infiltration of the bronchial tree associated with airway 
narrowing. It is a syndrome characterized by symptoms such as (dyspnea, wheeze, 
chest tightness, and cough), airway dysfunction and airway inflammation with 
eosinophils and met achromatic cells [131].Causes of asthma include allergies, cold air, 
air pollutants, drugs, cigarette smoke, molds, exercise, and infections.  
 
Asthma attacks (rapid worsening of symptoms) typically occur in episodes. 
Scientists now believe that asthma attacks vary according to the time of day.  
 
The occurrence of asthma attacks is not random during day. Asthma symptoms 
frequently worse at night (nocturnal) for majority of asthma sufferers. The incidence of 
asthma attacks was more (100 times greater) during nighttime sleep, especially around 
4 a.m., than it was during the middle of the day [132]. 
 
CIRCADIAN REGULATION: 
 
Nocturnal asthma is variable exacerbation of underlying asthma condition 
associated with increase in symptoms, need for medication, airway responsiveness, 
and worsening of lung function. These changes are related to sleep and circadian 
events (24 hours) taking place at day time (diurnal) and at night time (nocturnal). The 
function of circadian regulation is to impose temporal organization on physiological 
processes and behavior. Disorders in circadian regulation may provoke exaggeration of 
disease symptoms. 
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Circadian rhythms follows two principal features: they run freely in absence of 
temporal cues particularly in light-dark cycle and under normal environmental 
circumstances entrained to light dark cycle [133]. 
 
These features indicate a neural system that expresses and regulates circadian 
function which involves circadian pacemaker(s); photoreceptors and visual pathways 
that transduce photic information into a neural information and transmit it to the 
pacemakers which  output to the effector systems that expresses circadian function 
[134]. 
 
These effector systems then expresses physiological control mechanism over 
lung function and immunology. In asthma, there is a progressive increase in resistance 
across night, whether subjects is in sleep or not, the increase is much greater during 
sleep time [135].  
 
CIRCADIAN CHANGES IN PULMONARY FUNCTION: 
 
Normal and asthmatic subjects show circadian variation in pulmonary function as 
assessed by Spiro metric parameters such as forced expiratory volume(FEV1) and 
peak expiratory flow rate (PEFR), which lowest around 4 AM [136]. 
 
GUT- LUNG RELATIONSHIP 
Research suggest that there’s an apparent link between gut and the lungs. 
Scientist have come to realize that there is an increased rates of inflammatory bowel 
diseases in patients with asthma and COPD. 
Chronic lung disorders such as asthma, chronic obstructive pulmonary diseases 
(COPD), cystic fibrosis, all exhibit a component of intestinal disease manifestations and 
vice versa. 
Dr. talley sees relationship between the gut and lung, may be due to influx of 
cells called eosinophils. In his recent paper, he and his colleagues describe how 
patients with asthma and allergic rhinitis have abnormally high levels of eosinophils both 
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in their airways and in their large intestines. [137] Eosinophils are important immune 
system cells that are made in bone marrow and normally lines the mucous membrane in 
stomach, small intestine and colon. 
The main purpose of these cells is to defend against bugs and toxins. But in 
peoples with asthma , the eosinophilic response is exaggerated, and exposure to 
allergens can trigger an excess of these cells in both gut and lungs. 
Dr. talley said in an interview “I don’t think respiratory researchers have been 
terribly excited about gut problems, but I bet a lot of their asthma patients have gut 
problems if they ask them” 
Asthma patients who quite commonly suffer from gastroesophageal reflux 
disease (GERD) or more severe conditions in colon cause gut-lung overlapping and 
eosinophilic excess was found both in gut and in lung. 
Although eosinophils are normally protective in gut, but when in allergy, a glut in 
lungs and gastrointestinal tract reverses their function, causing damage to the mucous 
membranes. When this happens, the protective barrier in the gut is broken, allowing 
toxins to run into circulation causing inflammation. This increased leaky gut has been 
documented in asthma suffers. 
While respiratory symptoms wax and wane with the seasons, gastrointestinal 
symptoms may wind up becoming chronic. 
In the recent study published in the European respiratory journal, researches 
found an increased rate of inflammation in colon causing bowel diseases among 
patients with asthma and COPD. They finally concluded that peoples with asthma and 
COPD had a higher rate of colonic diseases [138]. 
Scientist believe that there is a connection between the lung and gut driven by 
number of factors including, 
1. Shared risk factors – including smoking and family history 
2. Prolonged inflammation- believed to be the root of many long term illnesses, 
including COPD and IBD 
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3. An abnormal immune system reaction to allergens and bacteria – in both 
respiratory and digestive tract. 
4. Similarities in the mucus secreting membrane- lining the gut and lungs. 
Pulmonary abnormalities, dysfunction or hyper responsiveness occurs in 
association with inflammatory bowel disease more frequently in colon. Emerging 
evidence suggests that subtle inflammation exist in colon among asthma patients and 
vice versa. Growing number of case reports shows that asthmatic patients develop 
rapidly progressive colonic inflammation such as IBD [139]. 
According to Chinese medicines, the lung and the intestine are pair of related 
organ systems (Biao-Li). IBD and COPD share many similarities in epidemiological and 
clinical characteristics, as well as in inflammatory pathology [140]. 
 
Figure 4: Related organ system 
In a population-based cohort study, patients with COPD had significantly higher 
risk of IBD. Exposure to air pollution is an important environmental factor that directly in 
association with both asthma and IBD [141]. 
Local mucosal inflammation in airways may also be responsible for intestinal 
inflammation and vice versa. In view of the above phenomena, the lungs and intestine 
mainly colon are a pair of interacting organ systems[142-145]. Colby et al reported that 
bronchial hyper-reactivity occurred in 84 % of patients with colonic diseases[106]. 
Bronchial hyper-reactivity occurred in 71% of children and adolescents with CD[146].  
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The epithelial cells are considered not only the frontier sentinels and barriers, but 
also the central participants in innate and adaptive immune responses during mucosal 
inflammation. The airway and gut epithelial cells upon activation release large quantities 
of proinflammatory cytokines, growth factors and chemokines that attract inflammatory 
cells to initiate and sustain the inflammatory reaction[147-150]. 
 
Lung may duplicate atopic inflammation of the bowel and vice versa. Combined 
HRCT and histological examination have shown that there are multiple centers of 
airway epithelial (including goblet cells) responses and mucoid secretion in IBD [151-
156].The interaction of lung and large intestine is mutually affected by internal and 
external relationships. It means that the lung diseases often have colon syndromes and 
colon diseases have lung syndromes [157-164]. Hence, Airways intrinsically accompany 
the main inflammation in the bowel and vice versa. 
 
MECHANISM INVOLVED IN GUT LUNG RELATIONSHIP 
Common physiology of the respiratory and gastrointestinal tracts 
 
Respiratory and gastrointestinal epithelia share common embryonic origin in 
primitive foregut [165,166] which may account for similar inflammatory and immune 
components of these organs that are the cause of the overlap in pathological changes 
in respiratory and intestinal mucosal diseases. 
Pattern recognition receptors: 
Pattern recognition receptors highly conserved proteins that are expressed by 
cells of innate immune system. They recognize components termed “pattern-associated 
molecular patterns” of cellular stress signals, and damaged tissues. when activated, 
they induce production and secretion of inflammatory mediators and signalling 
molecules.  
Two pattern recognition receptors families were involved in mucosal 
inflammatory response,    
1. cytoplasmic NOD family of receptors 
2. membrane-bound Toll-like receptor (TLR) family.[167-169] 
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Increases in prevalence of NOD2 single-nucleotide polymorphism (SNP) was 
found in COPD and in colonic diseases. This SNP causes conformational change 
leading to activation of nuclear factor-κB which enhance inflammatory cytokine 
response upon stimulation [170]. 
Defects in NOD2 signaling leads to impaired epithelial barrier function, increased 
IL-1β, overcompensating TLR2 response, and promotes increases in serum IL-12 in 
both lung and in colon [171]. 
This inflammatory response was driven by IL-1β secretion from macrophages 
and neutrophil recruitment to lung tissue and in colon.  
Smoke exposure study also drives TLR4 activation-dependent IL-8 production in 
monocyte-derived macrophages found in lung [172]. 
Inflammatory cytokine signalling results in increased TLR4 expression on 
macrophages from intestinal epithelium and lamina propria in colon [173,174]. 
Thus TLR4 activation have a common role in gut and lung resulting in 
hypersensitivity and exaggerated immune response in epithelial tissues and mucus 
lining of lung and intestine. 
 
Figure 5: Factors involved in Gut – Lung relationship 
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Protease regulation in Lung and colon reflection: 
There is evidence that mal-regulation of protease activity have a role in both 
COPD and IBD. Increased levels of proteases break down connective tissue 
components which have been identified in COPD & IBD patients and modeled in 
animals [175]. 
Increased level of epithelial and leukocyte MMP-2, MMP-9, and MMP-12 
associated with the pathogenesis of COPD and IBD, which contributes to “runaway 
remodelling” process [176,177]. 
 
Immune cell homing and systemic factors: 
 
Both COPD and IBD are considered as correlated systemic inflammatory 
diseases and peripheral lymphocytic activity may contribute to pathogenesis [178 -181]. 
 
 During inflammation, bronchus-associated lymphoid tissue regulates the 
lymphocyte trafficking from lung tissue through general circulation [182]. 
This is mirrored by gut-associated lymphoid tissue. Both lung and intestinal 
lymphocytes migrate to other mucosal sites as a part of common mucosal immune 
response [183]. This trafficking is responsible for extra-organ inflammation associated 
with COPD and IBD. 
Lymphocytes migrate through circulatory system in response to antigen 
exposure. They express unique homing receptors, which are specific for their target 
tissues. There is an evidence of abnormal function in peripheral lymphocytes that 
contribute to extrapulmonary disease in COPD patients. 
Sauleda et al., [184 showed increased cytochrome oxidase (CytOx) activity in 
circulating lymphocytes of COPD patients, which correlated with the study conducted by 
Salmi et al., [185] with increased CytOx in IBD. 
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Analysis of sputum of IBD patients showed increased CD4/CD8 T-cell ratio in the 
lung tissue[186]. This represents lymphocyte mis-homing involved in pulmonary 
manifestations of IBD. Hence there relationship exist between gut and the lung.  
IL-6 Plays role in acute phase response to inflammation and has been implicated 
in pathogenesis of both COPD [187,188] and IBD [189,190]. High levels of IL-6 and 
associated cytokines were identified in mucosa of both colon and lung in COPD 
patients. 
IL-13 contribute to COPD progression and mutations in IL-13 promote 
pathogenesis in IBD. This activates macrophages, which in turn causes further IL-13 
production.[191-196] This leads to STAT (signal-transducer and activator of 
transcription)6-dependent goblet cell hyperplasia, causing smooth muscle hyper-
responsiveness in airway and in colon. [197,198]. 
GUT LUNG RELATIONSHIP AND CHANGE IN COLONIC pH IN ASTHMA 
Intraluminal gastrointestinal pH was measured in patients. A radio-telemetry 
capsule was used and its location in GIT was determined by fluoroscopy. pH of the 
gastrointestinal tract was measured with small, pH sensitive, radiotransmitting capsule. 
The transmission frequency of the capsule is modulated by the pH of its surroundings 
and the signals from it were detected by a receiver. pH values were found normal in 
stomach and in small intestine. And low pH values were found in proximal part of colon 
in patients with IBD and respiratory diseases like asthma and COPD [199]. 
The colonic contents have longer residence time upto 5 days and the colonic 
mucosa is known to facilitate the absorption of several drugs, making this organ an ideal 
site for drug delivery. 
Colonic pH is typically 5.5 to 7.0 for healthy persons but can drop to 4.7 and less 
in patients with asthma and colonic diseases which shows changes during attack. This 
can be ideally used for triggering drug release in colon using pH sensitive polymer 
technology [199]. 
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OXIDATIVE STRESS IN ASTHMA 
Asthma is aninflammatory illness with bronchial hyper reactivity with increasing 
number of inflammatory cells such as eosinophils, macrophages and lymphocytes found 
in bronchoalveolar lavage fluid in asthmatic patients (Caramori and Papi, 2004).  
Measuring the exhaled levels of NO concentration provides useful noninvasive 
method to predict the bronchial hyper-responsiveness, airway obstruction and 
inflammation in asthma (Nogami, Shoji and Nishima, 2003 ). 
Epidemiologic studies shows release of large number of inflammatory mediators 
associated with activation of lgE molecules, basophils and mast cells which involves 
synthesis of several proinflammatory mediators such as interleukin (IL)-4 and IL-13 
(Schroederand MacGlashan, 1997). Histamine and leukotrienes are released from mast 
cells where as IL-4 and IL-13 are released from basophils. 
Role of oxidative stress as a potential contributor to pathophysiology of asthma 
has been well explored. 
An increased oxidative stress in asthma  patients is associated with increased 
amounts of reactive oxygen species (ROS) like superoxide radial, hydroxyl radical and 
hydrogen peroxide generated by several inflammatory, immune and structural cells of 
the airways(Rahman, 2002). ROS play an important role in modulation of airway 
inflammation. 
This concept is supported by the presence of high levels of ROS and oxidatively 
modified proteins in airways of asthma patients. 
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DRUG PROFILE 
SALBUTAMOL SULPHATE 
 Salbutamol sulphate is a short-acting, selective β2-adrenergic receptor agonist 
used in the treatment of bronchial asthma and chronic obstructive pulmonary disease 
(COPD). Salbutamol sulphate is a racemic mixture of R- and S- isomer. R- isomer has 
150 times greater affinity towards  β2 – receptors. 
Structural formula: 
 
 
Synonym   : Albuterol sulphate 
Chemical name :  1-(4-hydroxy-3-hydroxymethylphenyl)–2–(t-butylamino)-ethanol 
sulphate. 
Molecular weight  : 288.35 
Molecular formula  : C13H21NO3, H2SO4 
Description   : Odourless, slightly bitter in taste, white or almostwhite powder. 
Melting point  : 150 ºC 
Pharmacology :  
Mechanism of action: 
 Salbutamol stimulates β2-adrenergic receptors (predominant receptors in 
bronchial smooth muscles) of lungs. 
 Stimulation of β2-receptors causes activation of adenyl cyclase enzyme that 
forms cyclic adenosine-mono-phosphate (AMP) from adenosine-tri-phosphate (ATP). 
High level of cyclic AMP lowers intercellular ionic calcium concentrations which inturn  
relaxes bronchial smooth muscles and reduces airway resistence. 
 High level of cyclic AMP also inhibits the release of histamine, leukotriene 
(bronchoconstrictor mediators) from the mast cells in the airways. 
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Absorption: 
 On oral administration, approximately 50 % of salbutamol sulphate is absorbed 
from the intestinal tract with slower onset of action reaching peak concentration at about 
2 hours. Through inhalation, only 10 – 20 % of salbutamol reaches lungs and the rest 
stays in mouth, stomach or on apparatus. The duration of action of salbutamol is 4 to 6 
hours. 
Distribution: 
 Salbutamol is not bound to plasma proteins and does not cross blood brain 
barrier to any significant extent. Salbutamol cross placental barrier, evidenced by 
increase in heart rate of fetus.   
Metabolism: 
 Salbutamol is metabolized in liver by the process of conjugation with sulphate. 
Excretion: 
 Salbutamol is excreted primarily via urine. Approximately 50 % is excreted as 
metabolites via urine and about 30 % is excreted as unchanged salbutamol in urine and 
rest in feces.    
Dose:  
Oral Immediate-releasetablets: 
Initial dose: 2 mg or 4 mg orally three or four times a day. Dosage may be 
increased stepwise up to a maximum of 8 mg four times a day as tolerated (maximum 
of 32 mg/day). 
Extended-release tablets: 
Initial dose: 4 mg or 8 mg orally every 12 hours. The dosage can be increased 
stepwise under the control of physician to a maximum of 32 mg/day in divided doses 
(e.g., every 12 hours). 
Use in pregnancy: 
Salbutamol is pregnancy category C drugs. It can be used in pregnancy only if 
absolutely essential. 
Use in nursing mothers: 
No adverse effects have been reported in breast fed babies of mother receiving 
salbutamol sulphate. 
Pediatric dose: 
Not recommended in children below 2 years of age. 
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Precautions: 
To be used in caution in patients with hypertension, hyperthyroidism, diabetes 
mellitus, and cardiac arrhythmia. 
To be used in extreme caution with patients taking tricyclic antidepressant, 
monoamine oxidase inhibitors, thiazide diuretics. 
Overdose: 
Common symptoms include tremor, palpitation and tachycardia. It may also 
produce arrhythmia, seizures, fatigue, malaise, headache, dizziness and dry mouth. 
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EXCIPIENT PROFILE 
 
1. CARBOPOL 971 P 
 
 
 
 
 
 
 
 
Chemical name : Carboxy polymethelene 
 
Empirical formula : (C3H4O2) x (-C3H5-sucrose) y 
 
Viscosity : 4,000 to 11,000 cps at 2°C (0.5% neutralized aqueous solution). 
 
Stability : It is unaffected by hydrolysis or oxidation and is resistant to bacterial growth. 
 
Applications : Excellent thickening, emulsifying, suspending and gelling agent. It is 
used as tablet binder in sustained release formulations affording zero-order release. It is 
used as bioadhesive component in mucoadhesive tablets. 
 
Safety : No primary irritation or any evidence of allergic reactions observed in humans 
following topical application. 
 
 
2. EUDRAGIT E PO: 
Aminoalkyl methacrylate copolymer 
Solubility : Dissolves in aqueous isopropyl alcohol, methanol, ethanol and acetone. 
Practically insoluble in ethyl acetate, methylene chloride, petroleum ether and water. 
 
Particle size : At least 95%, less than 0.25 mm. 
 
Film formation : When poured onto a glass plate, a clear film forms upon evaporation 
of the solvent. 
 
Applications : Eudragit E po is an acid soluble polymer and hence used to mask bitter 
taste of formulations through film coating of tablets and pellets.  
 
Storage : Protect from warm temperatures and against moisture. 
 
Safety : Polymethacrylate co-polymers are widely used as film coating agent in oral 
pharmaceutical formulations. They are also used in lesser extent in topical formulations 
and are generally regard as nontoxic and non-irritant materials. 
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3. HYDROXYPROPYL METHYLCELLULOSE (Methocel K 100 M LVCR) 
 
 
 
 
Molecular weight: Approximately 10,000 - 1,500,000. 
Applications : HPMC is used as tablet binder, extended release tablet matrix, 
suspending and thickening agent. It is used as wetting agent for hard contact lenses 
and as adhesive in plastic bandages. HPMC shows temperature dependent change in 
viscosity. Raise in temperature reduces the viscosity of HPMC. It undergoes reversible 
gel-sol transformation depending on temperature of the surrounding environment. 
Acidity / Alkalinity : pH = 5.5 - 8.0 (1% w/w aqueous solution). 
Density (tapped) : 0.50 - 0.70 g / cm3 
Melting point : 190-200 oC. Glass Transition Temperature170 - 180 oC. 
Solubility : Soluble in cold water and practically insoluble in ethanol (95%), ether and 
chloroform. But soluble in mixtures of ethanol and dichloromethane. 
Stability : It is stable in pH 3.0 to 11.0 
Incompatibilities : Incompatible with some oxidizing agents and will not complex with 
metallic salts and ionic organics. 
Safety : Extensively used in cosmetics, food products and widely used as an excipient 
in oral and topical formulations. 
 
4. PROTANAL CR 8133 (Sodium alginate) 
Description : Sodium alginate occurs as an odorless and tasteless, white to pale 
yellowish-brown coloured powder. 
Sodium alginate CAS registry no. is [9005-38-3].  
Application: Sodium alginate is the sodium salt of alginic acid. It is used in 
pharmaceutical formulations both as binders and disintegrants. It is also used in  
preparation of sustained release oral formulations as it delays the dissolution of drug 
from tablets.  
Solubility& Visocity: Sodium alginate is practically insoluble in ethanol and other 
organic solvents but soluble in water slowly forming a viscous colloidal solution. Various 
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grades of sodium alginate are commercially available ranging from 20-400 cps. Its 
viscosity decreases above pH 8.0.  
Stability: Sodium alginate is hygroscopic material. Stable if stored at low relative 
humidity’s and cool temperature. It is susceptible on storage to microbial spoilage which 
may affect the viscosity. The bulk storage in air tight container in cool, dry place. 
 
5. ETHYL CELLULOSE N 50 
 
 
 
 
 
 
 
 
Chemical name: Cellulose ethyl ether (CAS no. 9004-57-3).  
 
Nature of polymer : It is a derivative of cellulose in which some of the hydroxyl groups 
in repeating glucose units were converted into ethyl ether groups. 
 
Typical characteristics: It is available as free flowing powder, white to off-white in 
color with a density of 0.4g/cm2. It is practically insoluble in water, glycerol and propane-
1-2-diol, but soluble in organic solvents. Ethyl cellulose containing 46-48% of ethoxyl 
group is freely soluble in ethanol, methanol, chloroform and ethyl acetate. Neutral to 
litmus. 
 
Applications: It is mainly used as thin-film coating material. It is used as matrix in 
extended release matrix systems and provides improved lipophilic properties by 
increasing surface area. This flexibility is enhanced to modify release profiles when 
ethyl cellulose is used in combination with water-soluble excipients such as  HPMC. 
 
Stability : Ethyl cellulose is stable, slightly hygroscopic material. It is chemically 
resistant to alkalis.  
Storage : Ethyl cellulose is prone to oxidative degradation in presence of UV light. Ethyl 
cellulose should be stored at a temperature not exceeding 32°C in a dry area and away 
from heat. 
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6. MICROCRYSTALLINECELLULOSE pH 102 
 
 
 
 
Synonyms 
Avicel PH; Celex; cellulose gel; Celphere; Ceolus KG; crystalline 
cellulose; E460; Emcocel; Ethispheres ; Fibrocel; Pharmacel; Tabulose; 
 
Chemical Name and CAS Registry Number : Cellulose [9004-34-6] 
 
Empirical Formula and Molecular Weight : (C6HO105)n = 36 
000,where n =220. 
 
Functional Category : Adsorbent, suspending agent, tablet and capsule diluent and 
tablet disintegrant. 
 
Applications in Pharmaceutical Formulation or Technology: 
Microcrystalline cellulose is widely used in pharmaceuticals, primarily as a 
binder/diluent in oral tablet and capsule formulations by direct compression processes. 
In addition to this, Microcrystalline cellulose is also used for its lubricant and disintegrant 
properties that make it useful in tableting. Microcrystalline cellulose is also used in 
cosmetics and food products. 
 
Uses of Microcrystalline cellulose. 
1. Adsorbent 20–90 % 
2. Antiadherent 5–20% 
3. Capsule binder/diluents 20–90% 
4. Tablet disintegrant 5–15% 
5. Tablet binder/diluents 20–90% 
 
Description 
Microcrystalline cellulose is a purified, partially depolymerized cellulose that 
occurs as white, odorless, tasteless, crystalline powder with porous particles.  
 
Typical Properties 
Density (bulk) : 0.32 g/cm  
Density (tapped) : 0.45 g/cm  
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Density (true) : 1 .512–1.668 g/cm 
Melting point : Chars at 260–270°C. 
 
Moisture content: Typically less than 5% w/w. However, different grades may contain 
varying amounts of water. Microcrystalline cellulose is hygroscopic. 
 
Particle size distribution: Typical mean particle size is 20–200μm. Different grades 
may have a different nominal mean particle size. 
 
Solubility: Slightly soluble in 5% w/v sodium hydroxide solution; practically insoluble in 
water, dilute acids, and most organic solvents. 
 
Stability and Storage Conditions: 
Microcrystalline cellulose is a stable though hygroscopic material. The bulk 
material should be stored in well-closed container in a cool, dry place. 
 
Incompatibilities 
Microcrystalline cellulose is incompatible with strong oxidizing agents. 
 
Safety 
Microcrystalline cellulose is widely used in oral pharmaceutical formulations and 
regarded nontoxic and non irritant. Microcrystalline cellulose is not absorbed 
systemically following oral administration. Consumption of large quantities of cellulose 
may have a laxative effect. 
 
 
7. CROSPOVIDONE XL-10 
 
 
Synonyms: 
Crosslinked povidone, E1202, Kollidon CL,Kollidon CL-M, Polyplasdone XL, 
PolyplasdoneXL-10, polyvinylpolypyrrolidone, 1-vinyl-2-pyrrolidinone homopolymer. 
 
Chemical Name and CAS Registry Number : 1-Ethenyl-2-pyrrolidinone homopolymer 
[9003-39-8] 
 
Empirical Formula and Molecular Weight : (C6H9NO)n >1 000000. The USPNF 23 
describes Crospovidone as a water-insoluble synthetic crosslinked homopolymer of N-
vinyl-2-pyrrolidinone. An exact determination of the molecular weight has not been 
established due its insolubility. 
 
Functional Category: Tablet disintegrant 
EXCIPIENT PROFILE 
Department of Pharmaceutics                                                                        J.K.K.Nattraja college of pharmacy 63 
 
 
Applications in Pharmaceutical Formulation or Technology 
Crospovidone is water-insoluble tablet disintegrant and dissolution agent used at 
2–5% concentration in tablets prepared by direct compression or wet- and dry-  
granulation  methods. It rapidly exhibits high capillary activity and pronounced hydration 
capacity, with little tendency to form gels. Studies suggest that the particle size of 
Crospovidone strongly influences disintegration of tablets. Larger particles provide a 
faster disintegration than smaller particles. Crospovidone can also be used as solubility 
enhancer. With the technique of co-evaporation, Crospovidone can be used to enhance 
the solubility of poorly soluble drugs. The drug is adsorbed on to Crospovidone in the 
presence of a suitable solvent and the solvent is then evaporated. This technique 
results in faster dissolution rate. 
 
Description 
Crospovidone is white to creamy-white, finely divided, free flowing, tasteless, 
odorless or nearly odorless, hygroscopic powder. 
 
Typical Properties 
Acidity/alkalinity : pH = 5.0–8.0 (1% w/v aqueous 
slurry) 
Density : 1.22 g/cm3 
Density (bulk) : 0.35 g/cm3 
Density (tapped) : 0.45 g/cm3 
Moisture content : Maximum moisture sorption is approximately 60%.Particle size 
distribution : 50% greater than 50 m and maximum of 3% greater than 250 µm 
Solubility : Practically insoluble in water and most common organic solvents. 
Specific surface area : 1.0 m2/g 
Storage Conditions : Crospovidone is hygroscopic, it should be stored in an airtight 
container in acool, dry place. 
 
Incompatibilities 
Crospovidone is compatible with most organic and inorganic pharmaceutical 
ingredients. When exposed to a high water level, Crospovidone may form molecular 
adducts with some materials. 
 
 
Safety 
Crospovidone is used in oral pharmaceutical formulations and is generally 
regarded as nontoxic and nonirritant material. Short-term animal toxicity studies have 
shown no adverse effects associated with Crospovidone. However, owing to the lack of 
available data, an acceptable daily intake in humans has not been specified by the 
WHO. 
LD50 (mouse, IP): 12 g/kg. 
 
Handling Precautions 
Observe normal precautions appropriate to the circumstances and quantity of 
material handled. Eye protection, gloves and dust mask are recommended.  
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8. LACTOSE MONOHYDRATE DCL-11 
 
 
 
 
 
 
 
 
 
 
 
Description: Lactose monohydrate occurs as white, odourless, free flowing powder 
slightly sweet in taste. It is a natural disaccharide, obtained from milk, which consists of 
one glucose and one galactose moiety.  
Application :Lactose monohydrate, spray dried lactose and anhydrous lactose are 
widely used as diluent in tablets and capsule formulations. It produces a hard tablet and 
the tablet hardness increases on storage. Disintegrant is usually needed in lactose 
containing tablets. Drug release rate is usually not affected.  
Stability:It is usually non reactive, except for discoloration when formulated with amines 
and alkaline materials due to maillard reaction. It contains approximately 5% water.  
Processing: It needs high compression pressures in order to produce hard tablets. 
Lactose monohydrate (SuperTab® 30) is produced by fluid bed granulation and has 
good flow properties. It shows consistent compaction over a wide range of humidity.  
Storage:Mould growth may occur under humid conditions. Lactose should be stored in 
a well closed container and stored in cool dry place. 
 
9. Croscarmellose sodium: 
Chemical name : Cellulose carboxymethyl ether sodium salt 
Category: Tablets and capsule disintegrant 
Application in Pharmaceutical formulations: 
 Croscarmellose sodium is used in oral pharmaceutical formulation as 
disintegrant for capsules, tablets and granules. In tablet formulation, croscarmellose 
sodium can be used in both direct compression and wet-granulation process. 10 - 25 % 
can be used in capsules, 0.5 to 5.0 % used in tablets. 
Solubility : insoluble in water, swells rapidly 4 – 8 times its volume on contact with 
water. Practically, insoluble in acetone and ethanol. 
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10. MAGNESIUM STEARATE 
 
 
 
 
 
 
 
 
 
Magnesium stearate [CAS no. 557-04-0] is official in Ph.Eur., USPNF, BP and JP. 
 
Description :Magnesium stearate is white and solid at room temperature. 
 
Chemical formula: Mg (C18H35O2)2. It is the salt containing two equivalents of stearate 
(the anion of stearic acid) and one magnesium cation (Mg++).  
 
Safety :Magnesium stearate melts at about 88°C, is not soluble in water and is 
generally considered safe for human consumption at levels below 2500 mg/kg. 
 
Pharmaceutical application: 
 Magnesium stearate is used for its lubricating properties in tablets, capsule and 
powder, producing good flow properties of powder blend and preventing ingredients 
from sticking to manufacturing equipment during compression into tablets. Studies have 
shown that that magnesium stearate may affect release of active ingredients from 
tablets. Magnesium stearate is manufactured from both animals and vegetables. 
 
11. COLLOIDAL SILICON DIOXIDE(Aerosil) 
 
Colloidal anhydrous silica available under the trade name Aerosil 200 sourced 
from Evonik. Aerosil® 200 is hydrophilic fumed silica with a specific surface area of 
200m2/g with a particle size of about 15 nm. 
 
Molecular formula : SiO2 
CAS registry no: [7631-86-9] 
Molecular weight: 60.08. 
 
Descripton:It is loose, bluish-white colored, odorless, tasteless, non gritty amorphous 
powder.  
Pharmaceutical application: It is frequently used in pharmaceutical formulation to 
improve flow properties of powder blend in tablet and capsule manufacturing. Aerosil 
200 is intended specifically for pharmaceutical industry, tested in accordance with 
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European, American and Japanese pharmacopeia. Addition to 0.2 - 1.0% by weight of 
Aerosil® colloidal silica. In many formulations, hydrophilic Aerosil® colloidal silicon 
dioxide increases the rate of tablet disintegration and release of active ingredients. 
 
12. PURIFIED TALC: 
Emperical formula :Mg6 (Si2O5)4(OH)4 
Category: Glidant, tablet and capsule lubricant. 
Description: Very fine, white to grayish white, odourless powder. It adheres readily to 
skin and is free from grittiness. 
Solubility: Insoluble in dilute acids, alkalis, organic solvents and water. 
Stability and storage: Stable material and can be sterilized by heating at 160 °C. It can 
be sterilized by exposure to ethylene oxide and gamma irradiation and should be stored 
in well-closed container in cool place. 
Incompatibilities: Incompatinble with quarternary ammonium compounds. 
Applicaton: Used as lubricant in tablet formulations, In novel powder coating for 
extended release pellets and as adsorbent. 
Stability: croscarmellose sodium is stable. 
 
13. EUDRAGIT - L100 
 
Molecular weight : approximately 135,000. 
 
Solubility : Dissolves in aqueous isopropyl alcohol,methanol, ethanol and acetone. 
Practically insoluble in ethyl acetate, methylene chloride, petroleum ether and water. 
 
Particle size : At least 95%, less than 0.25 mm. 
 
Film formation : When poured onto a glass plate, a clear film forms upon evaporation 
of the solvent. 
 
Applications : Polymethacrylates are primarily used in oral capsule and tablet 
formulations as film coating agents. Depending on the type of polymer used, films of 
different solubility characteristics can be produced. Used in enteric coating formulations 
to target drug solubility at pH above 6 in GIT. 
 
Storage : Protect from warm temperatures and against moisture. 
 
Safety : Polymethacrylate co-polymers are widely used as film coating agents in oral 
pharmaceutical formulations. They are also used to a lesser extent intopical 
formulations and are generally regard as nontoxic and non-irritant materials. 
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MATERIALS & INSTRUMENTS 
8.1 Materials used for formulation of Mucoadhesive  tablet: 
s.no Name of the chemicals Mfg./ gifted by Control / lot 
number 
1 Salbutamol sulphate Supriya life science ltd S/114/15-16 
2 Carbopol 971 P (acrypol)  Corel pharma chem 44215008 
3 Eudragit E PO Evonik industries B131203014 
4 Methocel K 100 M LVCR 
(ID2964) 
Colorcon GA448695    
5 Protanal CR 8133 FMC health & Nutrition GQB0204703 
6 Ethyl cellulose EC-N 50 TaianRuitai cellulose N502012100288 
7 Microcrystalline cellulose ph 
102 
DFE pharma 170425W2 
8 Magnesium stearate Amishi drugs & chemicals 270417 
9 Aerosil Wacker YA46966 
 
8.2 Materials used for formulation of Immediate release tablets: 
s.no Name of the chemicals Mfg./ Gifted by Control / lot number 
1 Salbutamol suphate Supriya life science ltd S/114/15-16 
2 Lactose monohydrate DCL-
11 
DFE pharma 1016ZD5 
3 Microcrystalline cellulose ph 
102 
DFE pharma 170425W2 
4 Magnesium stearate Amishi drugs & 
chemicals 
270417 
5 Crospovidone XL-10 Huangshan Bonsun 
pharmaceuticals 
BP20170303 
6 Croscarmellose sodium Amishi drugs & 
chemicals 
ACRMC/03-0/240317 
 
8.3 materials used for Enteric coating of capsule shell: 
s.no Name of the chemicals Mfg./ Gifted by Control / lot 
number 
1 Eudragit E PO Evonik industries B131203014 
2 Opadry enteric coating 
system (white)          
940580000 - eudragit L100 
colorcon TNL59653 
3 Lactulose Lactose india limited L15009 
4 Triethyl citrate Indo-GSP 1702TEC028 
5 Isopropyl alcohol Hazchem 1219 
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Empty hard gelatin capsule shell “2” size and “0 el” size was purchased from natural 
capsules ltd. 
All chemicals and reagent used were of AR grade. 
 
INSTRUMENTS USED 
s.no Instrument name Company Equipment number 
1 Weighing balance Vibra – Essae teraoka FD/INS/039 
2 UV spectrophotometer 
(UV-1800)  
Shimadzu A114550 
3 FT-IR spectrometer Perkin elmer AD/INS/066 
4 Differential scanning 
calorimetry 
- FD/INS/005 
5 pH meter MP-1 plus Susima AD/INS/086 
6 Roche friabilator EF-2 Electrolabs AD/INS/011 
7 Monsanto Hardness tester Shankar FD/INS/021 
8 Digital vernier caliper Mitutoyo FD/INS/022 
9 Mini Tableting machine 
MRT-8 
Kambert FD/INS/006 
10 Octagonal blender 10L Sams techno mech FD/INS/007 
11 Capsule filling machine 
MFD-418 
ACG-pam pharma tech FD/INS/014 
12 Coating machine Sams techno mech FD/INS/017 
13 Dissolution apparatus Electrolabs ETC15LX 
14 Syringe pump Electrolabs ESP-124(B) 
15 Sample collector Electrolabs ESC-12DX 
16 DT apparatus ED-2L Electrolabs FD/INS/018 
17 Tray dryer Rays scientific 
instruments 
FD/INS/011 
18 Multi mill Sams techno mech / 
croma 
FD/INS/010 
19 Packing machine        
(Ezee blist) 
Mechtek FD/INS/035 
20 Leak test apparatus Labpro FD/INS/020 
21 Tap density tester Electrolabs FD/INS/013 
22 Electromagnetic sieve 
shaker 
Electrolabs FD/INS/036 
23 Lab scale stirrer Remi motors FD/INS/024 
24 Stability chamber Thermolabs FD/INS/038 
 
PUNCHES & TOOLING: 
S.no Punch description Tooling Mfg by 
1 5.5 mm circular standard 
concave plain punch 
B tooling Eliza tools 
2 6.35 mm circular standard 
concave plain punch 
B tooling Eliza tools 
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PREFORMULATION 
Preformulation is the first step in rational development of dosage forms which 
involves investigation of physical and chemical properties of drug substances alone and 
in combination with excipients. 
Preformulation supports pharmaceutical and analytical investigation with efforts 
formulation and development of the dosage form. 
9.1 Organoleptic properties: 
9.1.1 Color and nature: 
A small quantity of the sample was spreaded on a piece of paper and examined 
visually 
9.2 Physical characteristics: 
9.2.1 Flow properties: 
The flow property of the powder blend is crucial for uniform filling of blended 
drug-excipient powder into die cavity for effective compression of tablets. 
Angle of Repose: 
 
Angle of repose is the maximum angle between the surface of pile of powder and 
the horizontal plane. The angle of repose was determined by the funnel-method. The 
accurately weighed Quantity of powder blend was taken in a funnel. The height of the 
funnel was adjusted in such a way that the tip of the funnel just touches the apex of the 
pile formed. The powder blend were allowed to flow through the funnel freely onto the 
surface of the graph paper. The diameter and height of the pile formed is measured and 
angle of repose was calculated using the equation. 
 
θ = tan-1 h/r 
θ = Angle of repose 
h = height of the pile 
r = radius of the pile 
Table 4: Angle of repose 
 
Angle of repose Flowability 
< 25 Excellent 
25 - 30 Good 
30 - 40 Passable 
>40 Very poor 
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Determination of Bulk Density: 
 
Bulk density is the ratio of mass of the powder to the bulk volume. Bulk density is 
determined by measuring the volume of known mass of the powder blend using a 
graduated cylinder. 
 
An accurately weighed quantity of the granules/ powder (m) was carefully poured 
into the graduated measuring cylinder and the volume (Vb) was measured. The bulk 
density of the powder blend is denoted by gram perml. it is calculated using the formula, 
 
ρb = m / Vb 
 
ρb= bulk density 
m = mass of the powder 
Vb = initial / bulk volume 
 
Determination of Tapped Density: 
 
Tap density is the ratio of mass of the powder to tapped volume.The graduated 
cylinder which holds known initial volume and mass of the powder blend was closed 
with lid and set into the tap density tester (USP). The density apparatus was set for 100 
tabs and after that the volume (Vt) was measured. 
 
Tapped density was calculated using the following formula, 
 
ρt = m / Vt 
 
Compressibility Index (Carr’s Index): 
 
Compressibility index is the measure of propensity of powder blend to be 
compressed. It measures relative importance of inter particulate interactions. In case of 
free flowing powder, such interactions are relatively less and greater interaction was 
found in poor flowing materials. This difference can be observed in bulk and tapped 
density and reflected when compressibility index is calculated 
 
% compressibility = Tapped density – initial bulk density  x 100 
                              Tapped density 
 
Table 5 : compressibility index 
% Compressibility Flow ability 
5 – 12 Excellent 
12 – 16 Good 
18 – 21 Fair 
23 – 25 Poor 
33 – 38 Very poor 
More than 40 Very very poor 
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Hausner’s Ratio: 
 
It is the ratio of tapped density and bulk density.  
Hausner ratio = ρt /ρb 
 
Hausner found that this ratio was related to Interparticle friction and, as such, 
could be used to predict powder flow properties). Generally a value less than 1.27 
indicates good flow properties, which is equivalent to 20% of Carr’s index. 
 
 
COMPATIBILITY STUDIES: 
 
The compatibility of the drug with excipients was determined by assay. The study 
was done by filling 1:1 ratio of powder blend into the vial and loading it into accelerated 
stability chamber 40° C / 75% RH for a period of 30 days and analysed at Initial, 15th 
day and 30th day for Physical appearance (color change) and Assay of salbutamol 
sulphate. 
 The assay was determined by UV absorption spectroscopy against freshly 
prepared standard solution. 
 
 
Table 6 : Compatibility Studies of Drug and Excipients 
 
Ingredients 
Sample 
No. 
Condition Initial 
% 
40°C/75% RH 
condition 
Vial 15days 30days 
Salbutamol Sulphate (A) 
A-1 Open 
99.98 
99.93 99.89 
A-2 Closed 99.95 99.88 
Carbopol 971 P (B) 
B-1 Open 
- 
- - 
B-2 Closed - - 
Salbutamol sulphate + Carbopol 971 P 
AB-1 Open 
98.93 
98.89 98.87 
AB-2 Closed 98.91 98.86 
Eudragit E po 
C-1 Open 
- 
- - 
C-2 Closed - - 
Salbutamol sulphate + Eudragit E po 
AC-1 Open 
98.95 
98.90 98.86 
AC-2 Closed 98.85 98.79 
Salbutamol sulphate+ Carbopol 971 P + ABC-1 Open 98.89 98.81 98.76 
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Eudragit E po ABC-2 Closed 98.84 98.80 
Ethyl cellulose N 50 
D-1 Open 
- 
- - 
D-2 Closed - - 
Salbutamol sulphate + Ethyl cellulose N 
50 
AD-1 Open 
98.92 
98.89 98.77 
AD-2 Closed 98.90 98.85 
Protanal CR 8133 
E-1 Open - - - 
E-2 Closed - - 
Salbutamol sulphate + Protanal CR 8133 
AE-1 Open 98.94 98.84 98.72 
AE-2 Closed 98.81 98.76 
Hydroxypropyl methyl cellulose K 100 M 
LVCR 
F-1 Open - - - 
F-2 Closed - - 
Salbutamol sulphate +HPMC K 100 M 
LVCR 
AF-1 Open 98.91 98.83 98.75 
AF-2 Closed 98.86 98.74 
Mcc ph 102 
G-1 Open - - - 
G-2 Closed - - 
Salbutamol sulphate + Mcc ph 102 
AG-1 Open 99.46 99.26 98.87 
AG-2 Closed 99.27 98.92 
Lactose monohydrate DCL-11 
H-1 Open - - - 
H-2 Closed - - 
Salbutamol sulphate + Lactose 
monohydrate DCL-11 
AH-1 Open 99.64 99.43 99.19 
AH-2 Closed 99.52 99.24 
Crospovidone XL 10 
I-1 Open - - - 
I-2 Closed - - 
Salbutamol sulphate + crospovidone XL 
10 
AI-1 Open 99.71 99.62 99.51 
AI-2 Closed 99.63 99.45 
Croscarmellose sodium 
J-1 Open - - - 
J-2 Closed - - 
Salbutamol sulphate + croscarmellose 
sodium 
AJ-1 Open 99.73 99.46 99.25 
AJ-2 Closed 99.51 99.30 
Magnesium stearate 
K-1 Open - - - 
K-2 Closed - - 
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Salbutamol sulphate +Magnesium  AK-1 Open 98.84 98.49 98.38 
stearate AK-2 Closed  98.53 98.45 
Aerosil 
L-1 Open - - - 
L-2 Closed - - 
Salbutamol sulphate + aerosil 
AL-1 Open 99.61 99.40 99.31 
AL-2 Closed 99.47 99.39 
Carbopol 971 P + Eudragit E po + mcc 
ph 102 + magnesium stearate+ Aerosil 
M-1 Open - - - 
M-2 Closed - - 
Salbutamol sulphate + Carbopol 971 P + 
Eudragit E po + mcc ph 102 + 
magnesium stearate+ Aerosil 
AM-1 Open  
98.69 
98.51 98.36 
AM-2 Closed 98.72 98.63 
Carbopol 971 P + Eudragit E po + 
ethyl cellulose + mcc ph 102 + 
magnesium stearate+ Aerosil 
N-1 Open - - - 
N-2 Closed - - 
Salbutamol sulphate+ Carbopol 971 P + 
Eudragit E po + ethyl cellulose + mcc ph 
102 + magnesium stearate+ Aerosil 
AN-1 Open 98.71 98.50 98.47 
AN-2 Closed 98.56 98.49 
Carbopol 971 P + Eudragit E po + 
Protanal CR 8133 + mcc ph 102 + 
magnesium stearate+ Aerosil 
O-1 Open - - - 
O-2 Closed - - 
Salbutamol sulphate+ Carbopol 971 P + 
Eudragit E po + Protanal CR 8133 + mcc 
ph 102 + magnesium stearate+ Aerosil 
AO-1 Open 
98.67 
98.42 
98.36 
AO-2 Closed 98.45 
98.31 
Carbopol 971 P + Eudragit E po + 
HPMC K100M LVCR + mcc ph 102 + 
magnesium stearate+ Aerosil 
P-1 Open - - - 
P-2 Closed - - 
Salbutamol sulphate+ Carbopol 971 
P + Eudragit E po + HPMC K100M 
LVCR + mcc ph 102 + magnesium 
stearate+ Aerosil 
AP-1 Open 98.66 98.44 98.30 
AP-2 Closed 98.49 98.38 
Lactose DCL - 11 + mcc ph 102 + 
crospovidone XL 10 + magnesium 
stearate 
Q-1 Open - - - 
Q-2 Closed - - 
Salbutamol sulphate+ Lactose DCL - 
11 + mcc ph 102 + crospovidone XL 
10 + magnesium stearate 
AQ-1 Open 98.91 98.65 98.54 
AQ-2 Closed 98.71 98.67 
Lactose DCL - 11 + mcc ph 102 + R-1 Open - - - 
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croscarmellose sodium + magnesium 
stearate 
R-2 Closed - - 
Salbutamol sulphate + Lactose DCL - 
11 + mcc ph 102 + croscarmellose 
sodium + magnesium stearate 
AR-1 Open 98.87 98.75 98.61 
AR-2 Closed 98.76 98.63 
 
 
 
SPECTROSCOPIC STUDIES: 
FTIR studies: 
Characterization of salbutamol sulphate: 
 
The infrared spectrum of pure salbutamol sulphate was recorded and spectral 
analysis was done. The dry sample of the drug was thoroughly mixed with potassium 
bromide and pressed into pellets and then directly placed in sample holder and 
analysed under FTIR. 
 
Characterisation of Interpolyelectrolyte complex: 
 
The infrared spectrum of Carbopol 971 P and Eudragit E po was recorded and 
spectral analysis was done to identify the formation of “Interpolyelectrolyte 
complex”.The dry sample of carbopol 971 P and Eudragit E po was thoroughly mixed 
with potassium bromide and pressed into pellets and then directly placed in sample 
holder and analysed under FTIR.Similarly, IR spectrums of salbutamol sulphate and 
polymers (1:1 ratio) was analysed. 
 
UV spectroscopy  (Determination of λ max): 
 
 UV spectrum of salbutamol sulphate was carried out in 0.1 N Hcl, pH 6.8 
phosphate buffer and pH 7.4 Phosphate buffer. Salbutamol sulphate was weighed 
accurately and transferred to 100 ml volumetric flask. This is dissolved and volume 
made up with distilled water. This solution was treated as stock solution and contains 
100 µg/ml of salbutamol sulphate. The solution was appropriately diluted with distilled 
water to obtain a concentration range of 10 µg/ml of salbutamol sulphate. The UV 
spectrum was recorded at 276 nm. 
 
Preparation of standard curve: 
 
Salbutamol sulphate (10 mg) was weighed accurately and weighed accurately 
and transferred to 100 ml volumetric flask. This is dissolved and volume made up with 
distilled water. This solution was treated as stock solution and contains 100 µg/ml of 
salbutamol sulphate. From this stock solution 0.2 , 0.4 , 0.6 , 0.8 , 1.0 , 1.2 ml were 
withdrawn and taken in separate 10 ml volumetric flask. The volume was made with 
buffer solution to obtain concentrations  of 2,4,6,8,10,12 µg/ml respectively. Absorbance 
of these solutions were measure at 276 nm for preparation of standard curve. Using 
absorbance concentration data, lamberts and beers graph was plotted. This is used for 
estimating the release of drug from its dosage form. 
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METHOD FOR TESTING SOLUTION STABILITY: 
 
Since dissolution was to be carried out for a period of 72 hours (3 days) the 
stability of the dissolution medium is important. 
The test is conducted by comparing the freshly prepared standard solution with 
that of the simulated dissolution medium which is priorly prepared and studied for a 
period of 75 hours.The analysis was carried out every 12 hours. 
 
Preparation of Fresh Standard solution: 
 
Standard solution of 10 µg/ml of salbutamol sulphate was prepared freshly in 6.8 
pH phosphate buffer medium whenever the study is being carried out. 
 
Preparation of dissolution medium for analyzing solution stability: 
 
Medium A :10 mg of salbutamol sulphate was accurately weighed and dissolved 
in 100 ml of 6.8 pH phosphate buffer such that its concentration ranges 100 µg/ml. The 
medium was stored in 1000 ml beaker and closed with lid. Samples where withdrawn 
every 12 hours interval and diluted to attain concentration of 10 µg/ml and analyzed 
against freshly prepared standard solution under spectroscopy at 276 nm. 
 
Medium B : 10 mg of salbutamol sulphate was accurately weighed and 
dissolved in 100 ml of 6.8 pH phosphate buffer containing 5 % of goat’s caecal content 
(100 µg/ml of salbutamol sulphate) . The medium was stored in 1000 ml beaker and 
closed with lid. Samples where withdrawn every 12 hours interval and diluted to attain 
concentration of  10 µg/ml and analyzed against freshly prepared standard solution 
under spectroscopy at 276 nm. 
 
Table 7: Method to test solution stability 
 
 
S.no 
Time interval 
(hours) 
Fresh Standard                      
(10 µg/ml ) 
Medium A Medium B 
Blank Test Blank Test 
1 Initial 100.00 % 0 % 99.93% 0 % 99.90% 
2 12th hour 100.00 % 0 % 99.84% 0 % 99.72% 
3 24th hour 100.00 % 0 % 99.79% 0 % 99.51% 
4 36th hour 100.00 % 0 % 99.81% 0 % 99.35% 
5 48th hour 100.00 % 0 % 99.73% 0 % 99.27% 
6 60th hour 100.00 % 0 % 99.68% 0 % 98.79% 
7 72th hour 100.00 % 0 % 99.57% 0 % 98.14% 
8 84th hour 100.00 % 0 % 99.36% 0 % 97.83% 
 
 
 
 
 
 
 
 
PREFORMULATION 
Department of Pharmaceutics                                                                        J.K.K.Nattraja college of pharmacy 76
 
PREFORMULATION STUDY FOR COATING: 
Eudragit E po: 
Eudragit E po is dissolved in IPA: methylene dichloride 50:50 ratio and triethyl 
citrate was used  in various proportion to confirm film formation using a glass slide. 10 
% triethyl citrate is sufficient to form better film. 
Eudragit E po dissolves completely in methylene dichloride but web like 
formation was found during automization from nozzle. 
Hence, IPA: water 90:10 ratio was used as recommended in literature published 
by Evonik. 
Talc was added as anti-tacking agent to prevent stickiness during coating 
process. 8 % talc is sufficient to prevent excess stickiness. 
Eudragit L 100: 
Eudragit L 100 is dissolved in IPA and triethyl citrate was used in various 
proportion was used to confirm film formation using a glass slide. 10 % triethyl citrate is 
sufficient to form better film. 
Eudragit L 100 dissolves completely in methylene dichloride but web like 
formation was found during automization from nozzle. 
Hence, IPA: water 90:10 ratio was used as recommended in literature published 
by Evonik. 
Talc was added as anti-tacking agent to prevent stickiness during coating 
process. 8 % talc is sufficient to prevent stickiness. 
 
FORMULATION 
Department of Pharmaceutics                                                                        J.K.K.Nattraja college of pharmacy  77 
 
FORMULATION 
FORMULATION OF MUCOADHESIVE TABLETS 
The main aim of formulation is to develop a mucoadhesive tablets as drug 
delivery system in colon which forms interpolyelectrolyte complex (IPEC) forming 
hydrogel in contact with water which delivers controlled release of drug as well as 
triggered release as per chronobiological aspects. 
The main theme of forming interpolyelectrolyte complex is advantageous such 
that the system regains its initial state when applied stress condition in removed. 
Through IPEC complex , initial burst release can be prevented, dose dumping 
can be prevented.  
The developed formulation should also be simple for ease of manufacturing and 
reproducibility such that cost effective dosage form can be delivered to patients. Hence, 
tableting process is adopted for this novel drug delivery system which is simple and 
easy to manufacture compared to complicated systems like microencapsulation and 
nanotechnology which involves high cost of production. 
Eudragit E po (Aminoalkyl methacrylate co-polymer) an anionic polymer and 
carbopol (cationic ) polymer (containing carboxylate backbone) was chosen for the 
formation of “interpolyelectrolyte” complex. Due to opposite charge of polymers, they 
attract each other and forms complex which reduces swelling and erosion. 
Carbopol 971 P is selected because of its good mucoadhesive property and 
recent report by Lubrizol that carbopol 971 P has the ability to form reversible gel to sol 
transformation inpresence of hydroxyl radicals and when pH is reduced.  
Salbutamol sulphate was chosen as the model drug since it is highly soluble and 
stable. Since it is potent drug, formulation of mini tablets system is merely possible. 
To develop a 3 days once dosage form, 24 mg of salbutamol sulphate is to be 
delivered as mucoadhesive mini tablets in capsule system.Each mini tablets containing 
6 mg of salbutamol sulphate. The dosage was aimed to delivereach 4 mg of salbutamol 
sulphate in colon for 12 hours in controlled manner as specified in USP. 
In the preformulation study it is known that combination of eudragit E po & 
carbopol 971 P possed poor flow. Hence direct compression method becomes 
impossible. 
The drug : polymer was prepared in various ratio’s and analysed under FTIR for 
determination interpolyelectrolyte complex forming hydrogel system. 
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Table 8 : Initial Formulation involving Wet granulation method: 
Formula 
trial 
Drug:polymerratio Salbutamol 
sulphate 
Eudragit 
E po 
Carbopol 
971 P 
Purified 
water 
Isopropyl 
alcohol 
Mccph 
102 
Mg. 
stearate 
Avg. wt 
FA1 1:1:1 6 mg 6 mg 6 mg Qs - 60 mg 2 mg 80 mg 
FA2 1:1:1 6 mg 6 mg 6 mg - qs 60 mg 2 mg 80 mg 
 
The blend was analysed in FTIR for the formation of hydrogel forming 
interpolyelectrolyte complex. FA1 batch which is granulated with purified water shows 
formation of interpolyelectrolyte complex hydrogel system. FA2 batch granulated with 
isopropyl alchohol, the complex formation was not clear. 
Hence, water is regarded as the mediator for formation of such hydrogel IPEC 
system. 
In wet granulation process a problem is faced during granulation. On addition of 
water during granulation it forms a sticky mass which is elastic in nature due to hydrogel 
complex formation. Since colon contains water content, and the system is capable of 
forming hydrogel complex in presence of water the development was focused on dry 
granulation (slugging process) to improve the flow property of the powder blend. 
In slugging process, carbopol 971 P and eudragit E po was blended in 1:1 ratio 
and various proportion of magnesium stearate was added to the blend to improve the 
flow property. But there is no improvement in flow property. Hence, combination of 
colloidal silicon dioxide (aerosil) and magnesium stearate was used to improve flow 
property and results are satisfactory. 
1:1:1 ratio of salbutamol sulphate ,carbopol 971 P and eudragit E po was 
blended and analysed under FTIR. The blend showed no such complex formation. But 
when the same blend was analysed by wetting it with small proportion of purified water 
it showed complex formation. Thus it is clear that combination of carbopol 971 P and 
eudragit E po forms hydrogel complex structure (peak appeared at 1561 cm-1 on FT-IR 
spectrum of carbopol-Eudragit E po IPEC which may be assigned to the carboxylate 
group of carbopol which formed ionic bonds with protonated amino group of eudragit E 
po). Hence, it has the capacity to  form complex in colon by observing fluids from the 
environment of large intestine. 
Slugging process: 
The powder blends are passed through 40# and blended. slugged using 16 mm 
circular flat punch at about 10 to 12 kg/cm2 of hardness. Deslugged in multi-mill and 
passed through 24 # mesh. Lubricated and compressed into mini tablets of 5.5 mm 
circular standard concave punch at about 12 kg/cm2 of hardness. 
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Table 9: Formulation containing Carbopol 971 P and Eudragit E po 
 
 
From the mucoadhesion strength of the tablets, it is observed that increasing the 
ratio of carbopol 971 P gave good mucoadhesion but its effiency to retard drug release 
was reduced. And at the same time increasing the concentration of Eudragit E po 
reduced the mucoadhesive strength of the tablets. 
Eudragit E po controls swelling. IPEC prevents intial burst release and gives 
controlled release. 
Increasing the concentration of Eudragit E po gave good controlled release and 
also gave triggered release when pH is lowered to resemble chronobiology. Hence, 
concentration of eudragit E po and Carbopol has to be optimized to get good 
mucoadhesion, controlled release and triggered release.  
Increase in concentration of Mcc ph102 , causes erosion type of swelling. 
From the study, 42 mg of carbopol 971 P in 90 mg of tablet is suffient to cause 
good mucoadhesion. Carbopol 971 p ratio is fixed 42 mg per tablet. By reducing the 
concentration of Eudragit E po good mucoadhesion was achived but the system fails to 
retard drug release for prolonged period but also gave triggered release when pH is 
lowered. By reducing the concentration of Eudragit E po, IPEC complex formation was 
not affected. 
Formulation involving Ethyl cellulose N 50: 
Hence attempt was made to include release retarding polymer like ethyl cellulose. 
Table 10: Formulation containing Carbopol, Eudragit and Ethyl cellulose N 50 
Formula 
trial 
Drug:polymer 
ratio 
Salbutamol 
sulphate 
Carbopol 
971 P 
Eudragit 
E po 
Ethyl 
cellulose 
N 50 
Mcc 
ph 
102 
Aerosil Mg. 
stearate 
Avg.wt 
FA13 1:7:1:1 6 mg 42 mg 6 mg 6 mg 28 mg 1 mg 1 mg 90 mg 
FA14 1:7:2:2 6 mg 42 mg 12 mg 12 mg 16 mg 1 mg 1 mg 90 mg 
FA15 1:7:2:4 6 mg 42 mg 12 mg 24 mg 4 mg 1 mg 1 mg 90 mg 
Formula 
trial 
Drug:polymer 
ratio 
Salbutamol 
sulphate 
Eudragit 
E po 
Carbopol 
971 P 
Mccph 
102 
Aerosil Mg. 
stearate 
Avg. 
wt 
FA3 1:1:1 6 mg 6 mg 6 mg 70 mg 1 mg 1 mg 90 mg 
FA4 1:2:2 6 mg 12 mg 12 mg 58 mg 1 mg 1 mg 90 mg 
FA5 1:3:3 6 mg 18 mg 18 mg 46 mg 1 mg 1 mg 90 mg 
FA6 1:3:4 6 mg 18 mg 24 mg 40 mg 1 mg 1 mg 90 mg 
FA7 1:4:5 6 mg 24 mg 30 mg 28 mg 1 mg 1 mg 90 mg 
FA8 1:4:6 6 mg 24 mg 36 mg 22 mg 1 mg 1 mg 90 mg 
FA9 1:4:7 6 mg 24 mg 42 mg 16 mg 1 mg 1 mg 90 mg 
FA10 1:4:8 6 mg 24 mg 48 mg 10 mg 1 mg 1 mg 90 mg 
FA11 1:5:8 6 mg 30 mg 48 mg 4 mg 1 mg 1 mg 90 mg 
FA12 1:4:9 6 mg 24 mg 54 mg 4 mg 1 mg 1 mg 90 mg 
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FA16 1:7:2:5 6 mg 42 mg 12 mg 30 mg - 1 mg 1 mg 92 mg 
 
 Ethyl cellulose was added to the formulation and was found its ability to retard 
drug release. Since 72 hours drug release to be achieved, concentration of ethyl 
cellulose was increased in the formulation. By increasing the concentration of ethyl 
cellulose drug release was retarded, but mucoadhesion property was also reduced. 
Formulation involving sodium alginate: 
 Hence , study was concentrated on hydrophilic polymers like sodium alginate 
and hydroxy propyl methyl cellulose. 
 This hydrophilic polymers helps in formation of hydrogel complex that readily 
absorbs water from the environment of colon and has the capacity to hold up water in it 
remaining in gel state. Thus providing, controlled release of drug from the dosage form. 
Since they are hydrophilic polymers, they also possess mucoadhesive property. 
Table 11: Formulation containing Carbopol, Eudragit and Protonal CR 8133 
Formula 
trial 
Drug: 
polymer 
ratio 
Salbutamol 
sulphate 
Carbopol 
971 P 
Eudragit 
E po 
Protonal 
CR 
8133 
Mcc 
ph 
102 
Aerosil Mg. 
stearate 
Avg.wt 
FA17 1:7:1:2 6 mg 42 mg 6 mg 6 mg 28 
mg 
1 mg 1 mg 90 mg 
FA18 1:7:2:4 6 mg 42 mg 12 mg 24 mg 4 
mg 
1 mg 1 mg 90 mg 
FA19 1:7:3:4 6 mg 42 mg 18 mg 24 mg - 1 mg 1 mg 92 mg 
FA20 1:7:2:5 6 mg 42 mg 12 mg 30mg - 1 mg 1 mg 92 mg 
FA21 1:6:3:5 6 mg 36 mg 18 mg 30 mg  1 mg 1 mg 92 mg 
FA22 1:5:2:7 6 mg 30 mg 12 mg 42 mg - 1 mg 1 mg 92 mg 
FA23 1:4:2:8 6 mg 24 mg 12 mg 48 mg - 1 mg 1 mg 92 mg 
 
 Protonal CR 8133 (Sodium alginate) retarded the delivery of drugs and provided 
drug release in controlled manner in pH 6.8 buffer medium. But in presence of goat’s 
caecal content the drug release was faster compared to normal pH 6.8 buffer medium. 
Its drug retarding property is not sufficient to provide drug delivery for 72 hours. Since, 
sodium alginate is also degraded by colonic microbiota drug release may be higher in 
colon. And also sodium alginate is an anionic polymer , it releases drug in pH 
independent manner when used in combination with Interpolyelectrolyte complex. 
Hence it lags in chronobiological based release profile. 
Formulation involving HPMC K 100 M LVCR: 
 Hydroxy propyl methyl cellulose is a non-ionic hydrophilic polymer that in 
combination with interpolyelectrolyte complex forms an hydrogel system. Hydroxypropyl 
methyl cellulose is not degraded by colonic microbiota.  
 In recent study it has shown temperature dependent release and it was reported. 
Hence, use of Hydroxyl propyl methyl cellulose is also advantageous in colon delivery of 
drug based on chronobiology since there exist an acute inflammatory reaction in colon 
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during asthma attacks which raises temperature and lowers pH in the lumen of the 
colon. 
Table 12: Formulation containing Carbopol, Eudragit and HPMC K 100 M LVCR 
 
 Presence of HPMC also increases the mucoadhesive property of the mini tablets. 
Since its mucoadhesion property is independent of pH and formation of good hydrogel 
system is taken into consideration. Controlled delivery of the drug from the dosage form 
is achieved and also provides effective drug release in combination with 
interpolyelectrolyte complex when triggered.  
 Higher viscosity polymers like HPMC k 100 M may cause initial burst release 
from the dosage form. but presence of carbopol , a low viscosity grade polymer 
prevents such burst release. 
 Final formula (1:7:3:4) provided control release of drug over a period of 72 hours. 
Releasing 1 mg of salbutamol sulphate in every 3 hours. (Resembling 12 hours dose of 
4 mg SR tablets as recommended in USP) . And also provided excellent drug triggered 
release when pH of dissolution medium is lowered (5 pH) by addition of  5 N Hcl. And 
the system had the capacity to regain its initial property of retarding drug release when 
condition is taken back to initial (6.8 pH) by addition of 5 N NaOH. 
 Note: The addition of 5 N Hcl and 5 N NaOH is involved to adjust the pH in 
dissolution medium within few drops. Because, addition of diluted 1 N Hcl and 1 N 
NaOH should not affect the volume of dissolution medium which may alternatively affect 
the result during UV absorbance study. 
Trigerring release based on severity of asthma: 
 pH of the dissolution medium was lowered to various pH levels. Since colon may 
have the pH of less than 4.2 during asthma attack. The pH of the dissolution medium 
was changed to 4.5 and 4.0 pH. The release of drug from the dosage form was noted. It 
is observed that as the pH lowers, drug release is triggered more. And the system had 
capacity to regain its original state when pH is reversed. Hence it is concluded that, 
drug release is achieved based on severity of asthma attack.  
Filling of mini tablets into capsules: 
 “2 size” empty transparent hard gelatin capsule was chosen as it can fit 4 mini-
tablets of 5.5 mm diameter into it. Filling was done in semi-automatic capsule filling 
Formula 
trial 
Drug:polymer 
ratio 
Salbutamol 
sulphate 
Carbopol 
971 P 
Eudragit 
E po 
HPMC 
K 100 M 
LVCR 
Mcc ph 
102 
Aerosil Mg. 
stearate 
Avg.wt 
FA24 1:7:2:2 6 mg 42 mg 12 mg 12 mg 16 mg 1 mg 1 mg 90 mg 
FA25 1:7:2:4 6 mg 42 mg 12 mg 24 mg 4 mg 1 mg 1 mg 90 mg 
FA26 1:7:2:5 6 mg 42 mg 12 mg 30 mg - 1 mg 1 mg 92 mg 
FA27 1:7:3:4 6 mg 42 mg 18 mg 24 mg - 1 mg 1 mg 92 mg 
FA28 1:6:3:5 6 mg 36 mg 18 mg 30 mg - 1 mg 1 mg 92 mg 
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machine. Transparent capsule shell was chosen to ensure that all capsules are filled by 
4 mini-tablets and there is no empty space left. 
 
FORMULATION OF IMMEDIATE RELEASE TABLETS: 
 Immediate release tablet of salbutamol sulphate 2 mg was prepared to give initial 
plasma concentration of drug. 
 The immediate release tablet is to be designed in such a way that it dissolves 
completely within few seconds in stomach. Hence, tablet formulation is based of fast 
disintegrating property of the tablets in 0.1 N Hcl. 
 To make the manufacturing process more easier direct compression method was 
adopted. 
Table 13: Formula for Immediate release Tablets 
Formula 
trial 
Salbutamol 
sulphate 
Mccph 
102 
Lactose 
Monohydrate 
DCL-11 
Croscar
mellose 
sodium 
Crospovidone 
XL 10 
Mg. 
stearate 
Avg.wt 
FB1 2 mg 35 mg 68 mg 4.0 mg - 1 mg 110 mg 
FB2 2 mg 35 mg 62 mg 5.0 mg - 1 mg 105 mg 
FB3 2 mg 40 mg 52 mg - 5.0 mg 1 mg 100 mg 
FB4 2 mg 45 mg 46 mg - 6.0 mg 1 mg 100 mg 
FB5 2 mg 50 mg 40 mg - 7.0 mg 1 mg 100 mg 
 
 Tablet was compressed using 6.35 mm standard concave punches at 5 kg/cm2 
hardness. 
 Formula FB5 showed fast disintegration < 15 sec and complete drug release was 
achieved within 15 min in 0.1 N Hcl dissolution medium. 
 Crosspovidone XL 10 have larger particle size compared to normal crospovidone 
and croscarmellose sodium, hence higher rate of wicking caused faster disintegration , 
thus resulting in faster drug release. 
 Increase in concentration of Mcc ph 102 and decrease in concentration of lactose 
DCL -11 showed significant improvement in disintegration and faster rate of drug 
release. 
Colon targeted coating: 
 Targeting Mucoadhesive mini tablets to colon have immense advantage such 
that it remains in colon for prolonged period of time release drug in a controlled manner. 
Mucoadhesive  Mini tablets can reside in colon for longer duration compared to other 
Larger dosage forms as it can withstand colonic force. 
 Since capsule is to be enteric coated, it reaches the colon faster than other 
dosage form due to its slippery nature and density. 
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 Since pH of the GIT varies from regions, coating by pH sensive polymers like 
Eudragit L100: S 100 combination alone is not suffient for colon targeting. 
 There is a possibility that this may release the dosage form in small intestine 
where the pH is above 7.hence colon targeting cannot be achieved. 
 Systems utilizing formaldehyde treatment of capsule for colon targeting may fail 
to release the drug in required site since transit time of GIT varies from individual to 
individual and also in diseased state. 
 These things have to be taken into consideration while developing a colon 
targeted drug delivery system. 
 Coating the gelatin capsule shell  with lactulose solution. Followed by coating 
with acid soluble polymer Eudragit E po and subsequent coating with Eudragit L 100. 
 Eudragit L 100 protects the delivery system in acidic pH of stomach for 2 to 3 
hours. When it reaches the small intestine, Eudragit L 100 coating dissolves in alkaline 
pH of small intestine (6.8 to 7.9). Eudragit E po which is acid soluble polymer protects 
the delivery system in alkaline pH of small intestine and delivers the drug to the colon. 
 After reaching the colon, Eudragit E po starts swelling due to slight acidic pH of 
colon (5.5 to 6.8 pH). Due to this swelling, fluid, enzymes and microbiota influx causing 
digestion of lactulose which creates acidic environment and starts dissolving the thin 
layer of Eudragit E po. Due to digestion of lactulose, water content in colon increases 
which is taken up by gelatin shell for its swelling and ruptures to release the mini tablets 
into the system. 
 These tablets adheres to mucus membrane of the colon and releases the drug in 
controlled manner. 
 The capsule is enteric coated and is small, dense and slippery , so that it reaches 
the colon soon compared to transit time due to density  of the tablets in capsule system 
and its slippery nature compared to other dosage forms. 
 
Weight of tablet filled capsule: 
Average weight of 1 tablets = 92 mg 
Total weight of 4 tablets = 92 x 4 mg = 368 mg 
Weight of “2” size empty hard gelatin capsule shell = 68 mg 
Final weight of tablets filled capsules = 436 mg 
Lactulose coating 
 Thin layer of 70 % lactulose solution is coated on to the delivery system. 
Minimum of 2 % to 3 % weight build up is suffient to cause complete film formation. 
3 % weight build up = [(436/100) x 3 ]+ 436 =  449.08 mg 
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Eudragit E po coating: 
 Various weight build up 3%, 4 %, 5 % was made and the dissolution was 
checked in 7.4 pH phosphate buffer. It was found that 4 % coating is sufficient to 
prevent drug release in simulated small intestinal fluid. 
Table 14: Eudragit E po Coating solution 
Ingredients Percentage used 
Eudragit E po 85 % 
Triethyl citrate 10 % 
Talc 8 % 
Isopropyl alcohol qs 
water qs 
 
 Coating solution prepared with 15 % solid content and 85 % of solvent. Isopropyl 
alcohol : water was used in the ratio of 90:10 proportion. 
Weight of lactulose coated capsule = 449.08 mg 
3 % weight build up = [(449.08/100) x3 ] + 449.08 = 462.55 mg 
4 % weight build up = [(449.08/100) x4 ] + 449.08 = 467.04 mg 
5 % weight build up = [(449.08/100) x5 ] + 449.08 = 471.53 mg 
Eudragit L 100 coating: 
 Various weight build up 8 % , 10 %  was made and the dissolution was checked 
in 0.1 N Hcl. It was found that 10 % weight build up is sufficient to prevent drug release 
in simulated gastric fluid. 
Table 15: Eudragit L 100 Coating solution 
Ingredients Percentage used 
Eudragit L 100 85 % 
Triethyl citrate 10 % 
Talc 8 % 
Titanium dioxide 2 % 
Isopropyl alcohol qs 
water qs 
 
 Coating solution prepared with 15 % solid content and 85 % of solvent. Isopropyl 
alcohol : water was used in the ratio of 90:10 proportion. 
8 % weight build up = [(467.04/100) x 8] + 467.04 = 504.40 mg 
10 % weight build up = [(467.04/100) x 10] + 467.04 = 513.74 mg 
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Filling of “Tablets in capsule system” and immediate release tablets : 
 The enteric coated capsule and immediate release tablet is filled into “0 el” size 
empty hard gelatin capsule. 
 
 
 
Figure 6 : Mucoadhesive tablets in capsule system 
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EVALUATION OF TABLETS 
WEIGHT VARIATION TEST: 
20 tablets from each formulation were individually weighed and average weight 
was calculated. Individual tablet weight was then compared with the average value to 
find out the deviation in weight. % weight variation is also calculated. 
Table 16: Specifications of weight variations for tablets as per IP 
s.no Average weight of 
tablets 
% Deviation 
1 80 mg or less 10% 
2 >80 mg but <250 mg 7.5% 
3 250 mg or more 5% 
 
THICKNESS: 
The thickness of the tablets was determined by using digital vernier caliper. Five tablets 
from each formulation was evaluated and average values were calculated. The readings 
were recorded as mm. 
HARDNESS: 
Hardness of 5 tablets from each of the formulation was determined using Monsanto 
hardness tester. The readings were recorded as kg/cm2. 
FRIABILITY: 
Friability test for each of the formulation was carried out in Roche friabilator. About 6.5 
gram of mini tablets/immediate release tablets were weighed and placed in the 
friabilator which was operated at 100 revolutions (25 rpm per min). The percent friability 
was determined using the formula, 
% Friability = Initial weight of the sample – final weight  x 100 
                                                  Initial weight of the sample 
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Limits for friability should be less than 1 % 
UNIFORMITY OF CONTENT: 
STANDARD SOLUTION: 
 Weigh accurately about 10 mg of salbutamol sulphate standard and transfer it 
into 100 ml volumetric flask. Dissolve it in distilled water and make up the volume to 100 
ml with distilled water. The solution was filtered through 0.45µ nylon filter. 5 ml of filtrate 
was diluted distilled water in volumetric flask so as to get final concentration of 24 µg/ml. 
SURFACE pH OF THE TABLET: 
 The surface pH of the tablet is measure by placing the tablet in petridish 
containing distilled water for 2 hours. The tablet was collected and surface ph of the 
tablet was determined by pH paper. 
In-vitro swelling index studies: 
The swelling index of mucoadhesive tablets was determined using phosphate 
buffer pH 6.8. The tablets were weighed individually and placed separately in watch 
glass containing 4 ml of phosphate buffer pH 6.8. The weight of the watch glass was 
taken as tare weight (w1). At regular 3 hours of intervals, the excess phosphate buffer in 
watch glass is removed using filter paper carefully. The weight of the watch glass along 
with tablet was noted (w2) and is subtracted from the tare value. Thus water uptake by 
the tablet is determined without disturbing the tablet. Fresh 4 ml of phosphate buffer 
was replaced resembling sink condition in colon. 
weight of swellen tablet = w2-w1 
Note: This method is advantageous over older methods of removing tablets from 
watch glass and studying swelling index, which may have the possibility of damaging 
the swellen tablets and affecting the study. This method also resembles maintaining  
sink condition in colon by replacing with fresh buffer. 
Swelling index was calculated using the formula, 
Swelling Index (SI) = weight ofswellen tablet –  initialweight of tablet  x 100 
      Initial weight of tablet  
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In-vitro bioadhesion study: 
Fabrication of test assembly: 
The weighing balance formed the basis for fabrication of In-vitro bioadhesion test  
apparatus. The apparatus consists of glass vial which is fixed to one side of the 
balance. To bottom surface of this glass vial, mucoadhesive mini tablet was made to 
adhere using adhesives. A glass bottle is placed in lower side of this assembly and 
Goat’s intestinal mucosal membrane is tied to mouth of this glass bottle which is filled 
with 6.8 pH phosphate buffer to maintain goat’s intestinal mucosal membrane in moist 
condition during the study. 
To another side of the balance, it carries a specific gravity bottle and the balance 
was adjusted to maintain equilibrium. Tare weight of specific gravity bottle was noted. 
The mini tablet which is attached to bottom of the vial was moistened with little 
amount of 6.8 pH phosphate buffer. And the tablet is made to adhere to the goat’s 
intestine. 
Water was slowly added to the specific gravity bottle little by little. The quantity of 
water required to detach mini tablets from the goat’s mucosal membrane was weighed. 
Measurement of adhesion force: 
The weight required to detach mini tablets from the goat’s mucosal membrane 
was measured in grams. This is then converted to kilopascals (kPa). 
The peristaltic force experienced in colon is 2.1 to 2.8 kilopascals. Hence, the 
tablet should withstand peristalsis in colon. 
1 kilopascals (kPa)= 10.197 gram force / cm2 
Bioadhesive force (kPa) = bioadhesive strength in grams 
                                             10.197 
Bioadhesive force can also be measured in newton force (N) which is calculated by 
following equation. 
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Bioadhesive force (N) = Bioadhesion strength in grams  x 9.81 
                                      100 
In-vitro drug release studies for “mucoadhesive tablets in capsule system”: 
The in-vitro drug release study of salbutamol sulphate from mucoadhesive mini 
tablets in capsule system was carried out in USP Type II apparatus (paddle method) at 
50 rpm using shinker. Medium used for drug release study was 500 ml of 6.8 pH 
phosphate buffer. During the course of study the medium was maintained at 37*c ± 
0.5*c. 5 ml of sample were withdrawn at regular 3 hours time intervals and replaced with 
fresh buffer. The amount of drug release from the dosage form was determined 
spectrophotometrically at 276 nm. 
In-vitro drug release studies for “Enteric coated tablets in capsule sytem”: 
The in-vitro drug release study of salbutamol sulphate from “enteric coated 
tablets in capsule system” was carried out in USP Type II apparatus (paddle method) at 
50 rpm using shinker. The drug release study was carried out in 500 ml of 0.1 N Hcl for 
a period of 2 hours (average gastric transit time is 2 hours), then the dissolution medium 
was replaced with 7.4 pH phosphate buffer for a  period of 3 hours (average small 
intestinal transit time is about 3 – 4 hours), finally study was continued with 6.8 pH 
phosphate buffer. During the course of study the medium was maintained at 37*c ± 
0.5*c. 5 ml of sample were withdrawn at regular  time intervals and replaced with fresh 
buffer. 
In-vitro drug release studies for “Enteric coated tablets in capsule sytem” in 
presence of goat’s caecal contents: 
The in-vitro drug release study of salbutamol sulphate from “enteric coated 
tablets in capsule system” was carried out in USP Type II apparatus (paddle method) at 
50 rpm using shinker. The drug release study was carried out in 500 ml of 0.1 N Hcl for 
a period of 2 hours (average gastric transit time is 2 hours), then the dissolution medium 
was replaced with 7.4 pH phosphate buffer and the drug release was tested for a  
period of 3 hours (average small intestinal transit time is about 3 – 4 hours), then finally 
the study was continued with dissolution mediumcontaining 5 % of goat’s caecal 
content. During the course of study the medium was maintained at 37*c ± 0.5*c and 
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with continuous supply of CO2 into the beaker to simulate anaerobic environment of the 
colon. 5 ml of sample were withdrawn at regular 3 hours time intervals and replaced 
with fresh buffer. 
Note: goat’s caecal content weighing 250 grams was added to 5000 ml of 6.8 pH 
phosphate buffer medium. 
In-vitro drug release based on chronopharmaceutics: 
The in-vitro drug release study was carried out using 6 jars in USP Type II 
apparatus (paddle method) at 50 rpm using shinker. Medium used for drug release 
study was 500 ml of 6.8 pH phosphate buffer containing 5 % goat’s caecal content. 
During the course of study the medium was maintained at 37*c ± 0.5*c and with 
continuous supply of CO2 into the beaker to simulate anaerobic environment of the 
colon. 5 ml of sample were withdrawn at regular 3 hours time intervals and replaced 
with fresh buffer. 
Since, the drug release profile must match chronobiological aspects the pH of the 
dissolution medium is lowered upto5.0 , 4.5 and 4.0 pH in between the study by addition 
of 5 N Hcldrop by drop with the help of pH meter, without disturbing the dissolution 
apparatus. Resembling the changes in pH of the colonic lumina during asthma attack in 
early morning hours. 
The pH of the dissolution medium was lowered at 24thhours.At 24th hour, pH was 
lowered to pH 5.0 in Jar : 1 and 2 by drop wise addition of 5 N Hcl into the dissolution 
medium. 
In the same manner, pH was lowered to pH 4.5 in Jar : 3 and 4, followed by pH 4.0 in 
Jar : 5 and 6.The temperature of the medium was maintained at 39*c ± 0.2*c 
After regular 3 hours interval, 5 ml of sample was withdrawn and 5 ml was 
replaced with fresh buffer. Then it is analysed for drug content under spectroscopy at 
276 nm. 
Then the pH of the dissolution medium was taken back to normal state of 6.8 pH 
by addition of 5 N NaOH drop by drop into the dissolution medium without disturbing the 
dissolution apparatus. The temperature of the medium was also brought back to 37*c ± 
0.5*c 
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Note: 5 N Hcl and 5 N NaOH was used instead of dilute solution to change the 
pH of the medium without affecting the volume of the dissolution medium. 
In-vitro drug release study for immediate release tablets: 
The in-vitro drug release study of Immediate release tablets of salbutamol 
sulphate was carried out in USP Type II apparatus (paddle method) at 50 rpm for a 
period of 15 min. The medium used for drug release study was 900 ml of 0.1 N Hcl. 
During the course of study the medium was maintained at 37*C ± 0.5*c. 5 ml of sample 
were withdrawn and analysed for the drug content spectrophotometrically at 276 nm. 
In-vitro Drug permeation: 
The in-vitro Intestinal drug permeation study of salbutamol sulphate through 
goat’s intestinal mucosal membrane (colon) was performed using Keshary-chien type 
glass diffusion cell at 37*c ± 0.2*c.Freshly slaughtered colon of goat was mounted 
between donor and receptor compartment. 4 mucoadhesive mini tablets was placed on 
to the mucosal membrane and the compartments are clamped together. The donor 
compartment was filled with 1 ml of phosphate buffer pH 6.8. The receptor compartment 
(15 ml capacity) was filled with phosphate buffer of pH 7.4 resembling pH in serosal 
side. Hydrodynamics in receptor compartment was maintained by stirring with magnetic 
bead at 50 rpm. A 1 ml sample was withdrawn at predetermined time intervals and 
analyzed for the drug content at 276 nm using UV spectrophotometer. 
In-vitro residence time of mucoadhesive mini tablets: 
The in-vitro residence time for mucoadhesive mini tablets containing salbutamol 
sulphate was determined using modified USP dissolution apparatus. The dissolution 
medium composed of 500 ml of pH 6.8 phosphate buffer maintained at 37*C ± 0.5*c. A 
segment of the Goat’s intestinal mucosal membrane was glued to the surface of each 
glass slide. 4 mucoadhesive mini tablets were wetted with phosphate buffer containing 
erythrosine supra dye   and made to adhere to the surface of intestinal mucosa. The 
slide was immersed in dissolution apparatus and height of the paddle to that of the 
tablet surface was adjusted at a distance of 5 cm and rotated at 50 rpm. The time 
required for complete erosion or detachment of the tablets from the mucosal membrane 
was recorded. 
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MECHANISM OF DRUG RELEASE: 
Various models were tested for explaining the kinetics of drug release. 
To investigate the mechanism of drug release rate kinetics from the dosage form, 
the obtained data were fitted with zero-order, first-order, Higuchi and korsmeyer-peppas 
release model. 
Zero order release rate kinetics: 
To investigate zero-order release kinetics, the drug release rate was fitted to the 
equation, 
F = Ko.t 
Where, 
F = drug release, K= release rate constant and t = time taken for drug release. Plot of % 
drug release versus time is linear. 
First order release rate kinetics: 
To investigate first-order release kinetics, the drug release rate data was fitted to the 
equation, 
Log (100 – F) = Kt 
A plot of Log % drug release versus time is linear. 
Higuchi release model: 
To investigate Higuchi release kinetics, the release rate data were fitted to the 
following equation. 
F = K t1/2 
Where K = Higuchi constant. 
In Higuchi model, plot of % drug release verses square root of time is linear. 
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Korsmeyer – peppas model: 
To investigate Korsmeyer – peppas release kinetics, the release rate data were 
fitted to the following equation, 
Mt/M∞ = K.t
n 
Where, Mt/M∞ = fraction of drug released. 
K = release constant. 
t= time taken for release. 
n= diffusion exponent. 
If n is equal to 0.89, the release is zero order. 
In this model, a plot of log (Mt/M∞) versus log time is linear. 
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RESULTS & DISCUSSION 
SPECTROSCOPIC STUDIES: 
UV spectroscopy (Determination of λmax): 
 The λmax for salbutamol sulphate was determined in different medium like 0.1 
Hcl, pH 7.4 phosphate buffer, pH 6.8 phosphate buffer & pH 6.8 phosphate buffer 
containing 5 % of goat’s caecal content. 
 The wavelength of maximum absorbance was found to be 276 nm. 
UV absorption spectrum of salbutamol sulphate in 0.1 N Hcl: 
 
Graph 1 : UV absorption spectrum of SS in 0.1 N Hcl 
UV absorption spectrum of salbutamol sulphate in 7.4 pH phosphate buffer: 
 
Graph 2 : UV absorption spectrum of SS in pH 7.4 phosphate buffer 
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UV absorption spectrum of salbutamol sulphate in 6.8 pH phosphate buffer: 
 
Graph 3: UV absorption spectrum of SS in 6.8 pH phosphate buffer 
UV absorption spectrum of salbutamol sulphate in pH 6.8 phosphate buffer 
containing 5 % Goat’s caecal content at 276 nm (colon simulated medium): 
 
Graph 4 : UV absorption spectrum of SS in colon simulated medium 
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Standard calibration curve of salbutamol sulphate: 
Calibration of salbutamol sulphate in 0.1 N Hcl at 276 nm: 
Table 17: Calibration curve of SS in 0.1 N Hcl 
s.no Concentration 
(µg/ml) 
Absorbance 
1 0 0 
2 2 0.054 
3 4 0.109 
4 6 0.163 
5 8 0.214 
6 10 0.267 
 
 
Graph 5: standard calibration curve of SS in 0.1 N Hcl 
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Calibration of salbutamol sulphate in pH 7.4 phosphate buffer at 276 nm: 
Table 18: Calibration curve of SS in 7.4 pH phosphate buffer 
s.no Concentration 
(µg/ml) 
Absorbance 
1 0 0 
2 2 0.067 
3 4 0.133 
4 6 0.193 
5 8 0.245 
6 10 0.316 
 
 
 
Graph 6: standard calibration curve of SS in 7.4 pH phosphate buffer 
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Calibration of salbutamol sulphate in pH 6.8 phosphate buffer at 276 nm: 
Table 19: Calibration curve of SS in 6.8 pH phosphate buffer 
s.no Concentration 
(µg/ml) 
Absorbance 
1 0 0 
2 2 0.063 
3 4 0.129 
4 6 0.189 
5 8 0.241 
6 10 0.312 
 
 
Graph 7: standard calibration curve of SS in 6.8 Phosphate buffer 
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Calibration of salbutamol sulphate in pH 6.8 phosphate buffer containing 5 % 
Goat’s caecal content at 276 nm (colon simulated medium): 
Table 20: Calibration curve of SS in colon simulated medium 
s.no Concentration (µg/ml) Absorbance 
1 0 0 
2 2 0.079 
3 4 0.147 
4 6 0.209 
5 8 0.263 
6 10 0.332 
 
 
Graph 8: standard calibration curve of SS in colon simulated medium 
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IR spectrum interpretation: 
IR spectrum of salbutamol sulphate: 
 
Table 21: IR spectrum of salbutamol sulphate 
Salbutamol sulphate 
Wave Number in cm-1 Characteristic bands 
3551.32  O – H stretching 
3402.32  N – H stretching 
2931.47  C – H stretching 
1622.30  C = C stretching 
1455.80  C – H Bending 
1142.94  C – O stretching Ether  
1018.19  C – O stretching 
873.33, 766.75, 669.19, 
602.15 
C – H (OOP) For 
Aromatic rings  
465.97, 450.74, 444.88, 
419.45 
C – X stretching 
 
IR spectrum of carbopol 971 P: 
 
IR spectrum of Eudragit E po: 
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IR spectrum of HPMC K 100 M LVCR 
 
IR spectrum of Protanal CR 8133 (sodium alginate): 
 
IR spectrum of Magnesium stearate: 
 
IR spectrum of colloidal silicon dioxide: 
 
IR spectrum of Drug with excipients:
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Formation of Interpolyelectrolyte complex by FTIR: 
 Eudragit E po showed characteristic band at 1,730 cm−1 which corresponds to 
absorbance of ester groups. The absorbance bands at 2,770 and 2,820 cm−1 can be 
assigned to non-ionized dimethyl amino groups.  
 
The IR spectrum of Carbopol 971P is characterized by principal absorption peaks 
at 3,110 (O–H stretching) and 1,720 cm−1 (carboxyl group). The FT-IR spectra 
indicated that drug bands were preserved within the tablets (mixed powders) and within 
IPEC without Salbutamol sulphate. 
 
 
In IPEC complex , Eudragit E po peak at 2,820 cm−1 was greatly minimized, and 
the peak at 1,730 cm−1 disappeared, in case of Carbopol 971P, the peak at 1,720 
cm−1 disappeared in IPEC containing Salbutamol sulphate. This can be attributed to 
the existence of Salbutamol sulphate as the major constituent. 
 
DSC of  Salbutamol sulphate: 
 
 
 
 
DSC of interpolyelectrolyte complex:  
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These results were also confirmed by DSC thermograms, which indicated that 
salbutamol sulphate was preserved in crystalline state in the formulation. The transition 
that appeared at temperature 195 °C in IPEC SS could be attributed to IPEC itself. This 
was further confirmed by existence of same transition in DSC trace of IPEC alone 
(without Salbutamol sulphate). Hence, formation of IPEC complex without affecting 
salbutamol sulphate in formulation was confirmed by FTIR and DSC. 
 
Reason for trigerred release in different pH: 
Carbopol  has three characteristic peaks when determined by IR spectroscopy 
between 1800 - 600 cm-1.  
1. C=O stretch band appears around 1695 cm-1, which corresponds to free 
carbonyl group. 
2. Hydrogen bonded C=O stretch band appears at lower 100 wavenumbers, 
usually as a shoulder of free C=O stretch band.  
3. The deprotonated carboxyl (COO-) group has absorption bands around 1560 
cm-1 due to its asymmetric stretching (COO- stretch asymmetric) and 1410  
cm-1 due to symmetric stretching (COO- stretch symmetric)  (Pretsch et al., 
2009). 
 
        IR spectra of IPEC complex, correspond to differently protonated state of carbopol 
molecule in different pH values. It can be noticed that there is a changes in intensity of 
COO- stretching bands when pH levels are altered. IR spectroscopy is able to detect 
increase or decrease in amount of  deprotonated carboxylic groups.  
         On other hand, asymmetric COO- stretching band shifted significantly to higher 
wave numbers at basic conditions and vice versa when pH is lowered, which indicates 
changes in chemical environment of molecule. These changes can be associated with 
swelling and rheological characteristics such as gel-sol transformation of polymers due 
to electrostatic repulsion between the groups, which in turn causes development of 
adjacent negatively charged carboxyl groups. 
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                C=O stretching band of Carbopol was easily detectable at lower pH values 
(1699 cm-1) and asymmetric COO- stretching of Carbopol at higher values pH 6.8 
(1557 cm-1). The progressive decrease of C=O stretching and increase of asymmertic 
COO- stretching as a function of pH indicated that IPEC complex responded to changes 
in pH of environment.  
                    It is important to note that drug release was higher at lower pH values 4.0 
and release rate was lowered at pH 6.8. Some state of swelling and de-swelling of 
matrix was also observed when pH is altered. Tan et al. (2001). 
 
Evaluation of tablets: 
Tablets containing Eudragit E po & Carbopol 971 P: 
Table 22: Blend parameters of FA1 – FA12 
Formula 
trial 
Bulk density 
(gm/ml) 
Tapped 
density 
(gm/ml) 
Compressibility 
index % 
Hausner ratio % drug 
content 
FA1 
0.412 0.489 15.746 1.187 
99.87 % 
FA2 0.401 0.481 16.632 1.200 99.73 % 
FA3 0.398 0.453 12.141 1.138 99.56 % 
FA4 0.391 0.447 12.528 1.143 99.23 % 
FA5 0.387 0.442 12.443 1.142 100.01 % 
FA6 0.382 0.436 12.385 1.141 99.99 % 
FA7 0.376 0.429 12.354 1.141 100.08 % 
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FA8 0.37 0.424 12.736 1.146 99.25 % 
FA9 0.363 0.42 13.571 1.157 99.87 % 
FA10 0.356 0.418 14.833 1.174 99.42 % 
FA11 0.35 0.411 14.842 1.174 100.06 % 
FA12 0.349 0.409 14.670 1.172 99.65 % 
 
Table 23: Tablet Physical parameters FA1 – FA12 
Formula 
trial 
Thickness 
(mm) 
Hardness 
kg/cm2 
% 
Friability 
Content 
uniformity 
Weight 
variation 
Surface 
pH 
FA1 3.3 mm ± 
0.3 mm 
10  kg/cm2 0.04 % 99.83 % complies 6.46 
FA2 3.4 mm ± 
0.2 mm 
10 kg/cm2 0.05 % 99.70 % complies 6.49 
FA3 3.2 mm ± 
0.1 mm 
10 kg/cm2 0.02 % 99.52 % complies 6.53 
FA4 3.3 mm ± 
0.3 mm 
12 kg/cm2 nil 99.21 % complies 6.56 
FA5 3.5 mm ± 
0.1 mm 
13 kg/cm2 nil 99.98 % complies 6.60 
FA6 3.3 mm ± 
0.2 mm 
13 kg/cm2 nil 99.89 % complies 6.63 
FA7 3.6 mm ± 
0.1 mm 
13 kg/cm2 nil 100.01 % complies 6.65 
FA8 3.4 mm ± 
0.2 mm 
13 kg/cm2 nil 99.15 % complies 6.70 
FA9 3.3 mm ± 
0.1 mm 
13 kg/cm2 nil 99.78 % complies 6.74 
FA10 3.3 mm ± 
0.2 mm 
13 kg/cm2 nil 99.41 % complies 6.77 
FA11 3.2 mm ± 
0.2 mm 
13 kg/cm2 nil 100.02 % complies 6.81 
FA12 3.3 mm ± 
0.3 mm 
13 kg/cm2 nil 99.61 % complies 6.84 
 
Table 24: swelling index of FA1 – FA12 
Trial FA1 FA2 FA3 FA4 FA5 FA6 FA7 FA8 FA9 
3 h 56.73 57.24 56.21 52.72 51.43 49.74 47.76 48.98 51.43 
6 h 45.19 45.70 44.67 60.41 66.86 64.66 62.09 63.67 66.86 
12 h    50.21 62.76 84.06 80.71 76.41 80.23 
18 h      70.04 78.16 91.69 96.28 
24 h        89.07 115.53 
30 h         110.27 
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Trial FA10 FA11 FA12 
3 h 53.62 50.32 54.74 
6 h 69.71 65.42 71.16 
12 h 87.13 81.77 81.12 
18 h 108.92 102.21 92.48 
24 h 136.14 127.77 105.43 
30 h 124.63 159.71 120.19 
36 h  149.03 117.79 
 
 
Graph 8: Swelling index of tablets containing Carbopol & Eudragit 
Table 25: Mucoadhesive strength & residence time of tablets FA1 – FA12 
formula 
trial 
Mucoadhesion 
strength (gm) 
Mucoadhesive 
force (kPa) 
Residence time 
(hours) 
FA1 5.21 0.511 11.76 
FA2 5.02 0.492 11.33 
FA3 5.59 0.548 12.61 
FA4 7.11 0.697 16.04 
FA5 9.89 0.970 22.32 
FA6 12.01 1.178 27.10 
FA7 15.13 1.484 34.14 
FA8 18.75 1.839 42.31 
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FA9 23.49 2.304 53.00 
FA10 25.81 2.531 58.24 
FA11 28.97 2.841 65.37 
FA12 29.37 2.880 66.27 
 
 
Graph 9: Mucoadhesive strength of formulation FA1 – FA12 
 
Graph 10: Residence time of Formulation FA1 - FA12 
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Table 26: Cumulative % Drug release - Dissolution test in 6.8 pH phosphate buffer 
medium: 
Trial FA1 FA2 FA3 FA4 FA5 FA6 FA7 FA8 FA9 
3 h 62.21 66.11 60.12 42.75 33.59 29.56 24.05 20.21 16.92 
6 h 98.42 98.21 98.39 77.51 56.18 46.11 36.11 31.41 27.84 
9 h    98.26 83.13 64.67 51.06 40.62 36.76 
12 h     98.35 84.22 64.21 54.82 46.68 
15 h      97.78 79.26 67.02 57.61 
18 h       91.32 77.23 67.53 
21 h       98.37 85.44 78.45 
24 h        97.64 89.37 
27 h         98.29 
 
Trial FA10 FA11 FA12 
3 h 12.75 6.18 8.81 
6 h 21.51 14.36 17.91 
9 h 32.26 23.54 25.86 
12 h 40.02 31.72 35.81 
15 h 49.77 41.90 45.77 
18 h 60.52 50.08 53.72 
21 h 70.28 57.25 61.68 
24 h 80.03 64.43 72.63 
27 h 91.79 74.61 82.58 
30 h 97.54 82.79 92.54 
33 h  
91.97 98.49 
36 h  
98.15 
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Graph 11: Cumulative % drug release of formulation FA1 – FA12 
From the mucoadhesion strength of the tablets, it is observed that increasing the 
ratio of carbopol 971 P gave good mucoadhesion but its effiency to retard drug release 
was reduced. And at the same time increasing the concentration of Eudragit E po 
reduced the mucoadhesive strength of the mini - tablets. 
Eudragit E po controls swelling. IPEC prevents intial burst release and gives 
controlled release. 
Increasing the concentration of Eudragit E po gave good controlled release and 
also gave triggered release when pH is lowered to resemble chronobiology. Hence, 
concentration of eudragit E po and Carbopol has to be optimized to get good 
mucoadhesion, controlled release and triggered release.  
Increase in concentration of Mcc ph102 , causes erosion type of swelling. 
 From the study, 42 mg of carbopol 971 P in 90 mg of tablet is suffient to cause 
good mucoadhesion. Carbopol 971 p ratio is fixed 42 mg per tablet. By reducing the 
concentration of Eudragit E po good mucoadhesion was achived but the system fails to 
retard drug release for prolonged period but also gave triggered release when pH is 
lowered. By reducing the concentration of Eudragit E po, IPEC complex formation was 
not affected. 
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Tablets containing Eudragit E po, Carbopol 971 P & ethyl cellulose: 
Table 27 :Blend parameters of FA13 – FA16 
Formula 
trial 
Bulk 
density 
(gm/ml) 
Tapped 
density 
(gm/ml) 
Compressibility 
index % 
Hausner 
ratio 
% drug 
content 
FA13 0.359 0.414 13.285 1.153 99.23% 
FA14 0.341 0.423 19.385 1.240 99.26% 
FA15 0.338 0.422 19.905 1.249 99.56% 
FA16 0.326 0.418 22.010 1.282 99.48% 
 
Tables 28 : Tablet Physical parameters of FA13 – FA16 
formula 
trial 
Thickness 
(mm) 
Hardness 
kg/cm2 
% 
Friability 
Content 
uniformity 
Weight 
variation 
Surface 
pH 
FA13 3.4 mm ± 
0.1 mm 
13 kg/cm2 nil 99.19% complies 6.81 
FA14 3.3 mm ± 
0.2 mm 
13 kg/cm2 nil 99.21% complies 6.84 
FA15 3.3 mm ± 
0.1 mm 
14 kg/cm2 nil 99.50% complies 6.88 
FA16 3.2 mm ± 
0.2 mm 
14 kg/cm2 nil 99.43% complies 6.91 
 
Tablets 29: Swelling index of FA13 – FA16 
Trial FA13 FA14 FA15 FA16 
3 h 52.85 49.36 47.01 43.95 
6 h 68.71 64.17 61.11 57.14 
12 h 79.70 89.84 75.78 63.99 
18 h 92.45 125.77 93.97 71.67 
24 h 89.57 176.08 116.52 80.27 
30 h  160.76 144.48 89.90 
36 h   179.16 100.69 
42 h   165.39 112.77 
48 h    126.31 
54 h    129.46 
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Graph 12: Swelling index of formulation FA13 – FA16 
 
Table 30: Mucoadhesive strength & residence time of tablets 
formula trial Mucoadhesion 
strength (gm) 
Mucoadhesive force 
(kPa) 
Residence time 
(hours) 
FA13 26.18 2.567 59.07 
FA14 23.62 2.316 53.30 
FA15 20.51 2.011 46.28 
FA16 18.02 1.767 40.66 
 
 
Graph 13 :Mucoadhesive strength of formulation FA13 – FA16 
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Graph 14 : Residence time of formulation FA13 – FA16 
Table 31: Cumulative % Drug release - Dissolution test in 6.8 pH phosphate buffer 
medium: 
Trial FA13 FA14 FA15 FA16 
3 h 19.96 13.85 10.95 3.74 
6 h 34.93 24.70 17.89 9.48 
9 h 45.89 33.55 24.84 14.22 
12 h 59.85 42.43 31.78 22.96 
15 h 73.81 54.26 39.73 26.70 
18 h 87.78 63.11 48.67 34.44 
21 h 97.74 71.96 53.62 41.18 
24 h  82.81 59.57 43.92 
27 h  93.66 66.51 50.65 
30 h  98.51 73.46 55.39 
33 h   77.40 61.13 
36 h   85.87 70.87 
39 h   93.40 76.61 
42 h   97.24 82.35 
45 h    88.09 
48 h    93.83 
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51 h    97.57 
 
 
Graph 15 : Cumulative % Drug release of formulation FA13 – FA16 
 Ethyl cellulose was added to the formulation and was found its ability to retard 
drug release. Since 72 hours drug release to be achieved, concentration of ethyl 
cellulose was increased in the formulation. By increasing the concentration of ethyl 
cellulose drug release was retarded, but mucoadhesion property was also reduced. 
 Hence , study was concentrated on hydrophilic polymers like sodium alginate 
and hydroxy propyl methyl cellulose. 
 This hydrophilic polymers helps in formation of hydrogel complex that readily 
absorbs water from the environment of colon and has the capacity to hold up water in it 
remaining in gel state. Thus providing, controlled release of drug from the dosage form. 
Since they are hydrophilic polymers, they also possess mucoadhesive property. 
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Tablets containing Eudragit E po, Carbopol 971 P & Protanal CR 8133: 
Table 32: Blend parameters of FA17 – FA23 
Formula 
trial 
Bulk 
density 
(gm/ml) 
Tapped 
density 
(gm/ml) 
Compressibility 
index % 
Hausner ratio % drug 
content 
FA17 0.382 0.456 16.228 1.194 99.67% 
FA18 0.365 0.443 17.607 1.214 99.85% 
FA19 0.346 0.440 21.364 1.272 99.59% 
FA20 0.378 0.432 12.500 1.143 98.20% 
FA21 0.362 0.421 14.014 1.163 100.00 % 
FA22 0.36 0.418 13.876 1.161 98.66% 
FA23 0.358 0.420 14.762 1.173 99.47% 
 
Table 33: Tablet Physical parameters of FA17 – FA23 
formula 
trial 
thickness 
(mm) 
hardness 
kg/cm2 
% friability content 
uniformity 
weight 
variation 
Surface 
pH 
FA17 3.2 mm ± 
0.2 mm 
12 kg/cm2 nil 99.60% complies 6.86 
FA18 3.3 mm ± 
0.1 mm 
12 kg/cm2 nil 99.79% complies 6.88 
FA19 3.3 mm ± 
0.2 mm 
12 kg/cm2 nil 99.43% complies 6.91 
FA20 3.4 mm ± 
0.1 mm 
13 kg/cm2 nil 98.03% complies 6.94 
FA21 3.5 mm ± 
0.1 mm 
13 kg/cm2 nil 99.86 % complies 6.99 
FA22 3.4 mm ± 
0.2 mm 
13 kg/cm2 nil 98.52% complies 7.01 
FA23 3.3 mm ± 
0.2 mm 
14 kg/cm2 nil 99.37% complies 7.04 
 
Tables 34: Swelling index of FA17 – FA23 
Trial FA17 FA18 FA19 FA20 FA21 FA22 FA23 
3 h 48.39 48.14 45.77 46.92 42.97 41.12 38.99 
6 h 62.91 62.58 59.50 61.00 55.86 53.46 50.69 
12 h 71.08 71.34 68.43 72.59 65.36 62.54 57.78 
18 h 69.87 81.33 78.69 86.38 76.47 73.18 65.87 
24 h  92.72 90.49 102.79 89.47 85.62 75.10 
30 h  90.17 104.07 122.32 104.68 100.17 85.61 
36 h   119.68 145.56 122.47 117.20 97.59 
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42 h   102.53 173.21 143.29 137.12 111.26 
48 h    165.34 167.65 160.43 126.83 
54 h     196.15 187.71 144.59 
60 h      219.62 164.83 
66 h      208.42 187.91 
72 h       214.22 
 
 
Graph 16: Swelling index of formulation FA17 – FA23 
 
Table 35: Mucoadhesive strength & residence time of tablets 
formula 
trial 
Mucoadhesion 
strength (gm) 
Mucoadhesive 
force (kPa) 
Residence time 
(hours) 
FA17 26.08 2.558 58.85 
FA18 29.21 2.865 65.91 
FA19 29.45 2.888 66.45 
FA20 31.21 3.061 70.42 
FA21 30.09 2.951 67.90 
FA22 29.17 2.861 65.82 
FA23 28.98 2.842 65.39 
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Graph 17: Mucoadhesive strength of formulation FA17 – FA23 
 
 
Graph 18: Residence time of formulation FA17 – FA23 
Table 36: Cumulative % Drug release - Dissolution test in 6.8 pH phosphate buffer 
medium 
Trial FA17 FA18 FA19 FA20 FA21 FA22 FA23 
3 h 19.38 12.77 10.55 7.55 5.44 4.67 4.21 
6 h 37.75 23.54 19.09 15.09 10.88 9.34 8.29 
9 h 56.14 33.31 26.64 22.64 16.32 14.01 12.37 
12 h 70.51 44.08 35.18 27.73 21.76 18.69 16.45 
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15 h 84.80 52.85 44.43 33.73 27.20 23.36 20.53 
18 h 98.26 61.61 52.27 40.28 33.64 28.03 24.61 
21 h 
 
70.39 58.82 46.82 38.08 32.70 28.69 
24 h  78.16 66.36 52.37 43.52 37.37 32.77 
27 h  87.93 73.91 59.91 49.91 43.04 36.85 
30 h  97.70 80.45 65.46 55.41 47.71 40.93 
33 h   87.00 73.01 60.85 51.39 45.01 
36 h   93.54 79.55 65.29 57.06 49.09 
39 h   98.09 86.10 71.73 60.73 53.16 
42 h    93.64 77.17 65.40 57.24 
45 h    98.19 83.61 71.07 61.32 
48 h     88.05 75.74 65.40 
51 h     93.90 80.41 69.48 
54 h     97.93 85.09 73.56 
57 h      89.76 77.64 
60 h      94.43 81.72 
63 h      98.10 85.80 
66 h      
 
89.88 
69 h       93.96 
72 h       97.91 
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Graph 19: Cumulative % drug release of formulation FA17 – FA23 
Tablets containing Eudragit E po, Carbopol 971 P & HPMC K 100 M LVCR: 
Table 37: Blend parameters of FA24 – FA28 
Formula 
trial 
Bulk 
density 
(gm/ml) 
Tapped 
density 
(gm/ml) 
Compressibility 
index % 
Hausner 
ratio 
% drug 
content 
FA24 0.397 0.473 16.068 1.191 99.66% 
FA25 0.376 0.467 19.486 1.242 99.84% 
FA26 0.364 0.451 19.290 1.239 99.64% 
FA27 0.348 0.44 20.909 1.264 98.61% 
FA28 0.333 0.422 21.090 1.267 99.36% 
 
Table 38: Tablet Physical parameters of FA24 – FA28 
formula 
trial 
thickness 
(mm) 
Hardness 
kg/cm2 
% 
Friability 
Content 
uniformity 
Weight 
variation 
Surface 
pH 
FA24 3.2 mm ± 
0.1 mm 
12 kg/cm2 nil 99.53% complies 6.97 
FA25 3.3 mm ± 
0.1 mm 
12 kg/cm2 nil 99.54% complies 
7.01 
FA26 3.3 mm ± 
0.2 mm 
13 kg/cm2 nil 99.24% complies 
7.04 
FA27 3.2 mm ± 
0.2 mm 
14 kg/cm2 nil 98.21% complies 
7.08 
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FA28 3.3 mm ± 
0.1 mm 
14 kg/cm2 nil 99.16% complies 
7.11 
 
Table 39: Swelling index of FA24 – FA28 
Trial FA24 FA25 FA26 FA27 FA28 
3 h 45.92 41.82 40.25 38.93 38.17 
6 h 59.70 54.37 52.33 50.61 49.62 
12 h 68.05 61.98 59.91 57.69 56.67 
18 h 77.58 70.65 68.60 65.77 64.71 
24 h 88.44 80.55 78.55 74.98 73.90 
30 h 100.82 91.82 89.94 85.48 84.40 
36 h 114.94 104.68 102.98 97.44 96.38 
42 h 131.03 119.33 117.91 111.09 110.07 
48 h 120.14 136.04 135.00 126.64 125.70 
54 h  155.08 154.58 144.37 143.55 
60 h  176.80 176.99 164.58 163.93 
66 h  170.62 202.66 187.62 187.21 
72 h   232.04 213.89 213.79 
78 h   230.40  244.15 
84 h     242.24 
 
 
Graph 20: swelling index of formulation FA24 – FA28 
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Table 40 : Mucoadhesive strength & residence time of tablets FA24 – FA28 
Formula Trial Mucoadhesion 
strength (gm) 
Mucoadhesive 
force (kPa) 
Residence time 
(hours) 
FA24 28.06 2.752 63.31 
FA25 30.01 2.943 67.71 
FA26 31.93 3.131 72.05 
FA27 32.24 3.162 72.75 
FA28 30.42 2.983 68.64 
 
 
Graph 21: Mucoadhesive strength of formulation FA24 – FA28 
 
Graph 22: Residence time of formulation FA24 – FA28 
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Table 41: Cumulative % Drug release - Dissolution test in 6.8 pH phosphate buffer 
medium: 
Trial FA24 FA25 FA26 FA27 FA28 
3 h 7.50 5.65 2.77 4.09 1.84 
6 h 14.01 10.30 6.55 8.19 5.48 
9 h 20.51 14.94 10.32 12.28 9.12 
12 h 27.05 19.59 14.10 16.37 12.76 
15 h 33.52 24.24 17.87 20.46 16.40 
18 h 40.02 28.89 21.65 24.81 20.04 
21 h 46.52 34.43 25.42 28.89 23.68 
24 h 54.03 39.18 29.19 32.97 27.32 
27 h 60.33 43.83 32.97 37.05 30.96 
30 h 66.03 48.18 36.74 41.12 34.60 
33 h 73.54 53.13 40.52 45.20 38.24 
36 h 80.04 57.78 44.29 49.28 41.88 
39 h 86.54 62.43 48.07 53.36 45.52 
42 h 93.05 68.07 51.84 57.44 49.15 
45 h 97.55 72.72 55.61 61.52 52.79 
48 h  76.98 59.39 65.59 56.43 
51 h  82.02 63.16 69.67 60.07 
54 h  86.71 66.94 73.75 63.71 
57 h  91.31 70.71 77.83 67.35 
60 h  94.96 74.48 81.91 70.99 
63 h  98.46 78.26 85.99 74.63 
66 h   82.03 90.06 78.27 
69 h   85.81 94.14 81.91 
72 h   89.58 98.07 85.55 
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75 h   93.36  89.19 
78 h   97.13  92.83 
81 h     96.47 
84 h     98.27 
 
 
Graph 23: Cumulative % drug release of formulation FA24 – FA28 
Dissolution test for enteric coated capsule: 
Table 42: % Drug release of enteric coated capsule system -  dissolution test in 
0.1 N Hcl for 2 hours 
Eudragit L 100 coating FA23 FA27 
8 % 6.17% 5.76% 
10 % - - 
12 % - - 
 
Table 43: % Drug release of enteric coated capsule system -  dissolution test in 
7.4 pH phosphate buffer for 3 hours: 
Eudragit E po coating FA23 FA27 
3 % 3.96% 3.55% 
4 % - - 
5 % - - 
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Table 44: Cumulative % Drug release of enteric coated capsule system -  
dissolution test in 6.8 pH phosphate buffer containing 5 % goat’s caecal content: 
Trial FA23 FA27 
hours % drug 
release 
hours % drug 
release 
hours % drug 
release 
hours % drug 
release 
3 h 
6.15 
39 h 
74.85 
3 h 
4.25 
39 h 
53.52 
6 h 10.92 42 h 82.42 6 h 8.35 42 h 57.60 
9 h 15.89 45 h 87.09 9 h 12.44 45 h 61.68 
12 h 22.04 48 h 92.76 12 h 16.53 48 h 65.75 
15 h 27.19 51 h 96.30 15 h 20.62 51 h 69.83 
18 h 34.38 54 h - 18 h 24.97 54 h 73.91 
21 h 39.18 57 h - 21 h 29.05 57 h 78.89 
24 h 45.35 60 h - 24 h 33.13 60 h 82.86 
27 h 52.02 63 h - 27 h 37.21 63 h 87.15 
30 h 58.69 66 h - 30 h 41.28 66 h 91.22 
33 h 62.51 69 h - 33 h 45.36 69 h 95.13 
36 h 69.18 72 h - 36 h 49.44 72 h - 
 
 
Graph 24: Cumulative % drug release of formulation FA23 and FA27                              
in colon simulated medium 
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 Protonal CR 8133 (Sodium alginate) retarded the delivery of drugs and provided 
drug release in controlled manner in pH 6.8 buffer medium. But in presence of goat’s 
caecal content the drug release was faster compared to normal pH 6.8 buffer medium. 
Its drug retarding property is not sufficient to provide drug delivery for 72 hours. Since, 
sodium alginate is also degraded by colonic microbiota drug release may be higher in 
colon. And also sodium alginate is an anionic polymer , it releases drug in pH 
independent manner when used in combination with Interpolyelectrolyte complex. 
Hence it lags in chronobiological based release profile. 
 Hydroxy propyl methyl cellulose is a non-ionic hydrophilic polymer that in 
combination with interpolyelectrolyte complex forms an hydrogel system. Hydroxypropyl 
methyl cellulose is not degraded by colonic microbiota.  
 In recent study it has shown temperature dependent release and it was reported. 
Hence, use of Hydroxyl propyl methyl cellulose is also advantageous in colon delivery of 
drug based on chronobiology since there exist an acute inflammatory reaction in colon 
during asthma attacks which raises temperature and lowers pH in the lumen of the 
colon. 
 Presence of HPMC also increases the mucoadhesive property of the mini tablets. 
Since its mucoadhesion property is independent of pH and formation of good hydrogel 
system is taken into consideration. Controlled delivery of the drug from the dosage form 
is achieved and also provides effective drug release in combination with 
interpolyelectrolyte complex when triggered.  
 Higher viscosity polymers like HPMC k 100 M may cause initial burst release 
from the dosage form. but presence of carbopol , a low viscosity grade polymer 
prevents such burst release. 
 
Table 45: Dissolution test based on chronobiology (pH modification) in 6.8 pH 
phosphate buffer containing 5 % goats caecal content (FA27): 
 
Trial FA27 a 
 
FA27 b FA27 c 
Time % drug 
release 
Time % drug 
release 
Time % drug 
release 
Time % drug 
release 
Time % drug 
release 
Time % drug 
release 
3 h 
4.16 
36 h 49.35 3 h 
4.12 
36 h 50.45 3 h 
4.20 
36 h 51.26 
6 h 8.26 39 h 
53.43 
6 h 8.22 39 h 
54.53 
6 h 8.30 39 h 
55.34 
9 h 12.35 42 h 57.51 9 h 12.31 42 h 58.61 9 h 12.39 42 h 59.42 
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12 h 16.44 45 h 61.59 12 h 16.40 45 h 62.69 12 h 16.48 45 h 63.50 
15 h 20.53 48 h 65.66 15 h 20.49 48 h 66.76 15 h 20.57 48 h 67.57 
18 h 24.88 51 h 69.74 18 h 24.84 51 h 70.84 18 h 24.92 51 h 71.65 
21 h 28.96 54 h 73.82 21 h 28.92 54 h 74.92 21 h 29.00 54 h 75.73 
24 h 33.04 57 h 77.90 24 h 33.00 57 h 79.00 24 h 33.08 57 h 79.81 
5.0 pH 60 h 81.98 4.5 pH 60 h 83.08 4.0 pH 60 h 83.89 
27 h 39.82 63 h 86.06 27 h 41.78 63 h 87.16 27 h 43.61 63 h 87.97 
6.8 pH 66 h 90.13 6.8 pH 66 h 91.23 6.8 pH 66 h 92.04 
30 h 42.19 69 h 94.21 30 h 44.15 69 h 95.31 30 h 45.63 69 h 95.34 
33 h 45.27 72 h 95.73 33 h 46.37 72 h - 33 h 48.18 72 h - 
 
 
Graph 25: Cumulative % drug release of formulation FA27                                              
in modified pH conditions 
 
 Final formula (1:7:3:4) provided control release of drug over a period of 72 hours. 
Releasing 1 mg of salbutamol sulphate in every 3 hours. (Resembling 12 hours dose of 
4 mg SR tablets as recommended in USP). And also provided excellent drug triggered 
release when pH of dissolution medium is lowered (5 pH) by addition of  5 N Hcl. And 
the system had the capacity to regain its initial property of retarding drug release when 
condition is taken back to initial (6.8 pH) by addition of 5 N NaoH. 
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 Note: The addition of 5 N Hcl and 5 N NaoH is involved to adjust the pH in 
dissolution medium within few drops. Because, addition of diluted 1 N Hcl and 1 N 
NaOH should not affect the volume of dissolution medium which may alternatively affect 
the result during UV absorbance study. 
 pH of the dissolution medium was lowered to various pH levels. Since colon may 
have the pH of less than 4.2 during asthma attack. The pH of the dissolution medium 
was changed to 4.5 and 4.0 pH. The release of drug from the dosage form was noted. It 
is observed that as the pH lowers, drug release is triggered more. And the system had 
capacity to regain its original state when pH is reversed. Hence it is concluded that, 
drug release is achieved based on severity of asthma attack. 
Table 46: Dissolution test based on chronobiology (Free radical induced) in 6.8 
pH phosphate buffer containing 5 % goats caecal content (FA27): 
 
Trial FA27 d 
hours % drug 
release 
hours % drug 
release 
3 h 
4.12 
39 h 
54.53 
6 h 8.22 42 h 58.61 
9 h 12.31 45 h 62.69 
12 h 16.40 48 h 66.76 
15 h 20.49 51 h 70.84 
18 h 24.84 54 h 74.92 
21 h 28.92 57 h 79.00 
24 h 33.00 60 h 83.08 
H2O2 addition 63 h 87.16 
27 h 
41.78 
66 h 91.23 
30 h 44.15 69 h 95.31 
33 h 46.37 72 h - 
36 h 50.45   
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Graph 25: Cumulative % drug release of formulation FA27                                              
in presence of Hydroxyl radicals 
Invitro Drug permeation study 
Table 47 : Invitro drug permeation of FA27 
Time (hr) % Drug release % Drug permeation 
3 h 4.09 3.14 
6 h 8.19 6.89 
9 h 12.28 10.64 
12 h 16.37 14.38 
15 h 20.46 18.12 
18 h 24.81 22.10 
21 h 28.89 25.83 
24 h 32.97 29.57 
27 h 37.05 33.30 
30 h 41.12 37.02 
33 h 45.20 40.76 
36 h 49.28 44.49 
39 h 53.36 48.22 
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42 h 57.44 51.96 
45 h 61.52 55.69 
48 h 65.59 59.41 
51 h 69.67 63.15 
54 h 73.75 66.88 
57 h 77.83 70.61 
60 h 81.91 74.35 
63 h 85.99 78.08 
66 h 90.06 81.80 
69 h 94.14 85.54 
72 h 98.07 89.13 
 
DRUG  RELEASE  KINETICS: 
Table 48: Drug release kinetics of FA27 
Time 
(hrs) 
Cumulative 
% drug 
release 
% drug 
remaining 
Square 
root of 
time 
Log % 
drug 
remaining 
Log 
time 
Log 
cumulative 
% drug 
released 
% drug 
released 
Cube root 
of % drug 
remaining 
(Wt) 
Wo - Wt 
0 0 100 0.000 2.000 0.000 0.000 100 4.642 0.000 
3 4.09 95.91 1.732 1.982 0.477 0.612 4.09 4.577 0.065 
6 8.19 91.81 2.449 1.963 0.778 0.913 4.09 4.511 0.131 
9 12.28 87.72 3.000 1.943 0.954 1.089 4.10 4.443 0.199 
12 16.37 83.63 3.464 1.922 1.079 1.214 4.09 4.373 0.269 
15 20.46 79.54 3.873 1.901 1.176 1.311 4.09 4.301 0.341 
18 24.81 75.19 4.243 1.876 1.255 1.395 4.09 4.221 0.421 
21 28.89 71.11 4.583 1.852 1.322 1.461 4.35 4.143 0.499 
24 32.97 67.03 4.899 1.826 1.380 1.518 4.08 4.062 0.580 
27 37.05 62.96 5.196 1.799 1.431 1.569 4.08 3.978 0.664 
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30 41.12 58.88 5.477 1.770 1.477 1.614 4.08 3.890 0.752 
33 45.20 54.80 5.745 1.739 1.519 1.655 4.08 3.798 0.844 
36 49.28 50.72 6.000 1.705 1.556 1.693 4.08 3.702 0.940 
39 53.36 46.64 6.245 1.669 1.591 1.727 4.08 3.600 1.042 
42 57.44 42.56 6.481 1.629 1.623 1.759 4.08 3.491 1.151 
45 61.52 38.49 6.708 1.585 1.653 1.789 4.08 3.376 1.266 
48 65.59 34.41 6.928 1.537 1.681 1.817 4.08 3.252 1.390 
51 69.67 30.33 7.141 1.482 1.708 1.843 4.08 3.119 1.523 
54 73.75 26.25 7.348 1.419 1.732 1.868 4.08 2.972 1.670 
57 77.83 22.17 7.550 1.346 1.756 1.891 4.08 2.809 1.833 
60 81.91 18.09 7.746 1.258 1.778 1.913 4.08 2.625 2.017 
63 85.99 14.02 7.937 1.147 1.799 1.934 4.08 2.411 2.231 
66 90.06 9.94 8.124 0.997 1.820 1.955 4.08 2.150 2.492 
69 94.14 5.86 8.307 0.768 1.839 1.974 4.08 1.803 2.839 
72 98.07 1.93 8.485 0.286 1.857 1.992 4.08 1.245 3.397 
Zero order Kinetics: 
 
Graph 26: Zero order kinetics of formulation FA27                                                                  
in colon simulated medium 
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Higuchi kinetics: 
 
Graph 27: Higuchi kinetics of formulation FA27                                                                  
in colon simulated medium 
Kors-peppas kinetics: 
 
Graph 28: Kors-peppas kinetics of formulation FA27                                                                  
in colon simulated medium 
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First order kinetics: 
 
Graph 29: First order kinetics of formulation FA27                                                                  
in colon simulated medium 
Hixson kinetics 
 
Graph 29: Hixson kinetics of formulation FA27                                                                  
in colon simulated medium 
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DRUG  RELEASE  KINETICS BASED ON CHRONOLOGICAL BEHAVIOUR: 
Table 49: Drug release kinetics of FA27 based on chronological behavior. 
Time 
(hrs) 
Cumulative 
% drug 
release 
% drug 
remaining 
Square 
root of 
time 
Log % 
drug 
remaining 
Log 
time 
Log 
cumulative 
% drug 
released 
% drug 
released 
Cube root 
of % drug 
remaining 
(Wt) 
Wo - Wt 
0 0 100 0.000 2.000 0.000 0.000 100 4.642 0.000 
3 4.20 95.80 1.732 1.981 0.477 0.624 4.20 4.576 0.066 
6 8.30 91.71 2.449 1.962 0.778 0.919 4.20 4.510 0.132 
9 12.39 87.61 3.000 1.943 0.954 1.093 4.09 4.441 0.201 
12 16.48 83.52 3.464 1.922 1.079 1.217 4.09 4.371 0.271 
15 20.57 79.43 3.873 1.900 1.176 1.313 4.09 4.299 0.343 
18 24.92 75.08 4.243 1.876 1.255 1.397 4.09 4.219 0.423 
21 29.00 71.00 4.583 1.851 1.322 1.462 4.35 4.141 0.501 
24 33.08 66.92 4.899 1.826 1.380 1.520 4.08 4.060 0.582 
27 43.61 56.39 5.196 1.751 1.431 1.640 4.08 3.835 0.807 
30 45.63 54.37 5.477 1.735 1.477 1.659 10.53 3.788 0.854 
33 48.18 51.82 5.745 1.714 1.519 1.683 2.02 3.728 0.914 
36 51.26 48.74 6.000 1.688 1.556 1.710 2.55 3.653 0.989 
39 55.34 44.66 6.245 1.650 1.591 1.743 3.08 3.548 1.094 
42 59.42 40.58 6.481 1.608 1.623 1.774 4.08 3.436 1.206 
45 63.50 36.51 6.708 1.562 1.653 1.803 4.08 3.317 1.325 
48 67.57 32.43 6.928 1.511 1.681 1.830 4.08 3.189 1.453 
51 71.65 28.35 7.141 1.453 1.708 1.855 4.08 3.049 1.593 
54 75.73 24.27 7.348 1.385 1.732 1.879 4.08 2.895 1.747 
57 79.81 20.19 7.550 1.305 1.756 1.902 4.08 2.723 1.919 
60 83.89 16.11 7.746 1.207 1.778 1.924 4.08 2.526 2.116 
63 87.97 12.04 7.937 1.080 1.799 1.944 4.08 2.292 2.350 
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66 92.04 7.96 8.124 0.901 1.820 1.964 4.08 1.996 2.646 
69 95.34 4.66 8.307 0.668 1.839 1.979 4.08 1.670 2.972 
72 97.91 2.09 8.485 0.320 1.857 1.991 3.30 1.279 3.363 
 
Zero order Kinetics: 
 
Graph 30: Zero order kinetics of formulation FA27                                                                  
in colon simulated medium when triggered 
 
Higuchi kinetics: 
 
Graph 31: Higuchi kinetics of formulation FA27                                                                  
in colon simulated medium when triggered 
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Kors-peppas kinetics 
 
Graph 32: Kors-Peppas kinetics of formulation FA27                                                                  
in colon simulated medium when triggered 
First order kinetics: 
 
Graph 33: First order kinetics of formulation FA27                                                                  
in colon simulated medium when triggered 
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Hixson kinetics 
 
Graph 34: Hixson kinetics of formulation FA27                                                                  
in colon simulated medium when triggered 
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EVALUATION OF IMMEDIATE RELEASE TABLETS: 
Table 50: Blend parameters of FB1 – FB5 
Formula 
trial 
Bulk density 
(gm/ml) 
Tapped 
density 
(gm/ml) 
Compressibility 
index % 
Hausner ratio % drug content 
FB1 0.421 0.523 19.503 1.242 99.52% 
FB2 0.426 0.527 19.165 1.237 99.64% 
FB3 0.432 0.531 18.644 1.229 99.35% 
FB4 0.429 0.519 17.341 1.210 98.76% 
FB5 0.418 0.521 19.770 1.246 99.50% 
 
Table 51: Tablet Physical parameters of FB1 – FB5  
Formula 
Trial 
Thickness (mm) Hardness 
kg/cm
2
 
% Friability Disintegration 
time 
Content 
uniformity 
FB1 2.9 mm ± 0.3 mm 4  kg/cm 
2
 0.51 % 2 min 11 sec 99.45% 
FB2 2.8 mm ± 0.3 mm 4  kg/cm 
2
 0.45 % 1 min 56 sec 99.51% 
FB3 2.9 mm ± 0.2 mm 4  kg/cm 
2
 0.32 % 1 min 05 sec 99.26% 
FB4 3.0 mm ± 0.2 mm 5  kg/cm 
2
 0.24 % 46 sec 98.58% 
FB5 3.0 mm ± 0.1 mm 5  kg/cm 
2
 0.11 % 14 sec 99.23% 
 
Table 52: Cumulative % Drug release - Dissolution test in 0.1 N Hcl 
Trial FB1 FB2 FB3 FB4 FB5 
15 
min 
46.21 56.34 63.14 77.31 99.27 
30 
min 
67.07 71.18 79.65 99.43 
- 
45 
min 
97.13 97.47 98.79 
- - 
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Graph 35: Cumulative % Drug release of formulation FB1 – FB5                                                                   
 
 Formula FB5 showed fast disintegration < 15 sec and complete drug release was 
achieved within 15 min in 0.1 N Hcl dissolution medium. 
 Crosspovidone XL 10 have larger particle size compared to normal crospovidone 
and croscarmellose sodium, hence higher rate of wicking caused faster disintegration , 
thus resulting in faster drug release. 
 Increase in concentration of Mcc ph 102 and decrease in concentration of lactose 
DCL -11 showed significant improvement in disintegration and faster rate of drug 
release. 
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STABILITY  STUDIES : 
Stability studies was carried out in accelerated stability chamber 40ᵒC / 75% RH  for a 
period of 3 months and the results were found satisfactory. 
Table 53: Stability studies of Mucoadhesive tablets: 
FA27 1st month 2nd month 3rd month 
Result complies complies Complies 
 
Table 54: Stability studies of Immediate release tablets: 
FB5 1st month 2nd month 3rd month 
Result complies complies Complies 
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CONCLUSION 
 Chronopharmaceutical drug delivery can be used in case of diseases which 
shows circadian rhythm in their patho physiology which can tackle the problems as it 
is modulated to release the drug according to the biological clock. 
 Hence, a smarter drug delivery system is needed which alters drug release 
profile itself based on severity of asthma attacks and COPD. This benefits the 
maintenance of drugs in plasma and also releases more of the drug it holds when 
condition is severe based on the needs of the physiological system. 
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